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Colorectal cancer (CRC) is the second-leading cause of cancer-related death and a 
global burden in terms of incidence, person-years of life lost and public health costs. 
About 10-20% of sporadic CRCs develop through a pattern of DNA mismatch repair 
(MMR) insufficiency that leads to hypermutation, microsatellite instability (MSI) and 
a strong immunogenicity, exemplified by the higher number of immune cells 
infiltrating the tumours.  
Over the course of the past two decades, MSI was investigated and defined 
in the context of CRC and other solid tumours. MSI can be measured by length 
variation at selected mononucleotide repeats across the normal/tumour genomes, with 
specific panels and thresholds, and/or by immunohistochemical (IHC) analysis of 
MMR members such as MSH2 and MLH1. MSI CRCs are often located in the 
proximal colon, have better prognosis, and are to some degree refractory to a 
common CRC chemotherapy (5-fluorouracil). Further, MSI CRCs are better 
responders to anti-PD-1/PD-L1 immunotherapy, which is an exciting development in 
modern oncology. A variation of MSI, investigated exclusively at tetranucleotides, is 
elevated microsatellite alterations at selected tetranucleotides (EMAST). Studies on 
EMAST in CRC are scarce, no consensus on a panel of markers and their cut-off 
exists, and neither its clinicopathological implications nor its relationship with MSI is 
defined at present.   
In this work, EMAST was investigated in a highly selected archival cohort of 
non-metastatic CRC and associated with MSI, proximal colon location and a lower 
number of lymph nodes harvested at surgery (paper I). Loss of MSH3 has been 
proposed in the literature as a possible mechanism leading to instability at 
tetranucleotides, and therefore implicated with EMAST in CRC. To test this 
hypothesis, automated digital image analysis of IHC staining for MSH3 was 
performed in a consecutive cohort of CRC included prospectively in an ongoing 
biobank established in 2013 (paper II). Negligible degrees of MSH3 loss were found 
in this cohort, and were not associated with EMAST, thus suggesting alternative 
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mechanisms of instability at tetranucleotides. In the same second cohort, EMAST 
was found again to overlap with MSI, at higher incidences in the proximal colon, and 
with an improved recurrence-free survival (paper III). Notably, however, EMAST 
patients were shown to be older and display a higher incidence of pre-operatively 
recorded markers of frailty, such as anaemia, hypoalbuminemia and greater loss of 
weight. 
To establish whether EMAST, as MSI, correlates with a higher immunogenicity and 
could serve as a predictive marker for PD1 blockade immunotherapy, IHC analyses 
of T-lymphocyte markers CD3 and CD8, as well as PD-L1 were carried out. EMAST 
tumours were found to have higher degrees of T-cells, including CD8 cytotoxic T-
cells, and to express PD-L1, suggestive of an active immune evasion mechanism 
(paper IV). Prognostically, PD-L1 expression in tumour cells was not indicative, 
although its expression on peritumoral immune cells correlated with an improved 
recurrence-free survival, independent of EMAST status. Higher densities of T-
lymphocytes were also highly prognostic, both in terms of recurrence-free and overall 
survival. 
The data hereby presented suggests a role for EMAST in CRC 
clinicopathological analysis, although further subgroup analyses are required to 
establish whether MSI and EMAST are distinct mechanisms of instability. EMAST 
seems to be of comparable immunogenicity to MSI and shows expression of PD-L1 
possibly as an antagonising mechanism to it. Finally, results here presented suggest a 
prognostic value for PD-L1 expression in non-tumour cells, pointing at the 
importance of the cellular distribution of the PD1/PD-L1 axis. 
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1.1 COLORECTAL CANCER 
 
1.1.1 Epidemiology  
Colorectal cancer (CRC) is the fourth most diagnosed cancer world-wide, with an 
estimated 1.8M new cases and >800.000 deaths in 2018 1. In Norway, CRC is the 
second most diagnosed cancer in both men and women, at near-equal ratio, with 4332 
new cases in 2017 2. Median age at diagnosis is 73 for colon and 69 for rectal cancer, 
and it is thus mainly considered as diseases of the elderly2. Early-onset (diagnosis at 
<50 years of age) of CRC is however an emerging trend, especially in westernised 
countries 3. Norwegian age-standardised incidence (Figure 1) is increasing steadily, 
and was higher than the rest of northern/western Europe and the fourth-highest world-
wide in 2018 (42.9 per person-years) 1,4,5. When considered independently, however, 
rectal cancer’s incidence remained stationary for over 3 decades, as opposed to an 
increase in colon cancer in both men (+2.3%) and women (+6.6%) in the previous 5-
year period only 2.  
Globally, CRC is a “disease of the western world”, the risk of which is 
affected by lifestyle and environmental factors 6,7. Western-style dietary habits such 
as red and processed meat as well as elevated alcohol consumption are consistently 
associated with increased risk, while long-term, low-dose NSAIDs intake such as 
aspirin, and a high-fibre diet are generally considered as protective for CRC 6,8-12.  
The most prominent risk factor is age, as the incidence rate for precursor lesion 
increases steeply and steadily over the age of 50 13. Other risk factors include family 
history of CRC, inflammatory bowel disease, obesity, male gender and ethnicity 14 
(Figure 2).  
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Figure 1. Age-standardised incidence rate of CRC world-wide. Reproduced with permission 
from 3, Copyright © 2019 Springer Nature. 
 
Figure 2. Risk factors in colorectal cancer. Reproduced with permission from 15, Copyright © 
2019 Elsevier Ltd 
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Most CRCs are sporadic, but up to 30% are estimated to be of some inherited 
nature, although only ca. 5% are due to established congenital mutations. These 
include familial adenomatous polyposis (FAP), hereditary non-polyposis colorectal 
cancer (HNPCC, now known as Lynch syndrome) or juvenile polyposis (JPS) 16-18. 
 
1.1.2 Diagnosis and screening 
 Colonoscopy is the primary method of CRC diagnosis, which is confirmed 
histologically on a biopsy taken during the procedure. Other, explorative techniques 
include CT colonography, flexible sigmoidoscopy and barium enema, each with its 
own advantages (slightly reduced invasiveness) and limitations (sensitivity) and 
however still considered as inferior to colonoscopy 13,19,20. Given the uncomfortable 
nature of such invasive tests, compliance to undertake investigation is considered 
low. Non-invasive test alternatives have been developed in the past decades, such as 
stool-based tests like faecal immunochemical (FIT) and faecal occult blood (FOBT), 
to date the only screening test that has shown to decrease mortality in randomised 
controlled trials 21-23. Stool DNA tests to date lack standardisation, in some cases 
sensitivity, and/or are too expensive for integration into public health systems 13,24. A 
recent report from the international agency for research on cancer (IARC) reviewed 
the available literature on harm and benefits of various endoscopic and stool-based 
screening test, concluding that both FOBT and FIT, together with endoscopic 
techniques, reduced the risk of death from CRC 25. During the initiation of this thesis, 
no formal screening programme was in place in Norway. Hence, patients are largely 
diagnosed based on symptoms (e.g. blood in stool, anaemia, change in bowel habits, 
abdominal pain or weight loss) or incidentally during work-up for other conditions. 
 
1.1.3 Treatment 
Early lesions such as benign polyps and a small proportion of stalked polyps with 
non-infiltrating adenocarcinomas can be resected endoscopically, provided no 
evidence of poor cellular differentiation or infiltration in blood and lymphatic vessels 
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is present. Surgery is however the only curative intervention for CRC, and adjuvant 
and neoadjuvant treatment is offered on the basis of Norwegian Health Council’s 
guidelines 19.  
A proportion of rectal cancers are administered neo-adjuvant radiotherapy in hope of 
tumour remission and improvement of circumferential resection margins, considered 
proportionally related to survival 26,27. In primary colon cancer, a range of adjuvant 
chemotherapy regimens are offered to stage III (see later - staging) and “high-risk” 
stage II cancers. Regimens for stage III cancer are based on fluoropyrimidine drugs 
such as 5-fluorouracile (5FU, given in combination with leucovorin) or capecitabine. 
These are given in combination with oxaliplatin (FOLFOX, FLOX or 
XELOX/CAPOX), to patients <70 yo, based on degree of tumour invasion in the 
submucosa, extent of node involvement and presence of microsatellite instability 
(MSI). Depending on clinicians’ patient-to-patient individual assessment (age, 
general condition, comorbidity), monotherapies of either one fluoropyrimidine are 
considered for patients older than 70 years. 
Stage II patients are defined as “high-risk” when perforations are present near the 
tumour area, tumour growing through the serosa and low number (≤ 12) of assessed 
lymph nodes. In such cases patients are tested for microsatellite instability and 




The relative 5-year survival for the 2014-2018 period in Norway is estimated at 
65.4% and 69.8% for colon and rectum, respectively 2. In a recent multi-register, 
global surveillance study (CONCORD-3, referring to the period 2012-2014) Norway 
was placed in the top 15% of 68 reporting countries for 5-year net survival of CRC 28. 
The increasing survival and declining mortality from rectal cancer in both sexes are 
likely due to the improvement in patient care, as for example the introduction of total 
mesorectal excision and of preoperative radiotherapy in selected patients. However, 




Staging of colorectal cancer, traditionally based on anatomical features, has served 
pathologists as a prognostic tool since the 1920s. In 1932, Cuthbert E. Dukes, a 
pathologist at St. Mark’s Hospital in London, described an association between 
survival of patients who underwent surgery for rectal cancer and the extent of growth 
of the tumour in the surrounding tissue 30. Dukes’ classification is still often reported 
in pathology alongside the newer staging system, adopted in 1954 and maintained up 
to date by the American joint Committee on cancer (AJCC), known as tumour-node-
metastases (TNM). The 8th version of the AJCC cancer staging manual 31 was 
recently adopted, whilst the 7th edition (shown in figure 3)was in use at the time the 
present study was carried out.  
The TNM staging system aims at stratifying patients in prognostic stage groups 
according to anatomical extent of their disease, at the same time guiding clinicians to 
choose the appropriate treatment strategy. Staging also provides a tool for comparison 
of results and stratify patients in trials. Patients are assigned a stage I-IV, with tumour 
(T) invasion through the muscularis propria (T3) as the limiting step for stage I to II 
switch. Presence of tumour deposits and/or positive lymph nodes (nodal status N), in 
turn, is what determines the stage to advance from II to III, independent of T status. 
Any distant metastasis (M) at the time of diagnosis automatically classifies the 
disease as stage IV CRC.   
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Figure 3. The tumour-node-metastases (TNM) staging system as reported from the 
7th edition of the AJCC cancer staging manual. Reprinted with permission, 
Copyright © 2017 Springer. 
 
The recording of further prognostic factors is encouraged by the latest (8th) version of 
the AJCC manual, and these include: 
• Serum CEA (both pre-operatively and at regular intervals during surveillance) 
• Tumour regression score (in case of neoadjuvant chemo/radiotherapy) 
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• Circumferential resection margin (CRM) 
• Perineural invasion (PNI) 
• Microsatellite instability - MSI 
• Mutations in the RAS/RAF pathway (KRAS, BRAF, NRAS) 
 
 
Issues with current staging  
While the TNM system remains the strongest recognised prognosticator in CRC, it 
received much criticism during the past years. This is especially true since the 
stratification of stages II and III introduced from the 5th to the 6th edition of the AJCC 
staging manual. Amendments introduced in subsequent versions of the TNM system 
have led to “stage migration” in some groups, which attracted criticism 32-34. Among 
the main critiques was introduction of stage IIb (T4N0), for example, which showed 
poorer survival over the more advanced stage IIIa (T1-2N1) 35,36. This could be 
explained by the fact that, following the guidelines, stage III patients received 
adjuvant chemotherapy and stage II did not. Further, stage II patients could be under-
staged if an insufficient number of lymph nodes are resected at surgery or 
microscopically investigated, thus possibly missing N+ observations that could assign 
a stage III diagnosis. The number of lymph nodes resected during CRC surgery has 
been shown to be of prognostic relevance, especially in stage II-III patients 37,38. 
Despite suggestions upon ideal minimum number of lymph nodes to harvest at 
surgery, this is subject to a number of factors such as location of the tumour 
(proximal vs. distal), length of the resected specimen and age of the patient, as well as 
biological characteristics such as MSI status or mutations in the RAS pathway 39-43.  
 All revisions of the TNM strongly rely on nodal status (pN) to assess 
prognosis and recommend adjuvant chemotherapy, however up to 25% of stage II 
and 40% of stage III CRC present with relapse, regardless of treatment offered. The 
main shortcoming of the TNM system lies in its inability to account for differences in 
tumour biology, such as genetic and epigenetic heterogeneity, molecular composition 




1.2 CRC tumorigenesis 
 
1.2.1 Large intestine architecture and homeostatic dynamics 
Throughout the gastrointestinal (GI) tract, architectural conformation of the 
epithelium lining the lumen evolved to serve specific purposes. The proximal (from 
the small intestine to the first two thirds of the transverse colon) and distal (last third 
of transverse to the upper anal canal) portions of the intestine generate embryonically 
from the midgut and the hindgut, respectively 44.  The large intestine, the terminal 
tract of the GI tract, is composed right-to-left (or proximal-to-distal) by caecum, 
colon (ascendens, transversum and descendens and sigmoideum) and rectum. While 
the right-side colon is still partly dedicated to the remainder of the digestive function 
through absorption, the distal portion is mainly involved in compacting and 
lubricating the stool and allowing it to pass through by peristalsis.  
To increase overall surface and effective absorption, and to protect the stem cell 
compartment vital to tissue renewal and homeostasis, the lumen of the intestine folds 
into pits named crypts of Lieberkühn 45. At the bottom of every crypt, in the so-called 
stem cell niche, resides a group of undifferentiated cells, which have been extensively 
studied with the aid of mouse models, and were shown to express stem cell markers 
such as LGR5 and EPHB2 46-50. Their “stemness” is believed to be maintained by 
pericryptal myofibroblasts and – in the colon - by CD24 and KIT-expressing Goblet 
cells via WNT, NOTCH, EGF and BMP pathways signalling 51-53. By means of 
asymmetric division, the 6-14 stem cells in each crypt’s niche are alone able to 
recapitulate the entire diversity of intestinal cell populations 54,55.  
Daughter cells originating from a stem cell’s asymmetric division initiate a series of 
rapid division cycles (ca. 2 per day), whilst migrating upwards through the crypt’s 
mid-section (named transient-amplifying compartment), towards the lumen. 
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Figure 4. (Top) Macro- and microscopic structure of the human large intestine. Reproduced 
with permission (Copyright © 2013 Encyclopaedia Britannica). (Bottom) the structural and 
cellular organisation of the large intestine. Reproduced with permission from 48, Copyright © 
2014 Nature publishing group.  
 
 28
Differentiation takes place during this division-migration process, and transient 
amplifying cells become increasingly committed to one of the handful of terminally 
differentiated cells composing the intestinal epithelium (Figure 4 - bottom). These 
include mucin-secreting goblet cells, tuft cells, M cells, absorptive enterocytes and 
hormone-secreting enteroendocrine cells. Once reaching the surface, terminally 
differentiated cells undergo apoptosis and shed into the lumen, renewing the entire 
lining of the intestinal lumen within 6-8 days. This cell proliferation/death cycle is 
tightly regulated and kept at equilibrium under normal circumstances. A shift towards 
proliferation rather than cell death disrupts cellular homeostasis, causing the 
formation of neoplasms.  
 
1.2.2 Carcinogenesis 
In the current model of carcinogenesis, neoplasms undergo several rounds of random 
mutations that may ultimately lead to their malignant transformation into cancer. 
Pertinent to the stochastic model of mutation accumulation, no two cancer are 
genetically the same. Ultimately, however, the wealth of genetic and epigenetic 
alterations in each tumour serves the cancer’s independence from normal 
physiological signals in a set of cellular functions.  
The range of capabilities that neoplasms acquire during carcinogenesis were 
described as the ‘Hallmarks of cancer’ (Figure 5) 56,57. Self-sufficient propagation is 
achieved by the hijacking of proliferative signalling, and insensitivity to its anti-
proliferative counterpart. Evasion from programmed cell death is enabled by loss of 
intrinsic apoptotic pathways and/or inhibition of extrinsic ones. Gain of telomerase 
activity provides a “life extension” to cancer cells via circumvention of cellular 
senescence, which is normally induced by telomeres shortening at each replication 
cycle. Angiogenesis allows vascularization of the tumour, permitting access to the 
oxygen and nutrients needed to the growing lesion. Finally, modifying the cell-cell 
and cell-extracellular matrix adhesion mechanisms allows a portion of tumour cells to 
detach from the primary frame and use the newly built vascular connections to travel 
to distant organs. This is what ultimately leads to metastases, which cause most 
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cancer mortalities.  
Depending upon whether their amplification or inactivation aids the carcinogenic 
process, genes found to be involved in cancer are generally defined as oncogenes or 
tumour-suppressing genes, respectively. 
 
 
Figure 5. Hallmarks of cancer. Adapted with permission from 57, Copyright © 2011 Elsevier. 
 
Carcinogenic transformation is initiated by factors that are caused by the environment 
and/or are inherited, therefore producing somatic and/or inherited mutations. These 
two factors, however, do not fully explain the great variability in organ-specific risk 
of developing tumours. Such variability is for example evident in the GI tract, where 
cancers of the upper GI (i.e. stomach, small intestine, etc.) are less frequent than 
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those of the colorectum 2,58. The correlation of cancer incidence with increasing age 
and with tissue-specific rate of stem-cell division is well documented 58. Additionally, 
it is known that only a portion of the genetic mutations found in any cancer are 
identified as driver mutations (those affecting the hallmarks of cancer, i.e. APC, 
KRAS, TP53) (Figure 6), while the rest are passenger mutations, or silent. Thus, 
individual cancer risk should be considered as the complex interaction of 
environmentally driven mutations, inherited changes and the chance of acquiring 
hallmarks of cancer-hitting mutations 59. 
 
1.2.3 Adenoma-carcinoma sequence and pathways of colorectal 
carcinogenesis 
Chromosomal and microsatellite instability are the two main forms of genetic 
disorders that drive tumorigenesis of sporadic colorectal cancer (Figure 6). Based on 
discoveries on clonality and mutations underlying CRC, during the 1980s the 
‘adenoma-carcinoma sequence’ was developed as a model of carcinogenesis in CRC 
60-62. This is a stepwise timeline of genetic and epigenetic mutations underlining the 
transformation of normal epithelium to adenomas, to carcinomas and metastases. 
(Figure 6).  
 
Figure 6 Adenoma-carcinoma sequence showing molecular and cellular changes. 
Reproduced with permission from 63, Copyright © 2015 Springer Nature. 
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The adenoma-carcinoma sequence is driven by chromosomal instability (CIN) and is 
understood today that most (up to 85-90%) but not all sporadic CRCs develop 
through this pathway 14,15. CIN involves a fault during the chromosomal segregation 
at mitosis, and cells following this pathway are characterised by aneuploid karyotype, 
copy number variations and further chromosomal aberrations 64. The earliest change 
of the normal intestinal epithelium is the formation of aberrant crypt foci (ACF), 
hyper- and sometimes dysplastic crypts that are not easily detected during normal 
endoscopic investigations 65. The proliferative advantage of ACF can stem from 
alterations of both MAPK (mainly KRAS gene) and WNT (either APC or beta-
catenin) signalling pathways. Only a small portion of ACFs develop into adenomas.  
Adenomatous polyps, or adenomas, are pre-cancerous lesions that are widely present 
throughout the population (up to 53% in individuals older than 50 years the US) and 
are classified according to their size and histological features 13. More than 99% of 
early adenomas (<10mm in size) are benign. A small share of adenomas eventually 
undergoes malignant transformation into full adenocarcinomas, by losing tissue 
architecture and cell polarization and growing to invade the underlying muscularis 
mucosae. Adenoma-to-carcinoma switch is usually initiated by mutations and loss of 
heterozygosity in members of the TGF-β signalling pathway such as SMAD4, as well 
as in the tumour suppressor gene TP53 63.  
A subset (10-30%) of CRC develops from a different type of polyps called 
sessile serrated polyps, which are commonly found in the proximal side of the colon 
and were until recently considered as unable to progress into adenocarcinomas 66,67. 
Defects in DNA mismatch repair (MMR) are more commonly associated with the 
serrated polyps pathway and are the cause of MSI, which is reported at rates between 
15 and 30% 68. MSI is the cell’s failure to repair single or multiple mismatched 
nucleotides during DNA replication. It can be experimentally evaluated by comparing 
the length of repetitive DNA sequences (microsatellites) obtained from normal and 
tumour tissue.  
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Figure 7. Pathways of colorectal neoplasia. Reproduced with permission from 14, Copyright 
© 2014 Elsevier. 
 
MSI cancers are predominantly located in the proximal colon, are mucinous and 
undifferentiated, with a more prominent immune infiltration and generally less 
aggressive. Molecularly, these cancers are associated with less frequent alterations of 
APC, KRAS and TP53, but rather with activating mutations in BRAF oncogene and 
the CpG island methylator phenotype (CIMP) 69,70 (Figure 7). CIMP is a type of 
epigenetic aberration that shows extensive methylation at CpG islands within 
promoter regions of tumour suppressor genes, thereby inhibiting their transcription 
and affecting their expression 63,64,71. 
Moreover, MSI is also present in >95% of hereditary non-polyposis colorectal cancer 
(HNPCC or Lynch syndrome 72). Lynch is an autosomal syndrome that greatly 
increases risk to develop a series of cancers, of which CRC and endometrium cancer 
are the most prominent 73.  
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1.2.4 Consensus Molecular Subtypes (CMS) of CRC 
Cancer is a rather heterogeneous disease and therefore challenging to characterize 
functionally. Tumour behaviour and cellular diversity are hardly derived by mutation 
profiles alone but are intrinsically linked by the way each singular gene is expressed 
and contributes to the overall picture. The advent of next generation sequencing 
(NGS) techniques and data sharing platforms in the past decade produced a surge in 
data available from gene expression studies. Multiple, large cohort studies based on 
gene expression profiling were produced in the past decade that provided an eye-
opening insight into tumour behaviour. For the first time, CRC was being classified 
according to its transcriptome (the degree of expression of each gene), rather than its 
genome, with implications for the development of the concept of personalised 
medicine. These efforts produced several gene expression signatures capable of 
grouping most CRCs into distinct molecular subtypes, albeit with limited inter-study 
reproducibility 74-79. In 2015, an international collaboration (the “CRC subtyping 
consortium”) developed a network-based approach applying each of the algorithms to 
18 pooled datasets, comprising >4000 CRCs. This effort lead to the identification of 4 
common molecular subtypes (Figure 8), defined Consensus Molecular Subtypes 
(CMS1-4) of CRC 80. 
The proposed CMS model identified four (1-immune, 2-canonical, 3-metabolic and 
4-mesenchymal) subtypes which not only recapitulated the genetic model of CRC 
carcinogenesis, but considerably expanded its understanding. The CMS1-immune 
subtype correlates well with the MSI carcinogenic pathway, with higher mutational 
burden, gene methylation and immune infiltrate. The other three CMSs further 
subdivided CIN-driven carcinogenesis according to genomic, epigenomic and 
transcriptomic pathways, type and degree of immune infiltration and its interaction 





Figure 8. Consensus molecular subtypes (CMSs) and their molecular/clinical associations. 
Reproduced with permission from 80 (top, Copyright © 2015 Springer Nature) and 81 





Figure 9. (Top) Schematic representation of CRC subtypes and their molecular 
characterisation and (bottom) their association with clinical traits. Reprinted with permission 
from 81 (top, Copyright © 2017 Springer Nature) and 15 (bottom, Copyright © 2019 Elsevier) 
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1.3 Microsatellite Instability in colorectal cancer 
 
Microsatellites are stretches of DNA containing repetitive blocks of 1-6 base pairs 
(e.g. An, AGn, AAGn, etc.), abundant and ubiquitous throughout eukaryotic and 
prokaryotic genomes 82. Also known as short tandem repeats (STRs) or simple-
sequence repeats (SSRs), they constitute about 3% of the whole human genome, with 
mononucleotide repeats (An, Cn, etc.) being the most abundant 83. Microsatellites in 
humans are mostly polymorphic by nature but conserved and of even length within 
each cell of the same individual, therefore useful in forensic, paternity and gene 
mapping applications 84,85. 
 In 1993, using a technique known as arbitrarily-primed polymerase chain 
reaction (PCR), it was discovered that tumour DNA of a small subset of CRC 
displayed small deletions, or band shifts, when compared to normal DNA from the 
same patient 86. This was particularly true in repetitive elements of DNA, and the 
authors described this subset of CRC as more prevalent in the proximal colon, in 
younger and non-metastatic patients 86.  
The same year, Thibodeau and Schaid reported increased survival and proximal 
location of tumours in patients demonstrating a similar pattern of instability in 
repetitive regions of DNA 87, which they termed microsatellite instability or MIN. 
Microsatellite instability was at the same time found in Lynch syndrome patients, 
referred to as RER (replication error) 88,89, and linked to a genetic locus subsequently 
identified as one of the mismatch repair (MMR) genes. 
After these initial findings, several other laboratories described the same phenomenon 
and a variety of methods to investigate it. Workshops held by the National Cancer 
Institute (NCI) in 1996-7 in Bethesda (MD, USA), eventually agreed upon and 
endorsed guidelines 90,91. Since the Bethesda workshop and over the course of the 
past two decades, a great deal of research was centred on MSI and its detection, 
molecular mechanisms and its clinical implications in terms of prognosis and 
response to therapy. 
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 In Norway today, a CRC patient may be considered for MSI testing if 
diagnosed under the age of 60 or generally considered at risk for Lynch syndrome, as 
well as those belonging to high-risk group in stage II (and therefore a candidate for 
adjuvant chemotherapy) 19. Moreover, guidelines suggest collecting MSI status of 
stage IV patients, as it could prove important should immunotherapy with 
pembrolizumab and nivolumab be approved in the near future by the health council 
19. 
 
1.3.1 Genetics of MSI and MMR deficiency 
DNA replication by polymerases during S phase of eukaryotic cells is the essential 
mechanism that ensures that daughter cells receive the same genetic information 
during cell division. DNA polymerases are to some degree error-prone 92,93, and 
occasionally introduce nucleotide mismatches during DNA replication. Such mishaps 
happen at a higher rate in microsatellite sequences, owing to their increased self-
complementarity and easier formation of a range of tertiary structures 85,94,95.  
The mismatch repair system (MMR) is the cell’s own proofreading mechanisms 
ensuring the fidelity of DNA replication. Single nucleotide mismatches and insertion-
deletion loops (IDLs, indels) occurring due to strand slippage are rapidly recognised 
and corrected by this system using a variety of enzymes 96,97. If left uncorrected, IDLs 
produce an equivalent loss or gain of nucleotides in the daughter cell, according to 
whether the IDL happened in the template or daughter strand, respectively (Figure 
10). Uncorrected gain/losses of nucleotides at or near protein coding sequences cause 
frameshift mutations, where the reading frame of a protein is altered due to insertion 
or deletion of base pairs, affecting protein functionality 68,70. Several genes involved 
in regulation of cell proliferation, mismatch repair and apoptosis contain 
microsatellite sequences that are affected in MSI 64,98, potentially contributing to 




Figure 10. Mechanisms of microsatellite instability. During DNA replication, «strand 
slippage» (strand denaturation and mis-realignment) can occur, particularly at high-
complementary sequences such as microsatellites. In an MMR-proficient cell the error is 
quickly corrected (see also figure 11). In an MMR-deficient environment, replication 
continues, producing a loss or gain in nucleotides in the newly synthesised DNA. Reprinted 
with permission from 73, Copyright © 2015 Springer Nature.   
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In sporadic CRC, members of the MMR system, particularly MLH1 and 
PMS2, are epigenetically silenced by promoter methylation, enhancing the 
association of MSI with CIMP phenotype 68,99,100. On the other hand, MSI in 
hereditary CRC such as Lynch syndrome is caused by germline defects in MMR 
genes, autosomal dominant mutations (and epimutations) that are inherited in 
kindreds 68,101. Owing in part to the discoveries by 2015 chemistry Nobel laureates 
Modrich and Lahue on mismatch repair function in bacteria 102,103, initial cloning of 
the human MSH2 gene were achieved in 1993 104. The authors mapped its location to 
chr. 2p, close to a locus that in the same year was associated with MSI in Lynch 
syndrome, making MSH2 the first MMR gene associated with MSI 89,104,105.  Yeast 
and mammals’ MMR homologue genes were cloned from bacterial mutS and mutL, 
thus acquiring the names MSH and MLH (mut S/L homologue), respectively. In 
humans, five MSH (MSH2, MSH3, MSH4, MSH5, MSH6) and four MLH (MLH1, 
MLH3, PMS1, PMS2) homologues were additionally cloned.  
MSH2 form heterodimers with either MSH6 (to form the MutSα complex) or MSH3 
(MutSβ) to scan and identify single mismatches and IDLs 64,97. MutSα has a higher 
affinity for single base mismatches 106, and recruits the MutLα complex to the 
mismatch site. The MutSα-MutLα complex is in turn able to slide across the newly 
synthesised DNA until reaching the DNA polymerase. The whole complex then uses 
proliferating cell nuclear antigen (PCNA) and an exonuclease enzyme to backtrack 
and excise all the newly bound nucleotides until the mismatch is reached and 
corrected (Figure 11). 
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Figure 11. Different MMR heterodimers interactions and functions. (A) Single mismatch 
recognition MutSα and recruitment of MutLα to the site. (B) exonuclease/PCNA-mediated 
base excision and subsequent resynthesis by DNA polymerase. (C) Possible MMR 
heterodimers variations upon insertion/deletion loop formation. 
Reprinted with permission from 107, Copyright © 2008 Elsevier. 
 
 
1.3.2 Testing for MSI in CRC 
The Bethesda guidelines defined microsatellite instability as “a change of any length 
due to either insertion or deletion of repeating units, in a microsatellite within a 
tumour when compared to normal tissue” 90, suggesting a panel of five microsatellite 
loci to assess for instability (Table 1). Three classes of CRC were also defined: MSI-
H (high) showing MSI at ≥2/5 loci, MSI-L (low) were those CRCs exhibiting 
instability at 1/5 loci, and MSS (microsatellite stable) or MSI-L CRCs, where no 
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unstable marker was detected out of the suggested five 90. 
The biological and clinical relevance of a MSI-L class is debated, as CRCs 
demonstrating instability at <30% of loci examined did not differ clinically from 
MSS ones 90. The significance of MSI-L is still widely contested at present 108-111, 
often quoting the intrinsic instability of CRCs and the possibility to find all CRCs as 
MSI-L should enough markers be analysed 112,113. It is thus not unusual to find MSI-L 
and MSS cancers grouped together in CRC studies. 
 The panel of mono- and dinucleotide markers suggested by the Bethesda 
group has been the subject of debate and revision, with a panel of five 
mononucleotides-only, of quasimonomorphic distribution, being considered as more 
specific for MSI-H (Table 1) 112,114,115. The new panel was also put forward to 
address concerns that dinucleotide repeats may be more specific to the MSI-L group 
than MSI-H, therefore once again highlighting discordance upon the subject. Notably, 
in the revised Bethesda guidelines 112 it was suggested to shift the threshold of MSI-H 
detection in the new mononucleotide panel from 2/5 (40%) to 3/5 (60%) markers. 
The revised quasimonomorphic panel is widely used today, albeit with the 40% 
threshold 
Table 1. Original (Bethesda) and revised (Quasimonomorphic) MSI panels 






Bethesda original       
 BAT-25 4q12 U62834 c-kit mono (A)25 
 BAT-26 2p21 U41210 MSH2 mono (A)26 
 D5S346 5q21-22 NM_005669 APC di (CA)26 
 D2S123 2p16 Z16551 MSH2 di (CA)21 
 D17S250 17q11.2-12 X54562 NF1 di (CA)24 
Quasimonomorphic       
 BAT-25 4q12 L04143 c-kit mono (A)25 
 BAT-26 2p21 U41210 MSH2 mono (A)26 
 NR-21 14q11 XM_033393 SLC7A8 mono (T)21 
 NR-24 2q11 X60152 ZNF-2 mono (T)24 
 NR-27 11q22 AF070674 BIRC2 mono (A)27 
              
 
Technically, both PCR and immunohistochemistry (IHC) for members of the MMR 
systems have been used, alone or in conjunction, to test for MSI. PCR is performed 
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using primers annealing at regions spanning either end of each microsatellite region 
in the five markers panels, and the resulting lengths of the amplified regions are 
compared between normal and tumour DNA. Immunohistochemistry is a colorimetric 
technique that can be used to show expression (or lack thereof) of proteins such as 
MLH1 and MSH2 in tumour tissue. Lack of MLH1 expression coincides in most 
cases with a defective MMR and consequently with MSI.  
Recently, the European society of molecular oncology (ESMO) systematically 
reviewed the current knowledge on definitions and methodologies of MSI testing 116. 
Among the study conclusions, the authors recommended the use of IHC for MLH1, 
MSH2, MSH6 and PMS2 as the primary method of MSI testing. In the case of 
difficult interpretation of IHC results, the more sensitive PCR method was 
recommended, and particularly with the use of the quasimonomorphic 
mononucleotides panel.  
 
1.3.3 MSI as a prognostic and predictive biomarker 
The notion that MSI represents a marker of less aggressive disease was noted 
immediately 87, and the panel held some years later in Bethesda suggested further 
exploration in the matter 90. In 2005, a systematic review of 32 studies and >7500 
patients with CRC concluded that patients with MSI had a significantly better overall 
survival (OS) than MSS ones 117. The exact mechanisms by which the immune 
system modulates MSI tumour growth and aggressiveness are yet to be fully 
understood. It is, however, widely accepted that the higher immune infiltration in 
MSI CRCs is the biological basis for their prognostic advantage over MSS cancers. 
Colorectal cancer arising through a defective MMR system harbours a notably higher 
number of frameshift and other mutations that produce truncated, dysfunctional 
proteins 111,118,119. Upon degradation, fragments of such proteins (termed 
neoantigens), are presented on the surface of tumour cells by major histocompatibility 
complex (MHC) molecules (Figure 12). By co-binding to MHCs on tumour or 
antigen-presenting cells, immune T-cells initiate maturation and become activated, 
with the whole process eliciting a specific immune reaction 118,120,121. This is for 
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example the case of TGFβRII, a gene containing an A8 microsatellite targeted by MSI 
within its coding sequence. The truncated peptides arising from its frame-shifted 
translation have been shown to interact with the population of immune cells 
infiltrating the tumour 122,123. At the same time, MSI-associated mutation in TGFβRII 
was also associated with improved survival in stage III CRC 124. 
 
 
Figure 12. Top: Mechanism of MHC-mediated T-cell activation/inhibition of activation by 
immune checkpoints (PD1:PD-L1, CTLA4:B7) and immunotherapeutic checkpoint inhibition. 
Bottom: differences in tumour-immune microenvironment between deficient- and proficient-
mismatch repair CRCs (dMMR and pMMR, respectively). Adapted from 125, copyright © 
2019 Springer Nature. 
 
Other than overall survival, MSI in CRC is thought to represent a prognostic 
biomarker of increased recurrence-free survival (RFS), too, as highlighted in reports 
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and meta-analyses 126,127. This observation holds true even when stratifying for stage 
II 128-130, which is important to define high-risk patients that may benefit from 
adjuvant treatment. The beneficial effect of MSI on RFS has also been reported as 
conditional to clinicopathological features such as proximal location 131,132, 
suggesting that right and left-sided MSI cancer behave differently. 
Some reports highlighted how the small proportion of MSI CRCs that develop 
recurrence do so preferentially at loco-regional (colorectum, peritoneum) rather than 
distant (lung, liver) sites. OS is usually worse in these patients 130,133. This is likely 
due to the higher rate of perforating tumours, eligibility issues for metastatic curative 
resection and the intrinsic resistance to common 5FU-based chemotherapies. 
The role of MSI as a predictive biomarker is multifaceted. When evaluated 
against traditional regimens of adjuvant chemotherapy, it is generally accepted that 
MSI patients do not benefit from 5FU adjuvant therapy, as opposed to MSS patients 
107,117,134-136. Resistance of MSI CRCs to 5FU-based regimens has been attributed to 
the overexpression of enzymes such as thymidylate synthase, a precursor of DNA 
synthesis specifically targeted by the drug 137,138. Treatment of stage III CRC is 
therefore mostly based on oxaliplatin. A study on stage III patients showed an 
improved RFS in MSI patients when irinotecan was supplemented to 5FU and 
leucovorin 132.  
Preclinical studies showed improved sensitivity of MSI tumour cells to irinotecan and 
mitomycin C, but the results need validation in clinical studies 139. Notably, the lack 
of precise data on MSI as a predictive marker of response to all the available 
chemotherapy warrants further investigation especially in stage II CRCs, where 
adjuvant therapeutic intervention is decided on a risk basis 140. 
 The same augmented immune response that is believed to improve prognosis 
of MSI CRC has recently proven of predictive value, too. At stage II, MSI CRCs 
have a better prognosis, however those that do progress to metastasise show poorer 
survival 141, as well as an increased expression of immune checkpoints regulators 
such as programmed death receptor 1 (PD1), its ligand PD-L1 and cytotoxic T 
lymphocyte antigen 4 (CTLA4) (Figure 12) 125,142. This observation prompted the 
 45 
notion that MSI cancers would respond better to immunotherapy, as recently 
confirmed in the case of PD-1 and PD-L1 blockade immunotherapy 143, not limited to 
CRC 144. At present, the Food and Drug Administration (FDA) in the US approved 
the use of anti-PD1 immune checkpoint inhibitors nivolumab and pembrolizumab in 
MSI CRCs, whilst the European medicine agency (EMA) has yet to evaluate the 
results of phase III studies 125.   
 
 
1.4 MSI in tetranucleotides (EMAST)  
 
After the initial discovery of microsatellite instability in 1993, researchers looked at a 
variety of microsatellites (mono-, di-, tri-, tetra-, penta-, and hexanucleotides) across 
a range of cancers. During the Bethesda meeting on MSI held in 1997, a variant of 
MSI concerning exclusively tetranucleotides was reported and defined as Elevated 
Microsatellite Alterations at Selected Tetranucleotides, or EMAST 90. Unstable 
tetranucleotides were by then found in lung, liver, head and neck, bladder, cervical, 
prostate, breast, colorectal and other cancers 145-151. EMAST, however, was not 
described in its molecular mechanisms and relationship to the better-defined MSI and 
was only briefly mentioned in the Bethesda report. 
Tetrameric repeats are approximately half as abundant as monomeric ones, and their 
density is higher in intronic and intergenic than exonic regions (Figure 13) 83. Exonic 
tetranucleotides densities are highest at chromosomes 7 and 22, and the most 




Figure 13. Microsatellites density in exonic, intronic and intergenic regions on individual 
human chromosomes. (A) Monomers (B) dimers; (C) trimers; (D) tetramers. Blue bars, 
exons; red bars, introns; yellow bars, intergenic regions. Adapted under creative commons 
(CC BY 4.0) from 83.  
 
Over the course of the past two decades, an increasing number of reports pointed to 
the presence of EMAST in a wide range of solid tumours, with diagnostic and 
pathological implications (Table 2, expanded from 152, appendix 1). 
Unlike MSI and despite the increasing number of reports linking EMAST to 
prognosis, no consensus exists to date upon which tetranucleotide markers and what 
cut-offs to use for its determination. Most of the EMAST markers used are found in 
non-coding regions, and it has been shown that tetranucleotides found in 
exonic/coding regions are not commonly unstable 153. A group of five markers, 
namely MYCL1, D20S82, D20S85, D9S242, D8S321, together with the two of five 
(40%) unstable markers as a cut-off is mostly used. 
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1.4.1 EMAST in non-colonic cancers 
In non-small cell lung cancer (NSCLC), instability at tetranucleotides was initially 
investigated in the early 2000s. EMAST was found at frequencies ranging from 35% 
to 65% of cases, associated with TP53 mutations and lacking phenotypical 
similarities with MSI 154,155. Further, in two studies reporting clinicopathological 
associations, EMAST was shown to correlate significantly with nodal metastases and 
squamous differentiation in one 156, and worse 5-year OS with no effect on DFS in 
the other 157. In three of the above-mentioned NSCLC studies EMAST was assessed 
as instability in at least one of 10-13 markers , whilst the last study grouped 
microsatellite assessment of di- and tetranucleotides together 156.  
EMAST was found also in tumours of the reproductive system, such as ovarian 
(13%) 158, endometrial (39%) 159 and prostate (3-25%) 145,160-162 cancer, usually with 
little or no overlap with MSI.  
Urinary tract cancers were also reported to display EMAST at incidences slightly 
higher in the bladder than in the kidney. In bladder cancer, association of EMAST 
with TP53 mutation is discordant 163,164, and association with clinical descriptives is 
yet to be fully described.  
Other non-colonic solid tumours displaying EMAST are head, neck, skin and 
pancreatic ductal adenocarcinoma 155,163,165,166, and a wider overview is given in 
appendix 1 152. 
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Table 2. Prevalence, study size and cut-offs of EMAST in published studies.  
Site Author, year Cohort size (n) markers cut-off Prevalence 
Bladder Xu et al. 2001 155 38 ≥1/12 21% 
 Danaee et al. 2002 163 57 ≥1/7 44% 
 Catto et al. 2003 167 89 ≥1/8 45% 
 Burger et al. 2006 164 117 ≥1/10 9% 
NSCLC Ahrendt et al. 2000 154 88 ≥1/13 35% 
 Xu et al. 2001155 47 ≥1/12 51% 
 Arai et al. 2013157 65 ≥1/10 65% 
Prostate Perinchery et al. 2000 162 40 ≥1/4 25% 
 Burger et al. 2006 160 81 ≥1/10 5% 
 Azzouzi et al. 2007 161 50 ≥2/4 4% 
Renal Xu et al. 2001 155 25 ≥1/12 12% 
 Catto et al. 2003 167 71 ≥1/8 23% 
Head and 
neck Xu et al. 2001 
155 18 ≥1/12 56% 
 Temam et al. 2004 165 54 ≥1/5 48% 
NM skin Danaee et al. 2002 163 61 ≥1/7 75% 
Ovarian Singer et al. 2004158 53 ≥1/6 13% 
Endometrial Choi et al. 2008 159 39 ≥1/6 39% 
PDAC Mori et al. 2018 166 40 ≥2/5* 45% 
CRC Haugen et al. 2008 168 117 ≥1/7* 60% 
only rectum Devaraj et al. 2010 169 147 ≥2/5* 33% 
 Yamada et al. 2010 170 88 ≥1/7 65% 
 Lee et al. 2010/2012 171,172 108 ≥2/5* 50% 
 Hamaya et al. 2015 173 230 ≥2/5 44% 
 Venderbosch et al. 2015 174 183 ≥2/5* 46% 
 Watson et al. 2016 175 151 ≥2/5* 23% 
 Koi et al. 2016 176 88 
≥1/7* and/OR 
≤2/7 of MSI 
panel 
62% 
 Lee et al. 2016 177 100 ≥2/5* 22% 
 Chen et al. 2019 178 1505 ≥2/5* 11% 
 Torshizi et al. 2019 179 159 ≥2/5 42% 
 Kuan et al. 2019 180 509 ≥2/5* 13% 
 Mohammadpour et al. 2019 181 157 ≥2/5* 40% 
Abbreviations: NSLC non-small cell lung cancer; NM skin non -melanoma skin; PDAC pancreatic duct adenocarcinoma; 
CRC colorectal cancer; MSI microsatellite instability. Studies marked with * utilized the same panel of five EMAST 
markers as in the present study, with or without additional markers. 





1.4.2 EMAST in CRC 
 
Prevalence 
EMAST, as MSI, remains most studied in CRC, where much of the available 
literature is concentrated. The frequency of EMAST in CRC is generally higher (up 
to 60%, Table 2) than the frequency of classical MSI (usually 15–20%) 152,170,171.  
Geographically, its prevalence was investigated prevalently in Asian cohorts, such as 
in Japan 168,170,176,182,183 (same core cohort, prevalence ca. 60%), Korea 171,172,176,177 
(22-50%) and Taiwan 178,180 (10-13%). In European 173,174 and Iranian 179,181 cohorts 
the recorded EMAST rate is at 40-46%. The only study in a USA-based cohort was 
based on rectal cancers separately, with a uniquely reported high rate of 33% for 
EMAST 169.  
The disparity of panels and cut-offs used, especially during the early discoveries on 
EMAST (Japanese cohorts), lead to a great variation in terms of frequencies reported. 
Of note, this issue is also supplemented by variation in cohort ethnicity background 
which, known to affect rates of canonical MSI, might have an influence in EMAST 
prevalence, too. 
 
Clinicopathological features and survival  
Presence of EMAST in adenomas and early-stage CRC is not well documented, with 
reports ranging from 0% 172 to 33% 171. In selected rectal cancers, EMAST was 
associated with advanced (stage III-IV) CRC 169. In unselected CRC, results are 
discordant 178,181, with most reports lacking significant association with TNM stage. 
Sidedness is also not unanimous, albeit a recent, large cohort study associated 
EMAST with cancers of the proximal colon 178.   
Histologically, patients with EMAST are often associated with poorly differentiated 
or mucinous (high grade) tumours 171,178,181,184, although some reports found no 
association with tumour grade 170,174,177 
EMAST CRCs were shown to harbour a greater infiltration of CD8+ T-cells in 
both the tumour and surrounding stroma 169,172, a feature usually associated with 
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better prognosis in MSI CRC.  
The relationship of EMAST with patients’ prognosis and survival is however not 
straightforward. On one hand, EMAST is most often reported as having no significant 
influence on survival 170,174,175,177,180,185. On the other hand, some reports associated 
EMAST with a worse prognosis, a shorter time to recurrence and development of 
distant metastasis in stage II and III CRC 179,182. These studies, however, grouped 
EMAST cancers with the MSI-L group, without addressing individual differences. 
Only one study, which is the largest to date (n >1500), reported improved disease-
specific survival in EMAST-positive patients 178. 
 
Biology of EMAST mechanisms 
The biological causes of EMAST are yet to be fully understood. Whether it is simply 
an exacerbation of the MSI mechanism, or a distinct pathway of instability is still 
unclear. MLH1 and/or MSH2 are the most common genetically (Lynch) or 
epigenetically (sporadic) silenced proteins in mononucleotides-confined MSI. MutSα 
(MSH2-MSH6) outcompetes MutSβ (MSH2-MSH3) at single mismatches repair, 
while repair IDLs longer than 1 bp (2-8) is shared between the two complexes in the 
current MMR model 106,186-190.  
On these bases, in 2008 Haugen and co-workers used the CRC cell line 
HCT116, harbouring biallelic inactivation of both MLH1 and MSH3 to examine 
stability at a series of mono and tetranucleotide repeats 168. The authors demonstrated 
an increase in the stability of microsatellites analysed when restoring either MLH1 or 
MSH3. Restoration of the MMR gene was achieved by whole chromosome transfer 
(chr. 3 for MLH1 and chr. 5 for MSH3), and a complete stabilisation of microsatellite 
repeats was observed upon concurrent 3 + 5 transfer. Although the effect on 
tetranucleotide loci was similar upon restoration of either member of the MMR 
system, the investigators concluded that MSH3 was alone responsible for instability 
at tetranucleotides (EMAST). The in vitro observation of limited mismatch repair 
activity at di- and tetranucleotides in MSH3-deficient CRC cell lines led to the 
suggestion that MSH3 deficiency could represent a shared mechanism for both 
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Figure 14. Putative culprits of MSH3 inactivation in EMAST, developed from data in 
183,191,192. IL-6: Interleukin-6. HIF-1α: Hypoxia-induce factor 1 alpha. ROS: reactive oxygen 
species.  
 
A proposed mechanism of MSH3 inactivation involves its translocation outside of the 
nucleus, and consequent loss of function, mediated by a chronic inflammation state 
and oxidative stress 185.  Both Interleukin-6 and reactive oxygen species (ROS, 
mimicked by H2O2 supplementation) were shown to dislocate MSH3 from the 
nucleus in CRC cell lines 191,192. Moreover, in vitro IL-6 treatment induced EMAST 
in otherwise microsatellite-stable CRC cells, in a process likely mediated by its 
downstream co-signalling molecule, STAT3 192 ( an overview of the proposed 
mechanisms is given in Figure 14). 
Transcriptional downregulation of MSH3 expression was also proposed as a 
mechanism for EMAST. GLUT1 (hypoxic marker) was found to be overexpressed on 
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EMAST CRCs, which were also linked to high-rate TP53 loss of heterozygosity 183. 
These observations led to the discovery of two putative hypoxia response element 
(HRE) in the promoter region of the MSH3 gene. It was thus hypothesised that two 
isoforms of hypoxia-induced factor 1 alpha (HIF-1α) could bind to such HREs under 
hypoxic condition, thus driving MSH3 protein downregulation 183 (Figure 14).  
DNA slippage in the poly(A) microsatellite contained in the coding region of 
the MSH3 gene, as well as single nucleotide variations, are relatively common 
(>30%) events in MSI CRCs 111,178. When isolating EMAST cases (EMAST+/MSI-), 
no specific MSH3 mutation correlation is seen at the genetic level 178. Epigenetic and 
post-translational modifications are, however, mechanism that can affect MSH3 
protein functionality without showing on sequencing experiments.  
Although mounting, the evidence on MSH3 involvement in EMAST is confined to in 
vitro models, as MSH3 expression in EMAST CRCs has been investigated by means 




1.5 The immune system and cancer 
 
The cells and function of the human immune system are grossly subdivided into two 
compartments, innate and adaptive (Figure 15). Innate immunity uses toll-like 
receptors to quickly recognise and tackle a broad spectrum of infecting microbes via 
either cytolysis or phagocytosis. Adaptive immunity, on the other hand, relies on T-
cell receptors’ exposure to antigens for a slower but highly specific immune response 
193,194. Other than cells, a series of soluble molecules such as chemo- and cytokines 




Figure 15. Components of the innate and adaptive immunity. Reproduced from 194, 
copyright © 2004 Springer Nature  
 
The host immune system presents with two opposing roles towards cancer 
development and progression. On the one hand, infectious pathogens, prolonged 
exposure to irritants or failure of self-regulating immune mechanisms all induce a 
state of chronic inflammation that can lead to inflammation-related cancers. 
Examples are H. pylori in the stomach, cigarette smoke and asbestos in the lungs, 
ulcerative colitis in the colon. Chronic inflammation resulting from exposure to such 
stimuli increases the local infiltration by immune effector cells belonging to the 
innate immune system, and may lead to pre-cancerous lesions 120.  
On the other hand, adaptive immunity can detect cancer-derived fragments of 
truncated, inactive proteins resulting from mutated and epi-mutated genes, called 
antigens 195,196. Tumour antigens are presented on the surface of immune cells 
engulfing dying tumour cells (or by the tumour cells themselves) via MHC 
molecules, effectively “educating” the adaptive immune system to react towards 
cancer, mounting an efficient immunosurveillance118,120. Main effectors of the 
adaptive immune system are B- and T-lymphocytes, of which multiple subclasses 
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exist. T-cells expressing the Cluster of Differentiation 8 (CD8) on their surface are 
referred to as cytotoxic T-cells, as they are able to induce apoptosis in those cells 
displaying antigens that activate an immune response 197.  
T-lymphocyte-mediated immune responses are initiated by the binding of their T-cell 
receptors to antigen-MHC complexes on antigen-presenting cells. This initial 
activation is complemented by a range of further receptor-ligand interactions, which 
can be co-stimulatory or co-inhibitory, thereby potentiating or suppressing immune 
response 196,198. Owing to their higher tumour mutational burden, and thus often 
referred to as hypermutated, MSI CRCs are associated with an increase output of 
tumour antigens. Their consequent higher immunogenicity is widely accepted 199 and 
found confirmation in the recent consensus molecular subtyping of CRC. As 
mentioned earlier, these cancers were classified on the basis of their transcriptomes 
within the “CMS1 MSI-immune” subtype 80.  
To survive, however, a tumour needs to escape and adapt to the host immune system 
and its multifaceted role57. In recent years, more light was shed on the acquired 
abilities of tumour cells to exploit some of the cellular mechanism fundamental to 
immune response to dampen or totally evade immunosurveillance (Figure 5). The 
reality of human anti-tumour immunity is extremely complex and the balance 
between immunity and tolerance is affected by a multitude of factors such as type of 
cells, molecules, metabolism, bacterial flora, as well as host and tumour’s genomic 
make-ups 196. 
The current knowledge in cancer-immune dynamics is only the “tip of the 
iceberg”, and already offers therapeutic targets and biomarkers that are currently 




An example of co-inhibitory mechanism parallel to antigen-TCR receptor binding are 
immune checkpoints, a complex system of intra- and intercellular signalling used by 
the adaptive immune response to decrease its magnitude. The discovery of co-
inhibitory signalling of CTLA-4 200 and programmed death receptor 1 (PD-1) 201, 
together with their suitability as immunotherapy targets in cancer, was awarded with 
the 2018 Nobel Prize in Physiology or Medicine to JP Allison and T Honjo 202. 
PD-L1 (also known as B7-H1 or CD274) is a single-pass transmembrane protein 
constitutively expressed on antigen-presenting cells and other non-hemopoietic cells 
203,204. PD-L1 expression can also be induced by cytokines and molecules such as 
interferons, tumour necrosis factor α (TNF-α), and vascular endothelial growth factor 
(VEGF) secreted by cells of the immune system in a paracrine fashion 203. 
Binding of T-cells’ PD-1 to its ligands PD-L1 and PD-L2 affects signalling of a range 
of molecular pathways (such as RAS, mTOR and p38 pathways) leading to 
diminished secretion of cytokines, as well as impaired proliferation and survival 203-
205. While fundamental to immune tolerance in healthy tissue, most cancers (including 
CRC) have been found to express PD-L1 and thus actively suppress the host T-cell-
mediated tumour toxicity (Figure 16) 203,205-208. PD-L1 expression in cancer is 
believed to be the result of either constitutive endogenous mechanisms, or induced as 
an adaptive response to the strong infiltration of PD-1- and interferon-γ (IFNγ)-
expressing lymphocytes 205,209. 
 Targeting of the PD-1/PD-L1 axis became thus of clinical relevance to 
overcome the resistance of a number of cancers to the surveillance of the immune 
system, with initial promising results in melanoma, lung and other cancers 205,207,210. 
Originally a poor therapeutic target in CRC 210, PD-1 blockade therapy regained 
momentum after the seminal finding of the increased expression and benefits of anti-
PD-1 immunotherapy in mismatch repair-deficient (dMMR)/MSI cancers 143. These 
effects were seen in terms of both objective response rate and progression-free 
survival. As a result, multiple phase II and III clinical trials are to date ongoing to 
assess the benefits of anti-PD1/PD-L1 therapy in this subgroup of CRC 125,211 (Figure 
16). As mentioned above, the FDA approved immunotherapeutic drugs 
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pembrolizumab and nivolumab in 2017 for second-line treatment of MSI CRC 125. 
The proportion of metastatic CRC with MSI is however low (2-5%), and reliable 
predictive biomarkers of anti PD-L1 immunotherapies are needed to expand the CRC 
population benefitting from it 211. 
 
Figure 16. Tumour immune response and its regulation. MSI produces high numbers of 
neoantigens. Neoantigen presentation by tumour cells to TCRs on naïve T-lymphocytes. In 
presence of co-stimulatory binding (not shown) determines the maturation of T-cells into 
effector lineages, thereby inducing immunity. Tumour cells able to express PD-L1 can 
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induce immunosuppression of effector T-cells. Reproduced with permission from18 , 
Copyright © 2018 Massachusetts Medical Society. 
 
This is especially true in light of the development of a class of immune checkpoint 
inhibitors (such as atezolizumab or durvalumab, currently in phase I-III combination 




Although not a new concept, the improved prognosis of CRC patients exhibiting a 
higher density of tumour-infiltrating T-lymphocytes has instigated further 
investigation in tumour immunology research in the past decade 120,212-214.  
One such example is the Immunoscore® (IS), which quantifies certain immune cells 
infiltrating the tumour area and correlates it to prognosis in CRC 215,216. In the initial 
development of the IS, expression of markers related to two lymphocyte populations 
(CD8, cytotoxic, and CD45RO, memory T-cells) was assessed in tumour centre (TC) 
and invasive margin (IM) of CRCs 217. Aided by digital image analysis, counting 
positive cells in each field produces a score between I0 and I4, representing the 
degree of immune reaction strength (Figure 16) 218. Patients with high densities of 
CD8 and CD45RO cells have better prognosis, with recurrence rates of I4 patients 
(high IS) as low as ca. 5%, and a 5-year overall survival rate of 86%. On the other 
hand, relapse rate of patients with low densities of CD8 and CD45RO-positive cells 
(low IS) was as high as 75%, with a 5-year overall survival of ca. 28% 217.  
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Figure 17. Immunoscore classification. The densities of CD3+ and CD8+ 
(immunohistochemistry, top panels) are categorized into Hi (high) or Lo (low) in each 
tumour region (TC and IM, lower left panel), giving four individual scores. Patients are then 
stratified accordingly into I0 to I4 groups, depending on the total number of high densities 
observed (lower right panel). Adapted from 219 Copyright © 2016 Oxford University Press. 
 
The general T-lymphocyte marker CD3 later substituted CD45RO to obviate 
recurrent background staining problems related to the memory T-cell marker 218. To 
further increase prognostic ability, both CD3 and CD8 are assessed separately in the 
tumour centre and invasive margins of each tumour 216,218,220.  
Both individually and – more strongly – combined, CD3 and CD8 abundance has 
been shown to be consistently lower in relapsing patients and superior to the TNM 
staging system in terms of prognostic ability 219,221,222. The prognostic ability of IS 
was also individually confirmed in rectal cancer 223. 
In a recent multicentre study, IS was validated by an international consortium as 
highly prognostic in both uni- and multivariate analyses independent of patient age, 
gender, T and N stage, MSI, and other prognostic factors 220.  
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The scoring system was “refined” in the last report to use three (low-intermediate-
high) rather than five (I0 through I4) categories. Methods, including cut-offs and 
mathematical operations, were also disclosed to aid reproducibility of the study 220. 
The consortium advocates for the implementation of the IS as an integrative 





1.6.1 Tumour biomarkers 
The bridge between the notion of no two tumours being alike (nor can be treated 
alike) and the recent excitement towards “personalised medicine” are cancer 
biomarkers. The National Institute of Health (NIH) defines biomarkers as 
  A biological molecule found in blood, other body fluids, or tissues that is a 
sign of a normal or abnormal process, or of a condition or disease 224 
A broader way to define biomarkers would include any measurable change imputable 
to a disease that would classify patients into subgroups relevant to a clinical endpoint. 
According to which endpoint it serves, in the clinical settings a biomarker is often 
described as: 
Diagnostic: as able to identify the presence/absence of a disease, therefore 
guiding towards a given diagnosis of a disease. 
Prognostic: as able to foresee the outcome of a diagnosed disease, for example 
survival. 
Predictive: as able to forecast the response to a therapy, as in the case of 
mutations in the RAS-pathway that predict no response to anti-EGFR therapies, as 
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the KRAS mutation is downstream of the EGFR receptor and anti-EGFR therapy is 
thus not able to block this pathway. 
Biomarkers can also serve as surrogate endpoints in very specific and validated cases, 
where reaching the clinical endpoint of an ideal trial is impractical or unethical 225. 
An example is using progression-free survival as a surrogate endpoint of overall 
survival for fluoropyrimidine use in advanced CRC 226. 
Consideration of patients’, tumours’ and tumour biology’s heterogeneity have today 
replaced the outdated concept of “one drug fits all” 227. Fluoropyrimidines such as 
5FU, however, are still the pillar of most adjuvant combination treatments in CRC, 
despite the progress in the understanding of cancer biology made since they were first 
proposed 228. 
Thanks to the rapid advancement of technology in the field of biomedical research 
(e.g. high-throughput techniques such as next-generation sequencing or microarrays), 
large numbers of promising putative biomarkers have emerged. Nevertheless, the gap 
between the number of proposed biomarkers and those entering clinical practice is 
vast 229,230, as are the resources lost in the process. The need for reliable biomarkers 
reaching clinical studies is therefore increasing and is addressed by the qualitative 
improvement of pre-clinical ones.  
 
 
1.6.2 Good practice in biomarker research 
A good biomarker candidate should satisfy a series of parameters assessing its 
analytical and clinical validity, as well as ethical and financial implications 229,231. 
Is the biomarker’s test reproducible and accurate? Are sensitivity and specificity of 
the test satisfactory? Does detection of the biomarker directly or indirectly improve 
health care? Do the benefits derived from the test outweigh the financial impact on 
public health? These all are issues that can halt the clinical implementation of a novel 
biomarker along the development process and need be addressed with rigorous, sound 
and peer-reviewed analysis. 
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To reach analytical validity, arguably the greatest issue in biomarker research is 
reproducibility of results from pre-clinical studies. Far too often the promising results 
generated in academic environment fail to reproduce in more advanced stages of 
biomarker discovery, as for example in the case of drug targets reaching phase II 
stage in industry 232,233. 
In 2011, a study from Bayer Health Care assessed reproducibility of 67 projects by 
comparing in-house obtained data with that originally generated in academic, pre-
clinical studies 234. The rate of concordance was as low as 20-25%. Similarly, only 
11% of pre-clinical studies considered could be reproduced at the biotechnology 
company Amgen, in results published the following year 235. 
Reasons for such a high rate of failure encompass everything from poorly designed 
trials to undetailed published methods, lack of standardisation and all the way down 
to inter-laboratory environmental and technical conditions 236.  
 
Sample acquisition 
In both prospective and retrospective cohort-based studies such as the present work, 
patient-derived substrates such as tissue and fluids constitute the primary source of 
study material. Sample acquisition practices, from collection to storage and further 
processing, can have a profound effect on the quality of nucleic acids, proteins and 
other molecules derived from such materials 237. In a typical example of formalin-
fixed, paraffin-embedded (FFPE) tissue samples, exposure to formalin for extended 
periods of time is known to induce fragmentation, cross-linking, strand breaks and 
denaturation of nucleic acids 238. Factors such as time from collection to fixation and 
time spent in fixative (formalin) solution can even affect protein expression, and 
therefore dramatically affect downstream analyses, such as alignment of sequencing 




Standardisation of methods 
Selection bias is a common threat in cohort and case-control studies, and is defined as 
“a non-random imbalance among treatment groups of the distribution of factors 
capable of influencing the end points” 241. Even the highest standards of sample 
handling can be nullified a priori by improper or (both voluntarily and involuntarily) 
biased subject selection. Efforts to avoid sources of bias and to openly address them 
upon their presentation is thus imperative for transparency and reproducibility of 
scientific research.  
A further issue, particularly common in explorative studies, is the standardisation of 
the methodology used. Gene/marker panels, cut-offs, antibodies, detection systems, 
laboratory consumables are but a few examples of the tools for which an ample 
selection is available both on the market and the scientific literature. Each can in turn 
add to the variability to pre-clinical experiments 236. In the example of EMAST, over 
the course of the past decade several different panels and individual markers have 
been used to assess its incidence, with obvious implication on results (Table 1).  
Insufficient description of the methods, or improper use of statistical methods have 
also become issues adding to the difficulties in reproducing results 236,242,243. 
A further layer of complexity can be found in analyses that are typically evaluated by 
subjective scoring, such in the case of IHC. Other than the fixation/storage processes 
and the type of antibody/staining protocol employed, inter-operator subjectivity can 
affect the final results of these type of analyses 244,245.  
The increasing use of automation, such as robot pipettors, autostainer instruments and 
digital image analysis software can however reduce technical variability and are 
being increasingly adopted in wet-lab practice 246,247. 
 
Calls for quality improvement in pre-clinical studies  
Transparency and accuracy of study reports are indispensable to assess their 
strengths, weaknesses, and impact. Scientists to clinicians to public healthcare 
legislators use the existing reported evidence in order to plan experiments, treatment 
strategies and healthcare guidelines. In other words, successful integration or 
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substitution of current practices depends on evidence, and an improperly reported 
study loses value even when it is flawlessly designed. 
The EQUATOR (Enhancing the QUAlity and Transparency Of health Research) 
network 248 is an international initiative aimed at the implementation of robust 
guidelines on study reporting, to strengthen the quality and usefulness of published 
health research.  
The initiative works as a repository for reporting guidelines tailored to specific study 
types, from case reports to randomised trials (CONSORT), systematic reviews 
(PRISMA), observational cohort studies (STROBE) and animal pre-clinical studies. 
Moreover, specific extensions to practices reporting such as biospecimen handling 
(BRISQ) and tumour biomarker prognostic studies (REMARK) are available to 
improve quality of reports. Guidelines commonly consist of n-item checklists for 
authors to fill and submit together with their manuscripts, of which we report three 
examples. 
The REMARK (REporting recommendations for tumour MARKer prognostic 
studies) 249 was developed jointly by the US National Cancer Institute (NCI) and 
European Organisation for Research and Treatment of Cancer (EORTC). The 
guidelines were issued to address the disproportionally low output of clinically useful 
biomarkers stemming from an ever-increasing number of research efforts and reports. 
The REMARK checklist is aimed at encouraging authors to consider and report on a 
number of common issues regarding design, method and analysis of tumour 
biomarker and prognostic studies 250,251. The study in paper IV (Watson et al., 
submitted) was submitted with the REMARK checklist. 
The STROBE (Strengthening the Reporting of Observational Studies in 
Epidemiology) checklist refers to the standardisation and improvement of 
observational study reports 252,253. It aims at correct presentation of planning, methods 
and findings, and was made available in multiple languages, both as a whole 
(combined) checklist and as sub-checklists specific to cohort, case-control and cross-
sectional studies. The study in paper II (Watson et al, Ann Sur Oncol, 2019) and 
paper IV (Watson et al. submitted) were submitted alongside the STROBE checklist. 
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The BRISQ (Biospecimen Reporting for Improved Study Quality) checklist 254 
was developed to address the gap existing in EQUATOR-endorsed guidelines on 
handling of human biospecimens. It is thus a checklist intended to be used alongside 
reporting guidelines for all studies involving human biospecimens. It is of particular 
importance especially when considering the experimental variability deriving from 
non-uniform handling of patient material before downstream analysis. The Methods 
section of this dissertation (3.2 Material and data collected) are written in 




2. AIMS OF THE STUDY 
The aim of this PhD work is to characterize a defined cohort of patients with CRC in 
terms of its microsatellite instability at both mono and tetra-nucleotides, as well as the 
type of immune cells infiltrating the tumours. The purpose is to explore potentially 
useful biomarkers that will aid in classification of patients into prognostic groups 
beyond the current TNM system. The identification of clinical and molecular traits 
that have an influence on patient prognosis serves to improve accuracy of cohort 
stratification and may allow for advanced management and surveillance. 
Specific aims of this project are: 
1. To investigate EMAST to MSI distribution in CRC, and the relationship with 
clinicopathological characteristics of patients <75 years undergoing systematic 
surveillance after surgery (paper I). 
 
2. To investigate MSH3 expression in CRC and assess whether loss of MSH3 is 
related to the EMAST phenotype (paper II). 
 
3. To further evaluate the clinical relevance of EMAST in a prospectively 
collected cohort of stage I-III CRC, including age- and comorbidity-related 
aspects (paper III). 
 
4. To investigate the immunological context in EMAST by quantitative profiling 
of CD3+ immune cells and CD8+ cytotoxic T-lymphocytes and PD-L1-









3.1 Study populations 
Two different cohorts were used in the present work. In both cases, patients were 
recruited at Stavanger University Hospital (SUS), Stavanger (Norway). The hospital 
covers today a primary catchment area of approximately 370,000 inhabitants of no 
extreme socio-economic disparities, under the Norwegian universal health coverage 
system. There are no private practices or competing clinical services in the region. 
The study cohorts can therefore be regarded as population-representative. 
The first study population (paper I) consists of a sub-cohort (N = 196) derived from 
larger (N = 314) study population of consecutive patients with stage I through III 
CRC who underwent surgery with curative intent with negative resection margins R0 
between 1996 and 1999. Of the 314 patients who underwent surgical resection, 196 
were enrolled on a systematic surveillance program in an intent-to-treat basis and 
according to the guidelines of the Norwegian Gastrointestinal Cancer Group 
(NGICG) at the time. This excluded patients >75 years and stage III (pN+) not fit for 
adjuvant chemotherapy. Further exclusion from the sub-cohort was applied in the 
case of distant recurrence, where the patients were deemed not fit for a second 
surgery.  
Clinicopathological information was recorded, and follow- up was updated as of July 
23, 2011, thus providing up to 15 years follow-up after surgery.  
The study was approved as a quality assurance project by the Regional Ethics 
Committee (REK) of the Health Trust of Western Norway (Helse Vest), document 
#2010/3414. 
The second cohort (papers II-IV) is a sub-group of the first patients recruited 
consecutively in the Assessment of Clinically Related Outcomes and Biomarker 
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Analysis for Translational Integration in Colorectal Cancer (ACROBATICC) project 
(Described in 255, appendix 2). ACROBATICC is a prospective and consecutive 
population-based biobank of primary and metastatic colorectal cancer, registered with 
the identifier NCT01762813 (www.clinicaltrials.gov). 
Patient recruitment started as of January 2013 and is to date ongoing (N>1100). Upon 
scheduling of curative surgery (either primary, metastatic or both), all consecutive 
patients aged ≥18 years of age amenable to curative-intent surgery for CRC and who 
could provide written informed consent were eligible for inclusion.  
The study was approved by the regional ethics committee (REK, #2012/742). 
 
3.2 Material and data collected  
3.2.1 Biobanking and database building 
Personal identifying information such a social security number (fødselsnummer) and 
names/surnames of the patients were censored via the use of a unique patient 
identifier stored in a password-protected file. This information was therefore not 
available to the analysts during data processing. 
Under the ongoing ACROBATICC study, each patient is assigned an ACRO-number 
upon inclusion in the study via signed informed consent. Each sample of patient-
derived material collected is then marked with unique material (m####) identifier 
numbers. Further, each processed material such as DNA extracted from tissue is also 
assigned a unique identifier (p####) (Figure 18). The vessels containing three 
aliquots of DNA extracted from a single patient-derived specimen would therefore 
each bear a label with a unique p-number, the same m-number linking to the original 
material from which it was derived, and an ACRO-number belonging to an individual 
patient. 
Fresh-frozen and FFPE tissue are obtained at each round of surgery (i.e. new 
collection upon eventual metastatic surgery) under the ACROBATICC study. Blood, 
plasma and serum are collected both pre-surgery (at inclusion) and again at the first 
follow up visit (scheduled according to health council guidelines 19). 
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 For data analysis, patients’ clinicopathological information was retrieved 
from the electronic patient record (EPR). All variables considered were appropriately 
classified and re-anonymised, connecting them to each patient’s ACRO-number. 
Coding of categorical variables was performed where appropriate and all the 
information plotted in a password-secured SPSS file (v. 25, IBM software). Statistical 
methods used were described in each individual paper. 
 
 
Figure 18. Example of biobanking and unique identifier assignation 
 
  
3.2.2 Formalin-fixed, paraffin embedded tissue (FFPE):  
Patient-derived tissue is fixated in a 10% neutral-buffered formalin solution, for a 
period that ranges between 8 hrs (e.g. biopsies, small specimens) to 96 hrs (e.g. 
hemicolectomies), according to sample size and to ensure full penetration of the 
fixative. Extended macroscopic analysis and excision of the tumour and normal 
sections are then performed by an experienced pathologist. Sections resulting from 
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the resection margins, deepest infiltration, tumour centre, eventual lymph nodes, 
eventual omentum, and normal epithelium are placed in colour-coded cassettes and 
embedded in paraffin. Formalin-fixed, paraffin-embedded blocks are then sectioned 
on a microtome to a thickness of 3-5µm and mounted on Superfrost glass slides for 
haematoxylin and eosin (H&E) staining, as well as eventual immunohistochemical 
colouring if requested by a pathologist. H&E slides are then used to confirm or 
eventually update the clinical staging of the tumour and provide additional 
microscopical information such as tumour cell content, degree of tumour infiltration, 
necrosis and mucinous content. Paraffin blocks are then stored in an archival room 
kept at 15 degrees Celsius (unstained, glass-mounted slides kept at 4 degrees) until 





3.3.1 Multiplex PCR and Fragment analysis 
PCR is a technique that relies upon modified polymerases, specifically designed 
primers and unbound nucleotide supplementation to amplify desired stretches of 
DNA from a template of choice. Primers are designed to be complementary to 
regions flanking the segment of interest. An initial step at high temperature allows the 
template DNA to denature, allowing the two complimentary strands to dissociate.  
Thereafter, temperature is cycled constantly at specific levels to allow annealing of 
the primers and the ligation of the correct series of nucleotides to replicate the 
template DNA. The constantly cycling denaturation-annealing-extension steps and 
the stoichiometric abundance of both primers and unbound nucleotides allows for an 
exponential number of copies of DNA to be created (2n copies at 100% efficiency, 
where n is the number of cycles). Length and G/C content of the primers greatly 
affect their melting temperature (Tm), at which at least 50% of the primers and their 
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complementary sequences on the template DNA are bound together. To allow for 
specific annealing of the primers, their careful design and relative reaction 
temperature conditions need to be achieved, as the energy required for each of the 
four nucleotides to bind to its complementary is specific.  
Multiplex PCR reactions can be carried out where more than one stretch of DNA is 
amplified, via the use of multiple pairs of primers. The high specificity of primers’ 
annealing temperatures therefore proves these experiments challenging in terms of 
optimisation. All the primers in the pool used should be designed to achieve: 
• A narrow Tm range (within 3-5ºC) and a balanced G/C content to allow for 
simultaneous PCR annealing 
• High degree of specificity to the targeted region to avoid biased amplification 
of one amplicon over another caused by competition of primers in the same 
reaction 
• Lack of inter-primer complementarity, which would cause primer 
dimerization and consequent stoichiometric imbalances 
The above-mentioned parameters are only a few of those affecting the outcome of a 
PCR reaction, and even established protocols need to undergo lab to lab optimisation. 
In the present work, both MSI and EMAST were assessed through two independent 
multiplex reactions, with five primer pairs each. 
  
3.3.2 Immunohistochemistry 
IHC is a technique used to spatially visualise specific antigens in a tissue (-histo) 
sample, which relies on specificity of antigen-antibody (immuno-) binding. To aid 
visualisation of antibody-bound antigens at the cell level under light microscopy, 
secondary antibody-linked molecules are used that precipitate upon incubation with a 
substrate (Figure 19). 
After sectioning to a thickness of 2-5µm, the FFPE tissue slice is mounted on a glass 
slide, which cycles through a series of steps. These are:  
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• rehydration of the sample  
• retrieval of eventually masked antigens by either heat-induced or enzymatic 
methods 
• blocking of endogenous enzymes that can interfere with the detection system 
• primary antibody binding and detection system (Figure 19 A-E)  
• substrate addition and chromogen precipitation (Figure 19 F-G) 
• counterstaining  
• dehydration of the sample 
• application of a glass cover 
Sample collection, pre-treatment (fixation, embedding) and storage can however 




Figure 19. Principles of immunohistochemistry. (A) direct antigen detection. (B-E) indirect 
antigen detection with secondary antibody conjugation methods. (B) secondary antibody 
conjugation. (C) Labelled streptavidin-biotin (LSAB). (D) Avidin-biotin complex (ABC) (E) 
Dextran backbone polymer conjugation. (F) Upon addition of a substrate, the chromogen 
precipitates. (G) The original antigen location is marked by the chromogen colour. 
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Choice of appropriate positive (e.g. a tissue known to contain the antigen, genetic 
knock-in) and negative controls (e.g. isotype controls, genetic knock-outs, tissue 
known not to express the antigen), especially in the clinical setting, is also important 
256. Selection of antibody, pH and chemical formulation of buffers, blocking of 
endogenous enzymatic activity and antigen retrieval methods need often fine-tuning 
before a staining can be considered true 244. 
The widespread use of IHC for diagnostic purposes brought the need for 
standardisation of methods, to avoid the multiple source of experimental variation 
this technique is subject to. Most protocols can therefore be largely automated today, 
with benefits towards reproducibility.  
 
3.3.3  Digital Image Analysis 
Traditionally used in pathology as a diagnostic tool, IHC is today increasingly 
employed in prognostic and predictive tests. As guidelines for treatment often rely on 
IHC analyses for disease biomarkers, interpretation of results should be as 
unequivocal as possible. 
Other than the cells of interest (those where the biomarker assessed has validity), 
histological samples contain numerous other structures, such as different cell types, 
blood vessels and lymph nodes. Moreover, rarely expressed antigens and artefacts 
induced by for example tissue folding or poor dispersion of reagents are all 
disturbances which might further complicate scoring of immunostaining. Manual 
(visual) interpretation of IHC is therefore time-consuming and requires highly skilled 
and experienced pathologists. One major pitfall is however the variation and 
involuntary bias intrinsic in the subjectivity of the scoring process, which often 
affects inter- and intra- operator reproducibility 257-259. 
Various semi-quantitative scoring methodologies have been proposed and are 
currently in place across laboratories. These are commonly obtained by multiplying a 
categorised score for staining intensity (e.g. absent, weak, strong) by the pure or 
classified percentage of cells stained. Examples are the histology-score (H-score, 
range typically 0-300) 260,261, staining index (SI, range 0-9) score or the Allred score, 
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where intensity and extent scores are added, not multiplied (range 0-8) 262. Although 
helping towards standardisation of methods, these score systems still largely rely on 
observer accuracy and establishment of cut-offs, thus open to interpretation 
variability. 
The development of automated and semi-automated digital image analysis software 
have the potential to reduce discrepancies in interpretation, and increase output 263. 
Digital image analysis means using computer-based algorithms to extract quantitative 
and qualitative information from digitalised images. The process of digitalisation 
converts an image into discrete quantitative variables (e.g. pixel depth, pixel 
connectivity, colour vectoring such as RGB or HSV). Once converted into numerical 
values, the images can be pre-processed and manipulated to achieve a series of 
enhancements, such as background noise reduction or sharpening of colour contrasts 
(Figure 20). The enhanced image can then be segmented using a range of supervised 
or unsupervised methods. Image segmentation refers to the process of effectively 
separating objects in defined classes based on any feature, such as texture in the case 
of tumour-stroma separation, or colour in positive-negative IHC stain. Classification 
algorithms can be applied in-line (e.g. one after the other) and developed using 
different methods. One such methods relies on Bayes’ probabilistic theorem 264, 
which simply stated makes decisions based on probabilities derived from the results 
of pre-existing data. Bayesian classification is a supervised method of segmentation, 
as it relies upon the establishment of a training set. 
Once appropriately classified, the image can be further manipulated to aid extraction 
of data, by for example colour-coding the created classes. Visual aids can be 
implemented, by stacking additional algorithms, to select areas in an unbiased way. 
An example is the inspection of rarely or over-expressed antigens, where manual 
picking of areas of max/min positivity can prove challenging. Creating visual 
hotspots based on classified positive/negative labels can help selecting the right 
region of interest. The hotspot approach has been implemented in the Norwegian, 
Danish and Swedish pathology guidelines 265-267 for its documented utility in the 
evaluation of biomarkers of difficult interpretation, such as Ki67 in breast cancer 268. 
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The use of digital platforms to capture, store, share, analyse and report pathological 





Figure 20. Colour deconvolution of a digital image, in this case CD8 staining (DAB staining, 
brown) in colon tissue (A). Through digital image analysis, the red, green and blue (RGB) 
components of the image can be isolated and manipulated, to highlight colour contrasts. In 
this case the blue haematoxylin (B), or the brown DAB staining (C) counterstain can be 
highlighted to provide the training parameters to a classification algorithm. The algorithm 
can then overlay a custom-coloured label to the component wanted (in this case 
membrane-bound DAB, labelled in pink) (D). The result can be viewed in the original RGB 
format, with labelled components (E) and mathematical operations can be performed based 






4. RESULTS OF THE STUDY 
 
 
In paper I (Watson et al., Cancer Medicine, 2016) we evaluated EMAST prevalence 
and association with MSI and other clinical and tumour-specific characteristics in a 
consecutive, population-based series of stage I–III colorectal cancers <75 years who 
were eligible for systematic surveillance according to national guidelines at the time 
(1996-1999). MSI and EMAST were assessed using multiplex PCR with primers 
amplifying two sets of five microsatellite markers. Of 151 patients included, 33 
(21.8%) had MSI and 35 (23.2%) were EMAST+, with an overlap of 77% for 
positivity, (odds ratio [OR] 61; p < 0.001), and 95% for both markers being negative. 
EMAST was more prevalent in colon than rectum (86% vs. 14%, p = 0.004). 
EMAST+ cancers were significantly more frequent in proximal colon (77 vs. 23%, p 
= 0.004), had advanced T-stage (T3-4 vs. T1-2 in 94% vs. 6%, respectively; p = 
0.008), were larger (≥5 cm vs. <5 cm in 63% and 37%, respectively; p = 0.022) and 
had poorly differentiated tumour grade (71 vs. 29%, p < 0.001). Furthermore, 
EMAST+ tumours had a higher median number of harvested lymph nodes than 
EMAST− (11 vs. 9 nodes; p = 0.03). No significant association was found between 
EMAST status and age, gender, presence of distant metastases or metastatic lymph 
nodes, and overall survival. Overall, survival was not influenced by the presence of 
EMAST, although a non-significant difference toward worse survival in node-
negative colon cancers was noted. 
In paper II (Watson et al., Translational Oncology, 2019), we sought to investigate 
and potentially validate whether EMAST was attributed to loss of MSH3 protein 
expression by IHC. Results from fragment analysis of multiplex PCR used to assess 
MSI and EMAST were cross-examined with MSH3 protein expression, using digital 
heatmap-derived hot spot image analysis (digital pathology). Of 152 patients, 
EMAST was found in 50 (33%) and exclusively in the colon. Most EMAST-positive 
cancers had instability at all five markers, and EMAST overlapped with MSI-H in 
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42/50 cases (84%). The most frequently altered tetranucleotide markers were D8S321 
(38.2% of tumours) and D20S82 (34.4%). Subjective evaluation of MSH3 expression 
by IHC in tumour cells found <10% negative cells in all samples, most being <5% 
negative. Digital analysis improved the detection but showed a similar spread of 
MSH3 loss (range 0.1-15.7%, mean 2.2%). Hotspot MSH3 negativity ranged between 
0.1 to 95.0%, (mean 8.6%) with significant correlation with the whole slide analysis 
(Spearman’s rho = 0.677 p < 0.001). Loss of MSH3 expression did not correlate with 
EMAST in our study, thus rejecting the causal mechanism hypothesis.   
In paper III (Watson et al., Annals of Surgical Oncology, 2019) we analysed a 
population-based, consecutive sub-cohort of surgically treated stage I–III CRC 
patients, derived from the first 200 included in the ACROBATICC study. MSI and 
EMAST, together with clinicopathological characteristics and associations thereof 
were reported as OR and survival was presented as hazard ratios (HR) with 95% CIs. 
Of 161 patients included, 25% were aged >79 years EMAST (31.7%) and MSI-H 
(27.3%). We found a large overlap in the prevalence of the two types of microsatellite 
instability, where 82.4% of EMAST were also MSI. EMAST had the highest 
prevalence in the proximal colon (OR 15.9, 95% CI 5.6–45.1; p < 0.001) and in 
women (OR 4.1, 95% CI 1.9–8.6; p < 0.001), and were poorly differentiated (OR 5.0, 
95% CI 2.3–10.7; p < 0.001). Compared with EMAST-negative patients, EMAST-
positive patients were older (median age 77 vs. 69 years; p < 0.001), leaner (median 
weight 67.5 vs. 77 kg; p = 0.001), had significantly higher rates of hypoalbuminemia 
(24% vs. 6%; OR 2.3, 95% CI 1.5–3.6; p = 0.002) and anaemia (45% vs. 20%; OR 
3.3, 95% CI 1.6–6.8; p = 0.001), and had elevated preoperative C-reactive protein 
(CRP) levels (51% vs. 34%; OR 1.9, 95% CI 1.0–3.9; p = 0.046). Improved 
recurrence-free survival was found in both MSI and EMAST subtypes. In 
multivariable analysis, node status (pN+), together with elevated CRP and MSI-
positive, were the strongest prognostic factors for recurrence-free survival. We thus 
found EMAST in CRC to be associated with an older, leaner, and frailer phenotype 
with a lower risk of recurrence.  
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In paper IV (Watson et al., submitted) the relationships between EMAST and PD-
L1, CD3 and CD8 expression in the invasive margin or tumour centre (Immunoscore) 
were investigated in relation to risk of disease recurrence. A total of 149 stage I-III 
CRCs patients, with a median follow up of 60.1 months were included, with 
recurrence-free survival (RFS) as the main endpoint. Difference in survival between 
groups were assessed by log rank test with univariate Cox regression for hazard ratios 
(HR) and 95% confidence intervals. Patients with PD-L1+ tumours (7%) were older 
(median 79 vs. 71 years, p = 0.045) and more likely to have EMAST+ cancers (OR 
10.7, 95% CI 2.2-51.4, p = 0.001). Recurrence-free survival was better in cancers 
with PD-L1+ immune cells (HR 0.35, 95%CI 0.16-0.76, p = 0.008, independent of 
EMAST) and high Immunoscore (HR 0.10, 95%CI 0.01-0.72, p=0.022). Patients with 
PD-L1+ immune cells showed also better disease-specific survival (HR 0.28, 95%CI 
0.10-0.77, p = 0.014).  
Only tumour-centre (but not peritumoral-immune) PD-L1 expression correlated with 
EMAST. Lymphocytic infiltrate and peritumoral rather than intratumoral PD-L1 








Despite the constant improvements in health care and disease management, CRC 
registers almost 900,000 deaths every year, its rates are steadily increasing, and it is 
projected to reach 2.5 million new cases in 2035. Improving accuracy of early 
diagnostic tools and patient stratification through reliable biomarkers is therefore of 
high importance. The prognostic and predictive value of biomarkers such as 
microsatellite instability and the concert of tumour-immune interaction, as they get 
better elucidated, show promise in this advancement. Although applying to relatively 
small subsets of the CRC population, ca 20% MSI cases out of 2.5 million in 2035 
still account for 500,000 patients, among which may be those who benefit from 
targeted therapies. Should EMAST, occurring at higher rates of both incidence and 
instability, prove of equal clinical value in the future, the effect may be even greater. 
It is thus important to keep on generating data that help resolve patient heterogeneity. 
 
 
5.1 The patient with EMAST in CRC 
 
We found EMAST incidences of 22% and 32% in our two cohorts. While the latter is 
more in line with other reports on EMAST in CRC, the lower incidence in the 
archival (paper I) cohort may be attributable to both the younger age (<75 years) and 
the higher prevalence of rectal cancers. In both cohorts we indeed associated EMAST 
with colon rather than rectum, a finding concurrent with other studies 174,177,178,184.   
The reported incidence of EMAST is subject to the range of markers analysed and 
cut-offs used in individual analyses. Initial reports described EMAST as being 
present at high rates in CRC (>60%) 168,170. The authors, however, used a low cut-off 
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(1/7 markers) and therefore identified high numbers of EMAST-positive patients 168.  
EMAST was also initially associated with the MSI-L subgroup of CRCs 168, however 
in the CRC population analysed by the authors both MSI-H and MSI-L overlapped 
completely with EMAST. It is thus unclear how the same association was not drawn 
between EMAST and MSI-H. Moreover, as mentioned earlier, there is debate upon 
whether MSI-L truly represents a subclass of CRC, and rather a consensus that it does 
not 111.  Notwithstanding the more frequently reported overlap with MSI-H phenotype 
174,175,177,178, the MSI-L/EMAST group is still sometimes reported in studies 176,185. 
A further point that may add to the variation in reported frequencies of EMAST is the 
ethnicity of the cohorts in which it is analysed. As discussed in papers II and III, is 
possible that EMAST, as canonical MSI, follows different patterns of prevalence 
across demographic characteristics 270,271, thus registering varying rates across 
cohorts. Should EMAST be investigated as a distinct form of microsatellite 
instability, a standardisation of panels and cut-off is warranted. 
 In our paper III, we identified a series of pre-operatively recorded variables 
indicative of an elderly, frailer phenotype that associated with EMAST. These 
included older age, a lower body mass index (BMI) with loss of >5% body weight 
prior to diagnosis, lower levels of haemoglobin and serum albumin. 
Older patients generally constitute a population affected by a range of comorbidities, 
impairments and syndromes that may have an influence on the outcome of clinical 
interventions 272. Frailty is often recognised as an aging-associated syndrome, 
corresponding to a weakened state and susceptibility to adverse health events 273,274. 
Several geriatric assessment and frailty scoring systems have been proposed to date, 
none however reaching unanimous consensus 272,275,276. A generally undernourished 
state, with specific biomarkers including BMI, low levels of albumin and 
haemoglobin and weight loss have been reported to predict frail status and poor 
outcomes, even against more extensive geriatric assessments 272,277-282. Genomic 
instability – or the accumulation of genetic and epigenetic aberrations - tends to 
increase and share mechanisms with biological and physiological aging 283,284. It is 
thus possible that EMAST, intended as an extension of the genetic perturbance 
otherwise reflected by canonical MSI, may help drawing frailer subgroups of 
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patients. EMAST was shown in paper III to correlate with improved RFS, although 
no differences in disease-specific and overall survival were noted. As >25% of the 
cohort was older than 79, older age and frailty might constitute modifiers in survival 
analyses, as indicators of an overall shorter lifespan.  
 
 
5.2 Role of MSH3 
 
Association of MSH3 loss with EMAST stems from effects seen in experimental 
studies on cancer cell lines 191,192. These led to the postulation of nuclear MSH3 
protein inactivation by extranuclear translocation as the leading cause of EMAST. In 
human CRC four studies showed some degree of MSH3 loss found in EMAST-
positive cancers 168,171,177,181. We have however identified issues in the findings in two 
of the studies. In one report, an initial analysis yielded no difference in median of 
MSH3-negative cells in EMAST groups, and the cut-off value was then altered thus 
introducing objective bias in the analysis 177. In the second report 181, the figure 
chosen to represent an MSH3-negative case, claimed to correlate with EMAST, 
showed normal colonic tissue. Normal colon should always express MSH3 unless 
germline inactivating mutations are present and such findings undermine the assay’s 
validity. 
Other groups found no significant association between MSH3 loss and EMAST in 
CRC 174 and pancreatic ductal adenocarcinoma 166.  
In our study on immunohistochemical expression of MSH3 (paper III), we aimed at 
validating whether MSH3 rather than MSH2 and MLH1, commonly involved in MSI, 
could drive EMAST. No striking downregulation of the protein was however found, 
with very low degrees of nuclear staining heterogeneity. Contribution to results 
discrepancy may stem from the fact that all studies employed different antibodies, 
where reported, and cut-offs to discriminate between MSH3 negative and positive 
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cases. Again, lack of standardisation in assays and methods results in great 
variability. 
A further issue to consider is that MutSβ (MSH2-MSH3) is erroneously thought 
to have higher affinity for insertion-deletion loops (IDL) repair than MutSα (MSH2-
MSH6) 285. In reality, while MutSα was shown to have higher affinity for single 
nucleotides mismatches by the group of Paul Modrich 106, the affinity of either 
complex was shown to be equivalent for 2-8 nucleotides IDLs 106,186-190. 
Both MSH2 and MLH1, the two proteins most reported as dysfunctional in canonical 
MSI are also integrally part of the MutSβ (MSH2-MSH3) and MutL(α-β-γ) (MLH1-
PMS2/PMS1/MLH3) heterodimeric complex (see Figure 10). According to the 
running theory of MSH3-deficiency being the culprit of instability at tetranucleotides, 
MutSβ and its cooperation with either one of the above-mentioned MutL should 
therefore be affected. The association, albeit apparently logical, is inconsistent with 
the role of MSH2 and MLH1 and PMS2, which could equally contribute to the lack 
of repair of IDLs longer than a single mismatch. Assuming – possibly erroneously – 
that all human Mut complexes and their functions have been discovered and 
described, each one of MSH2, MSH3, MLH1, PMS1, PMS2 and MLH3 could 
equally destabilise repair activity at tetranucleotide repeats. 
An additional issue is that the variation in amounts of MutS alpha and beta in human 
eukaryotic cells are attributed to available pools of MSH3 and MSH6, to which 
MSH2 binds to form either complex. Overexpression of MSH6 could therefore 
sequester available amounts of MSH2, stoichiometrically shift binding towards the 
MutSα complex. In such case, MSH3 would still be detected by IHC (as in our paper 
III) but would lack functionality unincorporated in MutSβ due to unavailability of 
MSH2. To date, no report described expression of MSH6 in relation to EMAST. 
Moreover, as for MSI, EMAST molecular mechanisms should be held true regardless 
of tissues. In pancreatic cancer EMAST was found in up to 40% of patients, but no 
evidence of MSH3 inactivation was found in those tumours 166. In endometrial 
cancer, another malignancy known for elevated EMAST frequencies 159, MSH3 
frameshift mutations were found to be not as common as in CRC 111. Lastly, near-
ubiquitous overlap of EMAST with MSI, as pointed out recently in a meta-analysis 
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174, suggests overlapping rather than mutually exclusive mechanisms. Taken together, 
all these observations at least question the proposed exclusive role of MSH3 in 
EMAST development.   
Better insight into the role of each MutS-MutL combination complexes in MMR 
mechanisms, as well as concomitant analysis of each individual protein in a multi-
organ tumour cohort, could shed more light into EMAST relationships with MMR. 
 
 
5.3 Tumour microenvironment 
 
To be able to reach a level of evidence sufficient for incorporation in clinical 
guidelines, biomarkers need to be validated thoroughly in randomized controlled 
trials and subsequently in systematic reviews after “proving their worth” in cohort 
studies. 
Constitutive activation due to mutations in the KRAS gene is to date the most reliable 
predictive marker in CRC, informing clinicians on the usefulness of anti-EGFR 
therapies such as cetuximab and panitumumab 286. Compared to KRAS, evidence on 
PD-L1 expression as a predictive biomarker is still in its infancy, albeit encouraging. 
It is therefore valuable to add to the body of evidence surrounding the role of PD-L1 
in CRC and interaction with the surrounding microenvironment. The tumour 
microenvironment was barely considered two decades ago, while search on PubMed 
for the terms returns >4000 publications in 2018. The reciprocal influence of tumour 
and its surrounding stroma, particularly components of the immune system, is an 
important dynamic to elucidate. 
In paper IV, we described a generally higher immune reaction in the tumour 
area of EMAST patients, exemplified by higher numbers of CD3 and CD8 cells, and 
their collective indicator, IS. Higher levels of C-reactive protein (CRP), a systemic 
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indicator of active immune response, was also described in paper III. CRP is an 
acute phase protein produced by hepatocytes in response to secretion of pro-
inflammatory factors such as interleukin 6 287. Its levels are increased in plasma 
during infection, inflammatory disease, trauma and cancer. 
These findings were in line with a study reporting higher density of CD8 T cell 
infiltrations in both tumour centre and stroma of EMAST patients 172.  
Expression of PD-L1 on cells from various tumours is believed to be either 
inducible by IFNγ secreted by tumour-infiltrating lymphocytes, or constitutively 
activated via oncogenic signalling 205. These two distinct mechanisms have been 
termed innate and adaptive immune resistance, respectively 205,209,288. It was thus 
proposed that further stratifying tumours for both PD-L1 expression and tumour-
infiltrating lymphocytes (termed TILs) may have superior predictive value for 
response to PD-1 blockade immunotherapies 209,289,290. In this model, termed Tumor 
Immunity in the MicroEnvironment (TIME) 290,291, only the group showing both PD-
L1-positive tumour cells and presence of TILs (PD-L1+/TILs+) would benefit from 
immunotherapy. The other three groups (PD-L1+/TILs-, no immunosurveillance and 
innate immune resistance; PD-L1-/TILs+, TILs not producing IFNγ; and PD-L1-
/TILs-, lack of immunosurveillance and response to immunotherapy) would not 290. 
In paper IV we showed a good correlation between EMAST and tumour PD-L1 
expression, which coupled with the higher IS (and therefore TILs) could align with 
the narrative of generalised instability at microsatellites and increased 
immunogenicity. According to the TIME classification, it may be then speculated that 
EMAST predicts good response to immune checkpoint blockade. The number of PD-
L1-positive tumours were however too low to draw sub-stratification according to 
both PD-L1 and TILs in our cohort, something that by expanding the analysis to 
larger samples might be achievable. No clinical trial so far, however, included the 
TIME classification as a predictive biomarker of immunotherapy response .125 
We also describe an additional pattern of PD-L1 expression in CRC, with 
distinct implications for patients’ prognosis, namely PD-L1 expressed on cells 
outside of the tumour. More recent focus emerged on the role of PD-L1 expression in 
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tumour-infiltrating immune cells 142,292-294. As part of normal immune dynamics, PD-
L1 is expressed on antigen-presenting mononuclear cells such as macrophages. PD-
L1 is been described in peri- and intratumorally infiltrating immune cells in CRC, 
with distinct clinical and pathological connotations than on tumour cells 292. First, 
immune cells expression of PD-L1 is consistently higher than in tumour cells 
292,293,295-299, even when selecting for MSI patients. There is therefore a substantial 
proportion of microsatellite-stable CRC that display high levels of PD-L1-expressing 
immune cells. 
Second, PD-L1 expression on immune cells is almost unanimously associated with 
improved recurrence-free 297,299-301 and overall survival 293,299,300,302. Association of 
tumour PD-L1 expression is usually linked to poorer survival, although not 
consistently 292,300,302,303. Data on expression of PD-L1 in the immune component of 
the tumour microenvironment is nonetheless scarce, and prevalently available in 
Asiatic (Japanese, Korean) cohorts. It is necessary to establish the role of PD-L1-
expressing immune cells to better understand the tumour-immune system dynamics. 
This is especially true for clinical trials of PD-1 blockade, where an anti-PD-L1 
antibody would be direct towards both tumour and immune cells expressing its 
antigen. 
 It is known that a very small proportion (circa 5%) of metastatic colorectal 
cancer show MSI 125,211,304. At present, anti-PD1/PD-L1 therapy is only approved by 
the FDA as second-line treatment in metastatic MSI CRC (pembrolizumab, 
nivolumab or nivolumab in combination with anti-CTLA-4 ipilimumab). Only two 
trials are addressing safety and efficacy of immune checkpoints inhibitors in non-
metastatic CRC, NCT03026140 and NCT02912559 (ATOMIC trial). The former, an 
open label randomised trial 305, already showed promising results with 7/7 major 
pathological responses and 4/7 complete responses in the MSI group. The ATOMIC 
study is a phase III randomized trial comparing standard chemotherapy (FOLFOX) 
alone or in combination with atezolizumab (anti-PD-L1) as adjuvant treatment for 
stage III MSI colon cancer.   
Should a causality be established between immune resistance and progression to 
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metastases of MSI CRCs and PD-L1 expression, the latter may serve as stratification 
tool to identify “higher-risk” MSI CRCs. This in turn may strengthen the rationale for 
the use of anti PD1/PD-L1 immunotherapy in non-metastatic CRC. 
 Finally, an additional consideration should be made on the 
underrepresentation of older, frailer patients from clinical trials, as in the case of 
immune checkpoints inhibitors 306. As discussed earlier, in paper III we found that 
EMAST patients were associated with indicators of frailty and older age. We are not 
aware of other studies supporting the association of EMAST with clinical markers of 
frailty. A recent multicentre retrospective analysis, however, found no difference in 
survival (overall and progression-free) nor in immune-related toxicity between 
patients older or younger than 70 years 307. It thus of interest to gain further insight to 





5.4 Methodological considerations 
 
Several points related to limitations in the presented works need addressing. 
First, the size of both cohorts (N<200) are relatively small, especially when 
considering rare events such as MSH3 negative cells or PD-L1 positive ones. While 
the cohort used in paper I is of archival, retrospective nature, only a sub-cohort of 
the ACROBATICC study has been employed in the other publications. Since 5-years 
RFS and OS were the main endpoints considered in our analysis, limiting the 
sampling to the first 200 patients ensured acceptable median follow up lengths (52.5 
months in paper III and 68.8 in paper IV).  
Moreover, it is important to explicit criteria for patient selection to disclose possible 
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selection bias, a recurrent issue in both clinical trials and cohort studies. By selecting 
for patients <75 years and excluding stage III (pN+) not fit for adjuvant 
chemotherapy, as well as those deemed not fit for metastatic surgery, a bias towards 
the “fittest” patients might have been introduced. Notably, while no change in the 
treatment recommendations from the Norwegian health authorities took place for 
rectal cancers between 1996 and 1999, the introduction of neoadjuvant radiotherapy 
for advanced stage was introduced in the year 2000 308. For colonic cancers, on the 
other side, adjuvant chemotherapy (5FU monotherapy) for stage III patients aged 75 
or less was introduced in 1997, with documented benefits in terms of 5-year relative 
survival  308. 
Guidelines for systematic surveillance and regimen specifications for neoadjuvant 
(rectum) and adjuvant treatment have evolved considerably in the past two decades in 
Norway 19. It may be thus further speculated that the discrepancies in survival noted 
from EMAST in paper I (n.s.) and papers III-IV (improved RFS) might reflect 
improvements in standard of care.  
Analysis of MSH3 in paper II also need commenting. To date, two main 
functional mechanism of MSH3 inactivation have been proposed, one involving 
dislocation to the cytoplasm 191,192, and the other via downregulation at the 
transcription level 183. Neither could be noted in our results, as MSH3 staining looked 
strong and specific, and negligible nuclear-cytoplasmic heterogeneity was noted. 
However, it should be noted how other aberrations might affect MSH3. A 2012 study 
identified 25 sequence variants (not somatic mutations), of which none resulted in a 
truncated protein, although inaccurate splicing of MSH3 as a consequence could not 
be excluded 309. Moreover, the authors identified two regions where loss of 
heterozygosity was frequent in the tumours analysed, located at the far end of the 
coding sequence of the MSH3 gene. The anti-human MSH3 clone EPR4334(2) 
(AbCam, Cambridge UK) used in the study is a recombinant monoclonal antibody 
raised in rabbit, targeted to the 50-150 AA. region of the N-terminus of the MSH3 
peptide. Of all the antibodies used in previous studies, it was at the time the only 
commercially available and optimised for IHC by the manufacturer. Being however 
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raised against the peptides corresponding to the initial sequence, similarly to the 
antibody used in the afore-mentioned study, downstream protein modifications might 
have been missed by our antibody.  
The analysis of PD-L1 expression in the peritumoral compartment, 
simplified in the text of paper IV as related to immune cells, is incomplete. PD-L1 is 
known to be expressed in activated cells including T- and B-cells, dendritic cells, 
macrophages, mast cells, natural killer cells, activated vascular endothelial cells and 
mesenchymal stem cells 204,208. Our analysis was however limited to PD-L1, lacking 
additional cell-specific markers and thus not allowing us to speculate upon which 
type of non-tumour cell expressed it in our samples. More in-depth marker analysis 
should be done to resolve the components of the tumour microenvironment in our 
samples. 
Finally, a limitation that deserves note in our paper III is the lack of 
standardised measure of frailty in our CRC cohort. We have shown the association of 
EMAST with markers that have been often associated in the literature, although no 
values pertaining any of the frailty score systems so far proposed were reported. This 
is partly due, as mentioned earlier, to the lack of consensus on frailty assessment. 
Only the American Society of Anesthesiologists (ASA) classification system was 
reported for our cohort, as the one routinely assessed and recorded in preoperative 
settings. Should the association of EMAST with markers of frailty hold true in 
expanded and more extensive studies, it should be tested against more standardised 




6. CONCLUSIONS AND FUTURE PERSPECTIVES
In these works, we investigated EMAST in CRC, for the first time in a Norwegian 
cohort, and established its relationship with patients’ characteristics that are routinely 
recorded for their value in the clinical setting. The EMAST patients often have 
instability at mono- other than tetranucleotides, are older and show markers of frailty, 
although with a better outlook in terms of recurrence-free survival. EMAST was also 
an indicator of a stronger immunosurveillance activity, exemplified by the increased 
presence of CD3 and CD8 expressing immune cells. Further, as for MSI tumours, 
EMAST cancers were linked with immune evasion, by increased PD-L1 expression. 
Owing to the great degree of overlap between MSI at mononucleotides and EMAST 
in our cohorts, the two mixed groups EMAST-/MSI+ and EMAST+/MSI- were 
underrepresented in our studies. It was thus not possible to achieve a level of 
statistical significance in order to carry out extensive subgroup analysis. Whether 
these two types of instability should be studied independently, or as a mutually 
propagating phenomenon therefore still needs further investigation. To date, EMAST 
was investigated only once in a large cohort. The ACROBATICC cohort is to date 
ongoing and counts >1100 patients, with an average of 22 specimens from each 
patient, including FFPE and fresh tissue, serum and plasma. In operable metastatic 
patients the number of samples collected doubles, all in highly standardised and 
optimal conditions. The ACROBATICC biobank represents therefore an invaluable 
source for future projects. 
Statistical power would benefit from the expansion of the analyses performed in this 
study to increasing number of patients, to finally allow for separation of rare 
subgroups such as EMAST+/MSI-, EMAST-/MSI+ as well as the tumour PD-L1+. 
EMAST and MSI showed combined association with improved RFS, CD3 and CD8 
immune infiltration and PD-L1 tumour expression. Specific subgroup analyses would 
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allow to establish whether these associations are dependent or independent from 
EMAST and MSI reciprocal status. 
Moreover, mutational status of markers such as KRAS, BRAF and TP53, commonly 
reported in clinical CRC studies, was not available outside of the cases where its 
assessment fell under diagnostic prescription, and is thus not included in the analysis. 
Genome- and transcriptome-wide association studies are necessary to truly link the 
clinical, genetic and biological contexture of each CRC patient in the ACROBATICC 
cohort. With the technical and cost-effectiveness evolution of next-generation 
sequencing platforms, and expansion of project-allocated resources, these high-
throughput analyses are possible. 
In the context of the tumour microenvironment, a future goal of this project 
should be to better characterize the cells infiltrating the EMAST tumour area, such as 
those expressing PD-L1. IHC has evolved considerably to allow for highly 
multiplexed staining of tissue samples, by coupling with mass cytometry (CyTOF) 
311,312.  The full implementation of digital pathology via digital image analysis 
algorithms, increasingly developed on the backbone of artificial intelligence 259, is 
also an exciting near-future perspective. Standardised and reliable biomarker analyses 
are needed to establish any “common denominator” able to identify subgroups of 
patients to be investigated prospectively in clinical trials. Examples are the above-
mentioned immune checkpoints inhibitor trials in early stage CRC, or trials that are 
targeted at the improvement of metastatic CRC health care. Of the over 400 people 
diagnosed with CRC yearly in Norway, circa 20% present with synchronous 
metastases and an additional 15-20% will develop metachronous ones 19. 
Implementation of improved peri- and preoperative techniques increased possibilities 
for treatment of metastatic CRC considerably in the past decade, although no more 
than 20-30% of patients are actually eligible for surgery. The present work focused 
exclusively on stage I-III patients, but planning is underway to extend analyses to 
ACROBATICC patients with hepatic metastases. These include collaborations with 
research groups both within and outside of Stavanger University Hospital, improving 
quality and dissemination of results to a larger audience. 
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 Last, the basic molecular biology research should not be neglected as the 
understanding of its mechanisms of action is at the base of every reputable biomarker. 
Patient material is invaluable and modern biomedical sciences offer incredible 
opportunities. Primary cell cultures can be established ex vivo that give the 
opportunity of studying tumour cells belonging to the very same patient included in 
the study. This can be done in 3D structures such as spheroids or organoids which, 
albeit not perfect models of in vivo disease, constitute an incredible advancement 
compared to 2D monolayers cultures. Three-dimensional cultures and co-cultures 
with cells typically found in the tumour microenvironment offer a better insight into 
cell-cell interactions, diffusion gradients of nutrients or therapeutics, and real-time 
cellular changes. 
The “clinical endpoint” in translational research is improvement of patient 
care, and its “surrogate endpoint” is the deepening of our understanding of tumour 
biology. All the tested hypotheses, analyses, expended funds and hours in a 
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9.1 In paper I: 
• Patients and methods, DNA extraction and fragment analysis sub-chapter.
Second paragraph (5 lines from the top) should read:
“DNA extracted from tumor tissue and their corresponding normal tissue (from
surgical resection margins) was then PCR- amplified with five tetranucleotide 
microsatellites primer pairs (EMAST: D20S85, D20S82, D9S242, D8S321, MYCL1, 
5` fluorescently labeled) and five mononucleotide and dinucleotide microsatellite 
primer pairs (MSI: NR- 27, NR- 21, NR- 24, BAT- 25, BAT- 26, 5` fluorescently 
labeled).” 
• Discussion, first paragraph should read:
“In this cohort study, we found EMAST+ CRC to largely overlap with features
associated with MSI+ cancers, including a predominant location in the colon, 
association with high-grade histology, larger tumor size, and advanced depth of 
growth (T3- 4).” 
• Figure I, the significance (p) value for the MSI/EMAST association table was









Colorectal cancer (CRC) remains a formidable global health 
burden and represents one of the most frequent tumors 
in both genders [1]. Prognosis and treatment decisions 
are still largely based on the TNM system, but despite 
revisions to improve its predictive and prognostic value, 
this system is still under debate [2, 3]. Among the strong-
est prognostic factors is lymph node status, with node- 
positivity usually indicating a less favorable prognosis and 
a need for adjuvant chemotherapy after surgery. However, 
even the role of lymph nodes has been debated [4], as 
this is a fairly rough quality indicator and fails to avoid 
under- and overtreatment. The growing evidence for the 
role of genetic variability in cancer behavior and disease 
outcome has therefore called for a stratified approach to 
cancer care based on specific molecular traits.
The last decades have shed light on several important 
molecular mechanisms of CRC, allowing for useful clinical 
subtyping and making CRC a useful model for the 
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Abstract
Microsatellite instability (MSI) is associated with better prognosis in colorectal 
cancer (CRC). Elevated microsatellite alterations at selected tetranucleotides 
(EMAST) is a less- understood form of MSI. Here, we aim to investigate the 
role of EMAST in CRC±MSI related to clinical and tumor- specific characteristics. 
A consecutive, population- based series of stage I–III colorectal cancers were 
investigated for MSI and EMAST using PCR primers for 10 microsatellite mark-
ers. Of 151 patients included, 33 (21.8%) had MSI and 35 (23.2%) were EMAST+, 
with an overlap of 77% for positivity, (odds ratio [OR] 61; P < 0.001), and 
95% for both markers being negative. EMAST was more prevalent in colon 
versus rectum (86% vs. 14%, P = 0.004). EMAST+ cancers were significantly 
more frequent in proximal colon (77 vs. 23%, P = 0.004), had advanced t- stage 
(T3–4 vs. T1–2 in 94% vs. 6%, respectively; P = 0.008), were larger (≥5 cm 
vs. <5 cm in 63% and 37%, respectively; P = 0.022) and had poorly differenti-
ated tumor grade (71 vs. 29%, P < 0.01). Furthermore, EMAST+ tumors had 
a higher median number of harvested lymph nodes than EMAST− (11 vs. 9 
nodes; P = 0.03). No significant association was found between EMAST status 
and age, gender, presence of distant metastases or metastatic lymph nodes, and 
overall survival. A nonsignificant difference toward worse survival in node- 
negative colon cancers needs confirmation in larger cohorts. EMAST+ cancers 
overlap and share features with MSI+ in CRC. Overall, survival was not influ-
enced by the presence of EMAST, but may be of importance in subgroups such 
as node- negative disease of the colon.
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understanding of cancer initiation and progression [5]. 
Microsatellite instability (MSI) is one such important 
feature and has been associated with better prognosis and 
tumor- specific characteristics [6]. First described in the 
hereditary proportion of CRCs and associated with the 
Lynch syndrome, MSI also occurs in about 15% of  sporadic 
CRCs.
MSI represents a pathway of carcinogenesis that runs 
parallel to that of chromosomal instability and is of 
acknowledged prognostic, predictive, and potentially thera-
peutic relevance [6]. Instability at mono- and dinucleotide 
microsatellites is today included in the clinical and bio-
logical definition of MSI, for example, by the Bethesda 
criteria for MSI testing and definitions [7]. However, in 
a rapidly increasing number of studies, instability at tetra-
nucleotides has been described and considered as a par-
ticular subtype of MSI over a wide range of tumor types, 
from those originating in the aerodigestive organs to the 
gastrointestinal tract [8]. This newly described form of 
microsatellite instability was named “elevated microsatellite 
alterations at selected tetranucleotides” (EMAST).
In CRC, several recent findings have suggested potential 
molecular mechanisms underlying EMAST [9–13]. 
However, the clinicopathological relevance and difference 
with “canonical” MSI in CRC is still poorly investigated. 
Thus, we aim to investigate the role of EMAST in rela-
tion to clinical- and tumor- specific data, including MSI 
status, and analyze the effect on survival.
Patients and Methods
Study cohort
The study cohort represents consecutive patients with 
non- metastatic colorectal cancer (stage I–III) who were 
<75 years of age at diagnosis and who entered into an 
in- hospital, surgeon- led systematic surveillance program 
per national standards at the time[14], and as previously 
described at the time [15–17]. All included patients pre-
sented between 1996 and 1999 and underwent curative 
surgery for colorectal cancer at the Department of 
Gastrointestinal Surgery, Stavanger University Hospital, 
Norway. Clinicopathological information was recorded, 
and follow- up was updated as of July 23rd, 2011, thus 
providing up to 15 years follow- up after surgery [16].
Notably, as this cohort represents patients who were 
eligible for a systematic surveillance program at the time 
of surgery, patient >75 years and stage III (pN+) not fit 
for adjuvant chemotherapy were excluded [15, 16]. Patients 
with stage III disease and who were otherwise fit were 
offered adjuvant chemotherapy according to national 
guidelines at the time, typically consisting of 5- fluorouracil 
and leucovorin (5- FU/LV) [18]. Thus, elderly patients and 
those deemed unfit for adjuvant chemotherapy or, in the 
case of distant recurrence, deemed not fit for a second 
surgery were not included in this cohort.
From the above- described initial cohort (n = 196), there 
were 151 specimens (98 from colon and 53 from rectum) 
with available tissue for DNA extraction from formalin- 
fixed, paraffin- embedded (FFPE) tumor and tumor- free 
resection margin tissues for this study.
Ethics
The study was approved as a quality assurance project 
(REK#2010/3414) by the Regional Ethics Committee of 
the Health Trust of Western Norway.
Gross and histopathological assessment
All tumors were assessed for gross and histomorphological 
characteristics, and staged according to TNM- classifications 
per routine at the time. For the current analyses, a patholo-
gist reviewed the slides to ensure appropriate selection of 
tumor tissue and blocks with appropriate high tumor 
content (>50% viable tumor tissue) per block used for 
DNA extraction.
DNA extraction and fragment analysis
Following inspection by an experienced pathologist, four 
consecutive tumor and tumor- free 10 μm sections were cut 
from FFPE blocks for DNA extraction, using the Tissue 
DNA E.Z.N.A. kit (Omega BioTech®, Norcross, GA, USA) 
according to manufacturer’s instructions. DNA extracted 
from tumor tissue and their corresponding normal tissue 
(from surgical resection margins) was then PCR- amplified 
with five tetranucleotide microsatellites primer pairs (EMAST: 
D20S85, D20S82, D9S242, D8S321, MYCL1, 5` fluorescently 
labeled) and five mono- and dinucleotide microsatellite 
primer pairs (MSI: NR- 27, NR- 21, NR- 24, BAT- 25, BAT- 26, 
5` fluorescently labeled). PCR conditions were as follows: 
initial denaturation step of 5′ at 95°C, followed by 37 cycles 
of denaturation (30″ at 95°C), annealing (90″ at 55°C), and 
extension (30″ at 72°C), and concluded by a final elonga-
tion step (30′ at 60°C). The primers sequences, expected 
amplicon sizes and fluorescent dyes are provided in Table 1.
The PCR products were analyzed for fragment lengths 
on a 3130xl GeneticAnalyzer (Applied Biosystems, Foster 
City, CA, USA), with GeneMapper v3.7 software (Applied 
Biosystems, Foster City, CA, USA). Tumor samples were 
compared with their corresponding normal samples. Those 
showing any number of extra peaks at ±4n (n ≠ 0) (tetra-
nucleotides markers, EMAST), and/or ±1n or 2n (n ≠ 0) 
(mono- and dinucleotide markers, respectively, MSI) were 
scored as unstable for that marker.
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Definition of EMAST and MSI
To detect EMAST either direct sequencing or fragment 
analysis are generally used, with most laboratories adopt-
ing a panel of five tetranucleotide polymorphic markers 
(at least two unstable markers to score EMAST positivity). 
In CRC, up to seven microsatellite markers have been 
reportedly used, with EMAST considered present 
(EMAST+) when at least one marker was found unstable. 
In this study, we adopt the most used definitions of at 
least two out of five tetranucleotide markers unstable to 
confirm EMAST.
Samples showing instability in at least two out of five 
markers (40%) were recorded as EMAST- positive and/or 
microsatellite instability- high (MSI- H), while instability of 
one out of five markers was scored as EMAST- negative 
and/or microsatellite instability- low (MSI- L). If no unstable 
markers were found, the specimens were considered as 
microsatellite- stable (MSS). MSI analysis was done as 
previously described [17, 19]. Two investigators completed 
the scoring process independently, blinded to each other’s 
results. Discordance among investigators’ scoring was 
addressed by rerunning the samples by PCR followed by 
rescoring.
Statistical analysis
All statistical analyses were performed on IBM® SPSS® 
Statistics for Mac and Windows, version 23 (Armonk, 
NY, USA). Continuous variables were tested for normality 
by the Shapiro–Wilks test and for comparison by Mann–
Whitney U test. Relationships between categorical variables 
were investigated via Fischer’s exact and Chi- square tests, 
as appropriate. Overall and recurrence- free survival was 
assessed by Kaplan–Meier analysis using the log rank test. 
All tests are two- tailed and statistical significance was set 
at P < 0.050.
Results
Of the 151 patients included, the age and gender distri-
bution together with other clinicopathological character-
istics are presented in Table 2. The frequencies of MSI- H 
and EMAST were of 33 and 35 (22 and 23%) out of 
151 patients included, respectively (Table 2). Seventy- seven 
percent of EMAST cases (27/35) were also MSI- H for an 
odds ratio (OR) of 61.9, (95% CI: 19.8–193.3; P < 0.001). 
The distribution of MSI- and EMAST- positive tumors 
across the different sections of the large intestine are 
presented in Figure 1. Dual positive cases (both EMAST+ 
and MSI+; n = 27), were predominantly located in the 
colon (n = 25; 92.6%) compared to rectum (n = 2; 7.8%). 
The ascending and transverse colon had the highest number 
of dual positive cases, for seven and eight each (25.9% 
and 29.6%, respectively).
Of the 53 rectal and 98 colon tumors, five (9.4%) and 
30 (30.6%) were positive for EMAST, respectively (cumu-
lative: 86% colon, 14% rectum, P = 0.004). EMAST+ 
tumors had a higher prevalence in proximal versus distal 
colon (77% vs. 23%, P = 0.004) and were also associated 
with advanced t- stage in both EMAST (OR 6.0, 95% CI: 
1.4–26.6; P = 0.008) and MSI cancers (OR 5.5, 95% CI: 
1.3–24.5; P = 0.013), respectively.
EMAST+ tumors had a higher median number of har-
vested lymph nodes than EMAST– (11 vs. 9 nodes; 
P = 0.029; Fig. 2), but no difference in the number of 
lymph nodes positive for tumor cells infiltration was found.
A total of 38 (25.2%) patients developed metastases 
and died from CRC in this cohort. Neither EMAST nor 
MSI predicted risk of development of distant metastases, 
nor was EMAST predictive for disease- specific and for 
overall long- term survival in this cohort (Fig. 3A). However, 
on subanalyses of colon cancers only, as these harbor a 
higher frequency of EMAST- positive cases in comparison 
with rectal cancers, a nonsignificant difference in 
Table 1. Name, size, fluorescent label, and primer sequences of the microsatellite markers investigated.
Marker Amplicon size (bp) Label Forward primer Reverse primer
EMAST primers
MYCL1 181 6- FAM TGGCGAGACTCCATCAAAG CCTTTTAAGCTGCAACAATTTC
D20S85 146 NED GAGTATCCAGAGAGCTATTA ATTACAGTGTGAGACCCTG
D8S321 237 VIC GATGAAAGAATGATAGATTACAG ATCTTCTCATGCCATATCTGC
D20S82 249 6- FAM GCCTTGATCACACCACTACA GTGGTCACTAAAGTTTCTGCT
D9S242 178 PET GTGAGAGTTCCTTCTGGC ACTCCAGTACAAGACTCTG
MSI primers
NR- 27 89 VIC AACCATGCTTGCAAACCACT CGATAATACTAGCAATGACC
NR- 21 110 6- FAM GAGTCGCTGGCACAGTTCTA CTGGTCACTCGCGTTTACAA
NR- 24 128 PET GCTGAATTTTACCTCCTGAC ATTGTGCCATTGCATTCCAA
BAT- 25 152 VIC TACCAGGTGGCAAAGGGCA TCTGCATTTTAACTATGGCTC
BAT- 26 182 NED CTGCGGTAATCAAGTTTTTAG AACCATTCAACATTTTTAACCC
EMAST, Elevated microsatellite alterations at selected tetranucleotides; MSI, Microsatellite instability.
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long- term cancer- specific survival was noted, particularly 
for the node- negative (stage I–II) patients (Fig. 3B). 
Furthermore, these depicted an apparent worse outcome 
for EMAST+ (Fig. 3C) compared to microsatellite- stable 
cancers, and those with either one form of microsatellite 
instability only.
Discussion
In this cohort study, we found EMAST+ CRC to largely 
overlap with features associated with MSI+ cancers, includ-
ing a predominant location in the colon, association with 
low- grade histology, larger tumor size, and advanced depth 
of growth (T3- 4). Despite a higher number of lymph nodes 
sampled for EMAST+ cancers, there was no difference in 
the number of malignant nodes (neither in actual numbers 
nor in the rate of pN+ cases) and no statistically significant 
effect on survival could be found. The nonsignificant yet 
apparent difference in survival curves between groups 
depicted in Figure 3 with a trend toward reduced survival 
in EMAST+ cancers, specifically for node- negative colon 
cancers needs verification in larger cohorts.
Several findings need comment in this study. We 
found a significantly lower prevalence of EMAST in 
Table 2. Characteristics of patient and tumors according to EMAST status 
n = 151
n (%) P n (%) P
EMAST− EMAST+ MSS MSI
Age (years) <65 58 (73.4) 21 (26.6) 0.299 57 (72.2) 22 (27.8) 0.062
≥65 58 (80.6) 14 (19.4) 61 (84.7) 11 (15.3)
Gender M 73 (79.3) 19 (20.7) 0.358 75 (81.5) 17(18.5) 0.210
F 43 (72.9) 16 (27.1) 43 (72.9) 16 (27.1)
Tumor location Colon 68 (69.4) 30 (30.6) 0.003 69 (70.4) 29 (29.6) 0.002
Rectum 48 (90.6) 5 (9.4) 49 (92.5) 4 (7.5)
Tumor stage T1–2 31 (93.9) 2 (6.1) 0.008 31 (93.9) 2 (6.1) 0.013
T3–4 85 (72.0) 33 (28.0) 87 (73.7) 31 (26.3)
Tumor grade Poor/mucinous 10 (50.0) 10 (50.0) 0.002 8 (40.0) 12 (60.0) <0.001
Moderate/well 106 (80.9) 25 (19.1) 110 (84.0) 21 (16.0)
Tumor size1 ≥5 cm 44 (68.8) 20 (31.2) 0.022 43 (67.2) 21 (32.8) <0.001
<5 cm 67 (84.8) 12 (15.2) 72 (91.1) 7 (8.9)
EMAST, Elevated microsatellite alterations at selected tetranucleotides; MSI, microsatellite instability; MSS, microsatellite stable. Values highlighted in 
bold indicate significance level of p < 0.05.
1Size missing in eight samples (5.3%)
Figure 1. Elevated microsatellite alterations at selected tetranucleotides (EMAST) and microsatellite instability (MSI) cancer distribution in colon and 
rectum. EMAST denotes elevated microsatellite alterations at selected tetranucleotides; MSI denotes microsatellite instability.
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our sample (23%) when compared with the majority 
of the studies available in the literature, reporting EMAST 
frequencies in CRC ranging between 33% and 64.8% 
[9, 12, 13, 20–22]. As previously reviewed [8], such 
variation could be due to the type and number of 
markers and the thresholds used in EMAST analyses, 
with the highest (60% and over) frequencies reported 
by groups using a less stringent approach to define 
EMAST [22]. The degree of overlap between MSI cases 
and EMAST (77% in this study), is in line with studies 
that report between 67% and 100% overlap, and thus, 
the selected cohort should be within the range of vari-
ation as reported elsewhere in the literature. The fact 
that most, and in some cases all, the MSI- H tumors 
are also EMAST+, and that the latter tumors are gen-
erally more prevalent, could suggest a cause–consequence 
relationship. It is also interesting to see the prognostic 
features shared by MSI and EMAST- positive cancers 
(Table 2), including larger size, poor differentiation, 
and depth of growth. While these features would nor-
mally be associated with a worse prognosis, some emerg-
ing data suggest that MSI and possibly EMAST cancers 
may be associated with specific immune reactions and 
T- lymphocyte infiltrations associated with a more favora-
ble outcome [10].
Neither EMAST nor MSI was found to significantly 
correlate with survival (neither overall nor recurrence- free). 
Of the four studies investigating survival, specifically in 
EMAST+ and EMAST− tumors currently available in the 
scientific literature, two found no significant difference 
in overall survival [9, 12]. However, one study of meta-
static CRC observed that MSI- H tumors that also displayed 
EMAST+ had significantly worse overall survival, compared 
to non- EMAST cancers with MSI- H [13]. This is in line 
with the nonsignificant findings in this study, albeit in 
early- stage colon cancers. A further study found a sig-
nificantly reduced recurrence- free survival (RFS) in 
EMAST+ cancers, when compared to MSI- H, but the 
degree of overlapping EMAST/MSI was not disclosed [23]. 
In both studies the MSI- H/EMAST- group was composed 
of a limited number of individuals.
As demonstrated in the current cohort, both MSI and 
EMAST produce larger tumors. If this is because of EMAST/
MSI tumors developing more quickly due to a much 
higher rate of mutation that a defective MMR system 
confers to the nest of cancer- initiating cells remains specu-
lative, but warrants investigation. Conversely, EMAST/MSI 
may be genetic events that occur as a side effect of other 
drivers of carcinogenesis, or merely reflects a high turnover 
and induction of genetic errors during rapid growth of 
the tumor cells. Some studies look into mechanisms of 
EMAST [11, 22, 24, 25], and point to a role of hypoxia, 
oxidative stress, and DNA repair mechanisms [26]. 
However, overall data are scarce and further understand-
ing is thus needed.
Some limitations should be considered when comparing 
our study cohort with other patient series. First, we included 
only patients who were <75 years and who entered a 
systematic surveillance program after surgery [15], and 
excluded elderly patients or those with comorbidities who 
were unfit for adjuvant chemotherapy or unlikely to toler-
ate metastatic surgery. Thus, we have introduced a clinical 
bias towards younger, fitter patients with stage I–III colo-
rectal cancers in this series. This should be taken into 
account when interpreting our findings, as the results 
could thus not apply to a more general patient cohort 
with higher age and that frequently included stage IV 
cancers. The latter may also be the reason for a nonsig-
nificant trend in the analyses, as others have found EMAST 
status of importance in stage IV and metastatic disease 
[13, 23, 27]. For example, Venderbosch et al.[13] found 
a statistically significant difference in survival between 
patients with and without EMAST. Notably, the included 
patients all came from clinical phase III trials (the Dutch 
CAIRO and CAIRO2 studies) of metastatic CRC, and 
thus all patients in the cohort had an unfavorable outcome 
[13]. Indeed, EMAST may be an accumulated effect of 
worse biology, higher mutational load, and thus play a 
Figure 2. Number of lymph nodes found in the resected specimen, 
according to elevated microsatellite alterations at selected 
tetranucleotides (EMAST) status. P- value for difference in median 
number between groups.
1585© 2016 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. 
EMAST in Colorectal CancerM. M. Watson et al.
Figure 3. Cancer- specific survival according to elevated microsatellite alterations at selected tetranucleotides (EMAST) status, stages, and location. 
(A) overall cancer- specific survival for all colorectal stage I–III cancers, with no significant difference, yet a somewhat poorer outcome in EMAST +
cancers. (B) cancer- specific survival for colon cancers only, again with nonsignificant poorer survival in EMAST+ patients. (C) outcome for node- 
negative (stage I–II) colon cancers, split into patients with microsatellite stable (MSS; blue line), microsatellite instability (MSI)- /EMAST+ (green),
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more prominent role in biology in late stage (e.g., meta-
static disease) compared with early (stage I–III) disease. 
Evidence that EMAST may act as a potential biological 
modulator among the different types of molecular classes 
(e.g., microsatellite instability, epigenetics, and chromo-
somal instability) involved in CRC have been proposed 
[28], and is further suggested in a combined series of 
metastatic disease in CRC [27]. Thus, EMAST may be 
more specific for tumor biology and disease outcome in 
late- stage groups [29], such as colorectal liver metastasis, 
but further studies need to corroborate these findings. 
Notably, several aspects in clinical practice, including a 
higher frequency of metastatic surgery and extending 
adjuvant chemotherapy to elderly patients have occurred 
since the late 1990s, so clinical differences in practice 
may have introduced selection and outcome bias in this 
cohort compared with more recent cohorts. However, 
long- term follow- up would not be possible with more 
recent cohorts, so the true eventual outcome of the patients 
(e.g., death from disease or other cause; still alive with 
no evidence of disease etc.) is likely to have been captured 
accurately in this series. The small cohort prevents from 
robust subgroup analysis and these should therefore be 
interpreted with caution. An apparent prognostic role in 
stage I–II CRC warrants further investigation. Finally, how 
EMAST should be determined lacks firm definition in 
the current literature, possibly explaining why our results 
deviate from others based on the choice of defined mark-
ers and numbers used for positivity. This methodological 
issue must be solved through further clarification of bio-
logical mechanisms and ability for robust and valid tests 
of selected markers or panels of markers.
While the clinical role of EMAST in CRC is still 
being investigated, the biological implications of recent 
investigations may yield findings of new mechanisms 
that have a clinical relevance in selected patients at 
both extremes of presentation, either as early cancers 
or as metastatic disease. Thus, further investigation into 
the biological mechanisms and their potential clinical 
implications should be pursued. Whether EMAST is an 
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Abstract
INTRODUCTION:EMAST is a poorly understood formofmicrosatellite instability (MSI) in colorectal cancer (CRC) for
which loss ofMSH3 has been proposed as the underlyingmechanism, based on experimental studies.We aimed to
evaluate whether MSH3 loss is associated with EMAST in CRC. METHODS: A consecutive cohort of patients with
stage I-III CRC. Digital image analysis using heatmap-derived hot spots investigated MSH3 expression by
immunohistochemistry. Fragment analysis ofmultiplex PCRwas used to assessMSI and EMAST, and results cross-
examined with MSH3 protein expression. RESULTS:Of 152 patients, EMASTwas found in 50 (33%) and exclusively
in the colon.Most EMAST-positive cancers had instability at all 5 markers, and EMAST overlapped withMSI-H in 42/
50 cases (84%). The most frequently altered tetranucleotide markers were D8S321 (38.2% of tumors) and D20S82
(34.4%). Subjective evaluation ofMSH3 expression by IHC in tumor found10%negative tumor cells in all samples,
most being5%negative. Digital analysis improved the detection but showed a similar spread ofMSH3 loss (range
0.1e15.7%, mean 2.2%). Hotspot MSH3 negativity ranged between 0.1 to 95.0%, (mean 8.6%) with significant
correlation with the whole slide analysis (Spearman’s rho ¼ 0.677 P < .001). Loss of MSH3 expression did not
correlate with EMAST. CONCLUSIONS: In a well-defined cohort of patients with CRC, loss of MSH3 was not
associated with EMAST. Further investigation into the mechanisms leading to EMAST in CRC is needed.
Translational Oncology (2019) 12, 1583–1588
Introduction
Microsatellite instability (MSI) is caused by defects in the mismat-
ch-repair (MMR) family of proteins [1]. This results in mosaic
populations of cells bearing microsatellite loci with diverse numbers
of repeats due to uncorrected slippages during DNA replication. Silent
or deleterious consequences arise according to the microsatellites
affected and their location within the genome. In colorectal cancer
(CRC), MSI is recognized as an alternative carcinogenic pathway
to the chromosomal instability model, with a series of clinical
and pathological implications [2]. MSI continues to be debated
as a prognostic factor in CRC [3e5], and is implicated
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in the “hypermutated” or “immunogenic” consensus molecular
subtype [6].
Elevated microsatellite alterations at selected tetranucleotides
(EMAST) is a variant of MSI described in lung, skin, prostate, and
other cancers, including CRC [7]. While MSI was initially defined as
instability at mono- and dinucleotide repeats (e.g. CAn) [8], today
commonly measured in a panel consisting exclusively of mono-
nucleotides [9], the definition of EMAST is based on instability
found in tetranucleotides (e.g. AAAGn).
MSI in CRC commonly displays loss of expression of MMR
proteins such as MLH1, MSH2, MSH6 and PMS2. The MSH2
member of theMMR family can dimerize with eitherMSH6 orMSH3
to form the MutSa or MutSb complexes [1]. The latter is believed to
have a higher affinity for repair of longer IDLs and mismatched
sequences occurring during replication, such as tetranucleotides.
MSH3 has therefore been implicated as a potential candidate to
explain instability at longer microsatellites, as found in EMAST.
In vitro, MSH3 dysfunction was associated to instability at several
tetranucleotide loci in MLH1- and MSH3-deficient CRC cell lines
via whole chromosome transfer, as well as silencing/knockdown
studies [10e12]. Additionally, it has been suggested that activity of
MSH3 could be impaired by its dislocation from the nucleus to the
cytosol, a process possibly mediated by interleukin-6 in a context of
oxidative stress in CRC cell lines [12,13]. Furthermore, the cancer
genome atlas (TCGA) consortium described MSH3 frameshift
mutationsdand not point mutationsdas common (40%) in a
subclass of CRCs defined as hypermutated and microsatellite-un-
stable [14]. Later, it was shown how MSH3, specifically in CRC,
represents a frequent target of frameshift mutation, as opposed to the
promoter hypermethylation that occurs atMLH1 in MSI CRCs [15].
The fact that theMSH3 gene contains a mononucleotide-repeat locus
could suggest that frameshift mutations in MSH3 are a consequence
of instability at mononucleotides initiated by loss of MLH1. In the
mentioned studies it was not reported whether the frameshift
mutations found in MSH3 were silent or non-silent, and their effect
on functionality of the protein can therefore not be inferred. Should
MSH3 be proven as the biological driver of EMAST, a causal
relationship between MSI and EMAST could therefore be speculated.
Thus, the relationship between MSH3 and EMAST need to be
investigated in clinical cohorts. However, to date only 3 studies in
human tissue have investigated immunohistochemical (IHC) staining
of MSH3 in patients, and are discordant in the association between
MSH3 expression with EMAST [10,16,17].
The aim of this study was to assess if MSH3 loss could explain
EMAST in colorectal cancer and, if so, to develop a standardized
method to more accurately assess protein loss in the samples.
Materials and Methods
The patient cohort was derived from the ACROBATICC project [18]
(clinicaltrials.gov identifier: NCT01762813) and is conducted in
accordance to national regulations and approved by regional ethics
committee (REK Helse Vest, #2012/742). Written informed consent
was obtained from each participant prior to inclusion in the study.
Patient Material
Formalin-fixed, paraffin-embedded (FFPE) tumor and normal
tissue derived from stage I-III surgically removed CRC was used in
this study. Appropriate slides were assessed by a certified pathologist
and representative tissue blocks selected for DNA extraction,
fragment analysis and immunohistochemistry.
EMAST and MSI Analyses
FFPE blocks were selected by an experienced pathologist and 4 
10 mm sections were cut at a microtome. Automated DNA extraction
was carried out using AllPrep DNA/RNA FFPE kit (Qiagen, Hilden,
Germany) on a QiaCUBE instrument (Qiagen) according to
manufacturer's instructions. Nucleic acid concentration and purity
were measured on a NanoDrop 2000 (ThermoFischer scientific,
Waltham, USA).
Multiplex PCR reactions (one for eachMSI and EMAST) were set up
for tumor and normal DNA from each patient. TypeIT microsatellite
(Qiagen) master mix, together with a blending of 5  50-fluorescently
labeled primer pairs was used for each reaction. PCR conditions were as
follows: 50 at 95 C (initial denaturation and enzyme activation),
followed by 37 cycles of 3000 at 95 C (denaturation), 9000 at 55 (MSI) or
57 C (EMAST, annealing) and 3000 at 72 C (extension). A final
extension step for 300 at 60 C. The primers for EMAST were specific to
the tetranucleotide loci MYCL1, D20S85, D20S82, D9S242 and
D8S321 [19]. The primers for MSI were specific for BAT-26, NR-21,
NR-24 and NR-27 [9,20], which are all quasimonomorphic mono-
nucleotide repeats with a high fidelity to high-frequency MSI (MSI-H)
as shown previously [21]. To define a tumor as EMAST and/or MSI-H,
at least 2/5 markers needed to be unstable in their respective panels.
MSH3 Immunohistochemistry
Antigen retrieval and antibody dilution were optimized prior to the
study onset. From FFPE blocks, 2 mm sections were cut and mounted
onto Superfrost Plus slides (Menzel, Braunschweig, Germany). The
sections were incubated at 60 C for 1 h and then placed in the Dako
Omnis autostainer (DAKO Agilent, Santa Clara, CA, USA).
Automated protocol from the manufacturer was followed. Following
deparaffinization and rehydration, antigen retrieval was performed at
97 C for 30 minutes, and the slides were then incubated with the
primary anti-MSH3 antibody (rabbit monoclonal anti-human
MSH3; AbCam, Cambridge UK), clone EPR4334 (2), diluted
1:100 for 1 h. A peroxidase-DAB detection kit (Envisionþ, DAKO)
was used to visualize the immune-complex. Sections were then
counterstained with hematoxylin, dehydrated in increasing concen-
trations of ethanol and mounted manually.
Subjective IHC Score
Slides were evaluated and scored by an experienced pathologist for
nuclear positivity of MSH3 (given as per cent, %) blinded to MSI and
EMAST status of each case. A composite high-resolution image at 20
magnification of each slide was obtained with a Leica SCN400 scanner
and uploaded onto an internal digital image hub for image analysis.
Digital Image Analysis
To increase scoring sensitivity of MSH3 expression, digitalized
whole-slide and hotspots scoring of positiveenegative nuclei in the
tumor portion of the sections was performed with the aid of Visiopharm
Integrator System software (VIS; Visiopharm A/S, Hoersholm, Den-
mark). An image analysis algorithm using Bayesian classification
methods was built in an app-based tool which allowed for identification
of tumor tissue within the scanned slides, and for the highlighting of its
contours (Figure 1, AeC). Manual revision of each slide ensured then
rigorous exclusion of tissue folds, stroma, necrotic areas, immune and
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blood cells, and normal tissue from the analysis. A second, app-based
algorithm was then developed to allow for the marking of positive and
negative cells with colored labels (Figure 1,DeK ). A heatmap based on
the label associated with MSH3-negativity was created for each of the
whole slides (Figure 1, E-F), for unbiased placement of one 0.8 mm2
hotspots on the areas where the concentration of MSH3-negative cells
was highest within the slides (Figure 1, G-H). RelativeMSH3 negativity
(both whole-slide and hotspots) was then derived from the ratio of
negative label area and total negative and positive label areas, as
calculated via the developed classifier.
Statistical Analysis
All statistical analyses were carried out using IBM SPSS statistics v.
25. Chi-square or Fishers Exact test were used for categorical
variables. Relationship between different operators (pathologist/
digitalized whole-slide/digitalized hotspot) in the scoring of MSH3
expression were tested using the Spearman's rank order correlation.
All tests were two-tailed with statistical significance set at P < .050.
Results
Patients Characteristics
Median age was 71.5 years (range 37.0e92.0), female patients
were 85 (56%). There were 31 (20%) rectum and 121 (80%) colon
cancers, 71 (59%) of which were in the proximal tract.
Tumor stages were equally represented with 51, 51 (34%) and 50
(33%) cases for Stage I, II and III, respectively.
EMAST and MSI Analysis
EMAST was present in 50 (33%, Figure 2, A and B) and MSI-H in
44 (28%) of 152 tumors, all of which in the colon (none in the
rectum) and 90% in the proximal part of the colon. EMAST was
positively associated with MSI (42/50 EMAST we also MSI-H, 84%
overlap; P < .001), but not with tumor stage.
Almost half of the cohort (45%) showed no instability at any
EMAST marker, while most EMAST-positive patients had instability
at all 5 markers (Figure 2, C and D). The most frequently mutated
marker was D8S321 (38% of tumors), followed by D20S82 (34%).
The marker with the least events in microsatellite-stable tumors (most
specific to EMAST status) was D20S85 (Table 1). Thirty-four (34)
tumors had one unstable EMAST marker and were thus classified as
EMAST-negative (Figure 2D).
MSH3 Analysis
Whole slide microscopical evaluation of tumor area for MSH3 loss
found only <10% of the tumor nuclei with negative stain in all
samples, most being 5% negative (Figure 3, A and B).
Digital analysis (Figure 3) showed a similar spread (range
0.1e15.7%, mean 2.2%). Hotspot MSH3 negativity ranged between
0.1 to 95.0%, (mean 8.6%) with a significant correlation between the
two sets of measurements (Spearman's rho ¼ 0.677 P < .001),
indicating that the measurements in the hotspots are indicative of the
rest of the tumor.
MSH3 loss in hotspots was categorized in subclasses according to
different cut-off points (1%, 5%, 10%, 25% and 50%) to establish
whether a certain degree of protein loss could account for EMAST
presence. None of the subclasses correlated with EMAST status, nor
MSI-H or disease recurrence.
Heterogeneous expression of MSH3 was noted in some cases, with
nuclei staining only partially positive for the protein (Figure 3C).
However, these findings were not related to EMAST nor MSI.
Discussion
Based on a robust, automated, and digitalized protocol of IHC
assessment with a verified MSH3 antibody, this study could not
demonstrate an association between loss of MSH3 and EMAST in
CRC. While other mechanistic contributions of MSH3 to EMAST
Figure 1. MSH3 immunohistochemistry virtual image analysis process.(A-C) An initial gross exclusion of stroma, tissue folds and normal
tissue is carried out, selecting a “work area”where an app-based algorithm is then run to specifically mark tumor cells and exclude
stroma. This results in a highlighted region of interest (ROI, marked in blue); (D) A second app-based algorithm classifies cells on the
basis of their positivity (green) or negativity (blue) for the MSH3 protein; (E-F) A heatmap is created to highlight areas on the whole
slide where the highest concentration of negative cells are located; (G) Based on the heatmap created in (E), a 0.8 mm2 round ROI
(hotspot, light blue circle) is placed and becomes the focus of the analysis; (H) Fully classified, hotspot-derived ROI.
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cannot be ruled out based on the current experiment, this study
suggests that neither protein loss, nor protein translocation (e.g. from
cytosol to nuclei) is likely to be the cause of EMAST in patients with
CRC. Thus, other mechanisms to EMAST must be considered
beyond the notion that loss of MSH3 is essential to EMAST
development [22]. Several points warrant further discussion.
The role of MSH3 expression in EMAST is debated and not yet
fully understood. Some previous mechanistic investigations have
based their experimental studies on effects seen in cancer cell lines
[12,13]. In human CRC, however, one study showed high degree of
MSH3 loss found in EMAST-positive cancers [16], but others have
found no significant association between MSH3 loss and EMAST
[17].
One possible explanation for the discordance between the current
findings and previous results could be the source and type of antibody
used for MSH3. One previous study used a clone to MSH3 that is no
longer on the market [17], while neither the source nor clonality of
the antibody used in a second study [16] could be reproduced. A third
study used an affinity-purified rabbit polyclonal antibody [10]. The
antibody used in the current study was developed and tested for
human immunohistochemistry protocols, thus thoroughly validated
using appropriate positive and negative controls.
Figure 2. EMAST analysis.Electropherograms of multiplex PCR fragment analysis are shown for (A) an EMAST-negative and (B) an
EMAST-positive patient. Arrows indicate extra PCR products at þ/ 4n bp in unstable markers. (C) Stacked bar population graph
showing frequency of instability (red) at each EMAST marker, in EMAST-positive and EMAST-negative populations. (D) bar chart
showing proportions of patients grouped by total number of unstable EMAST markers. For patients bearing only 1 marker mutated
(not EMAST, according to our thresholds) the bar is stacked to specify each marker’s abundance.
Table 1. EMAST markers, genomic loci (GRCh38/hg38 assembly), repeat type ( strand), and frequency of mutation.
MARKER LOCUS REPEAT EMASTþ EMAST- MSI MSS all tumors
MYCL1 *, n (%) 1p34.3 AAAG 40 (88.9) 5 (11.1) 38 (84.4) 7 (15.6) 45 (29.8)
D9S242 *, n (%) 9q33.3 AAAG 39 (84.8) 7 (15.2) 38 (82.6) 8 (17.4) 46 (30.5)
D20S82 *, n (%) 20p12.3 AAAG 41 (78.8) 11 (21.2) 36 (69.2) 16 (30.8) 52 (34.4)
D8S321, n (%) 8q24.21 AAAG 48 (82.8) 10 (17.2) 40 (69.0) 18 (31.0) 58 (38.2)
D20S85, n (%) 20q12 AAAG 26 (96.3) 1 (3.7) 25 (92.6) 2 (7.4) 27 (17.8)
* N ¼ 151.
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Subjective selection and cherry picking of regions of interest to
measure IHC stains may be another issue across studies. In the
current study, in order to account for variation and involuntary
selection bias in the analysis of MSH3 expression, we constructed a
heatmap-based hotspot analysis in addition to evaluation of whole
slides. The hotspot approach is presently proving useful in the
evaluation of prognostic biomarkers with thresholds of low
expression, such as Ki67 in breast cancer [23], and has been
implemented in the Norwegian, Danish and Swedish pathology
guidelines [24e26]. However, results will still largely depend on the
robustness of the antibodies used and their reproducibility. For
MSH3, the previous studies used antibodies that are no longer on the
market, thus difficult to reproduce.
Immunohistochemistry is a complex multi-step procedure,
performed by laboratories on a range of instruments and
interpreted subjectively by pathologists according to guidelines
that are often designed for a specific diagnostic test. Autostainer
instruments and digital image analysis have reduced the discre-
pancies originating from manual experiments [27], although this
technique is still often performed manually in research labs and as
such open to a multitude of sources of variation [28,29]. To reduce
bias and misinterpretation of results to the best of our abilities, this
study employed automated staining together with objective,
automated assessment.
We found no association between MSH3 expression and EMAST
in CRC in the present study. The findings may have implications
beyond CRC as EMAST has been described in tumors other than
CRC [7]. A recent study in patients with pancreatic cancer that
described EMAST in up to 40% of patients found no inactivation of
MSH3 in the tumors [30], which is in line with the current results,
although in a different cancer type. Furthermore, MSH3 frameshift
mutations were found to be specific to CRC, but not for endometrial
cancer [15], which is also known for harboring high levels of EMAST
[31]. These observations, taken together with the results of this study
and the general disagreement in the literature, discourage the
proposed role of MSH3 loss as a universal biological mechanism
underlying EMAST.
The large overlap of MSI and EMAST in CRC found in the
current study correlates well with results from the literature [17].
EMAST could represent an exacerbation of MSI rather than a
separate occurrence. In the current study we found EMAST to
occur in colon cancers and to be associated with MSI features, as
described previously [19]. Shared features between MSI and
EMAST include prevalence in the proximal part of the colon and,
in the case of the present study, an absence or low prevalence in
rectal cancers. Two reports [16,32] describe a high prevalence of
EMAST among rectal cancer patients, however in one (a
rectum-only study) EMAST prevalence was higher in African
American than Caucasian patients [32]. In the second report,
describing 61% of rectal cancers as EMAST, the cohort was based
on patients of Asian ethnicity [16]. In contrast, the present cohort
consists predominantly of Caucasian patients. Considering the
documented variation of MSI-H across demographic factors such
as gender and ethnicity [33], EMAST might well follow a similar
pattern, thus explaining discrepancy in rectal distributions. The
current results are nonetheless consistent with other studies
[16,17,34] finding EMAST prevalently in colon, and more
specifically in the proximal part of the colon.
In conclusion, the mechanism leading to genomic instability in
tetranucleotides and expressed as EMAST is still largely unknown at
present. Indeed, EMAST may, as suggested for conventional MSI, be
related to epigenetic mechanisms that occur with aging (e.g. epigenetic
loss of DNA repair mechanisms). EMAST may thus represent an
epiphenomenon of age and tumorigenesis rather than a specific
tumor-driving trait per se. On the other hand,MSI-induced frameshifts
could affect MSH3 functionalitydand lead to EMASTdin ways that
the antibody used in this study could not highlight. Further
investigations into the mechanisms of EMAST is warranted.
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Abstract
Introduction Microsatellite instability (MSI) predict response to anti-PD1 immunotherapy in colorectal cancer (CRC). CRCs 
with MSI have higher infiltration of immune cells related to a better survival. Elevated Microsatellite Alterations at Tetranu-
cleotides (EMAST) is a form of MSI but its association with PD-L1 expression and immune-cell infiltration is not known.
Methods A consecutive, observational cohort of patients undergoing surgery for CRC. EMAST and clinicopathological 
characteristics were investigated against PD-L1, as well as CD3 and CD8 expression in the invasive margin or tumour centre 
(Immunoscore). Difference in survival between groups was assessed by log rank test.
Results A total of 149 stage I–III CRCs patients, with a median follow up of 60.1 months. Patients with PD-L1+ tumours 
(7%) were older (median 79 vs 71 years, p = 0.045) and had EMAST+ cancers (OR 10.7, 95% CI 2.2–51.4, p = 0.001). 
Recurrence-free survival was longer in cancers with PD-L1+ immune cells (HR 0.35, 95% CI 0.16–0.76, p = 0.008, inde-
pendent of EMAST) and high Immunoscore (HR 0.10, 95% CI 0.01–0.72, p = 0.022). Patients expressing PD-L1 in immune 
cells had longer disease-specific survival (HR 0.28, 95% CI 0.10–0.77, p = 0.014).
Conclusions Higher Immunoscore (CD3/CD8 cells) and expression of tumour PD-L1 is found in CRCs with EMAST. 
Lymphocytic infiltrate and peritumoral PD-L1 expression have prognostic value in CRC.
Keywords Colorectal cancer · EMAST · PD-L1 · Immunoscore · Survival · Recurrence
Abbreviations
CRC  Colorectal cancers
EMAST  Elevated Microsatellite Alterations at Selected 
Tetranucleotides
MSI  Microsatellite instability
Introduction
Colorectal cancers (CRCs) with deficient mismatch repair 
(MMR) are often hypermutated, have microsatellite insta-
bility (MSI), are associated with improved prognosis and is 
defined to the ‘immunogenic’ class of consensus molecu-
lar subtypes [1]. Notably, MSI is determined by a panel of 
microsatellite markers, commonly mononucleotides, accord-
ing to established guidelines [2]. However, an alternative 
form of MSI is found in tetranucleotide-based microsatellites 
and labelled Elevated Microsatellite Alterations at Selected 
Tetranucleotides (EMAST) [3, 4]. Currently, the prognos-
tic value, molecular mechanisms and clinical implications 
of EMAST are unclear. EMAST was linked in vitro with 
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downregulation of MSH3, a member of MMR specifically 
implicated with repair of long indels [4]. This proposed 
mechanism has not been confirmed across patient series, 
with a previous study from our group refuting an associa-
tion between MSH3 and EMAST [5]. Prognostic data on 
EMAST is also scarce. In a previous study, we found that 
patients with EMAST+ were older, frailer and less likely to 
have recurrence from CRC [6].
CRCs with MSI are associated with a higher production 
of neoantigens and consequent immune system activation 
[7]. The understanding of host immune system and its rel-
evance for cancer control has evolved across several tumour 
types yet with varying potential for therapeutic interven-
tion and effect on disease trajectory [7]. In colorectal cancer 
(CRC), data suggest that type and density of immune cells 
are related to survival and may be used to improve TNM-
staging by incorporating an Immunoscore [8, 9]. Hence, the 
immune cells infiltrating in the tumour microenvironment 
have a functional role in CRC, although understanding of 
associated factors related to this peritumoral activation is 
poor at present.
Cancer immunosurveillance of the adaptive immune 
system may be disturbed through various mechanisms [10]. 
One example is the activation of immune checkpoints such 
as the receptor-ligand complex PD-1/PD-L1 that dampens 
the immune response and cause T-cell exhaustion [7, 11, 
12]. Data suggesting that PD-1 blockade therapy potentially 
benefits the MMR/MSI subsets of CRCs and other cancers 
[13–15], introduced immunotherapy for clinical use [16]. 
However, selection of patients who may benefit and respond 
is currently uncertain. Further, scarce evidence exists to date 
on the association of PD-L1 expression and prognosis and 
survival, both within and outside the predictive subsets of 
CRC. Data regarding the relationship between EMAST and 
PD-L1 expression and the associated T-cell infiltration are 
lacking.
The aim of the present study was thus to describe the 
prevalence of PD-L1 expression, Immunoscore, their rela-
tionship with MSI/EMAST and their relevance towards 




Patients were consecutively recruited during the 
01/2013–05/2015 period at Stavanger University Hospital 
(SUH), Norway. Norway has a universal health care cover-
age for all citizens and the university hospital serves a pri-
mary catchment region of about 370,000 inhabitants. With 
no selection or referral bias in the health care system, the 
study cohort can be considered as population representative 
and generalizable to similar regions in Northern Europe.
The present study cohort is part of an ongoing prospec-
tive project (ACROBATICC) approved by the regional eth-
ics committee (REK Helse Vest: 2012/742) and registered 
on clinicaltrials.gov (NCT01762813) [17]. All consecutive 
patients amenable to curative intent surgery, aged ≥ 18 years 
of age and who could provide written informed consent were 
eligible for inclusion into ACROBATICC. This observa-
tional cohort study of patients presenting with operable stage 
I–III disease and is reported according to the STROBE [18] 
and the REMARK [19] guidelines for biomarker studies.
Histopathology
All cancers were staged by an experienced pathologist fol-
lowing guidelines published in the 7th edition of the AJCC 
staging manual [20]. Proximal tumour location is intended 
as the region between caecum and transverse colon, while 
distal is intended as the region between the splenic flexure 
and sigmoid colon.
EMAST and MSI analysis
Analyses of EMAST and MSI, including primer sequences 
and PCR conditions, are described previously [21, 22]. 
Briefly, formalin-fixed paraffin blocks selected by an expe-
rienced pathologist were sectioned for DNA extraction. 
Macrodissection of areas indicated by the pathologist was 
employed where necessary to enrich for tumour cells. Auto-
mated DNA extraction was carried out using AllPrep DNA/
RNA FFPE kit (Qiagen, Hilden, Germany) on a QiaCUBE 
instrument (Qiagen), according to manufacturer’s instruc-
tions. Nucleic acid concentration and purity were measured 
on a NanoDrop 2000 (ThermoFischer scientific, Waltham, 
USA). Two separate multiplex PCR reactions (one for each 
MSI and EMAST) were set up for tumour and normal DNA 
in each patient. TypeIT microsatellite (Qiagen) master mix, 
together with a blending of 5 × 5′-fluorescently labelled 
primer pairs was used for each reaction. The primers for 
MSI were specific for the quasimonomorphic mononucleo-
tides BAT-26, NR-21, NR-24 and NR-27, while the EMAST 
marker panel consisted of MYCL1, D8S321, D9S242, 
D20S82, and D20S85. To define a tumour as MSI-H, at least 
2/5 markers needed to be unstable in their respective panels.
Immunohistochemistry
Paraffin sections consecutive to the haematoxylin–eosin 
(H&E) sections were cut to 2 µm and mounted onto Super-
frost Plus slides (Menzel, Braunschweig, Germany). Anti-
gen retrieval and antibody dilution were optimised for each 
induvial staining. All antibody protocols were optimized 
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before study onset. Paraffin sections consecutive to the 
haematoxylin–eosin (H&E) sections were cut to 2 µm and 
mounted onto Superfrost Plus slides (Menzel, Braunsch-
weig, Germany). Slides were incubated at 60 °C for 1 h 
and then transferred to a Dako Omnis (Dako, Glostrup, 
Denmark) instrument. CD3 (Dako, Clone F7.2.38) 
was used at a dilution of 1:75 and visualised by EnVi-
sion FLEX, High pH (Dako Omnis) (GV80011-2). CD8 
(Dako, Clone C8/144B) was used at a dilution of 1:50 and 
visualized by EnVision FLEX, High pH (Dako Omnis) 
(GV80011-2).with EnVision FLEX+ Mouse LINKER 
(Dako Omnis) (GV82111-2) signal amplification.
EnVision FLEX Antibody Diluent (Dako, K800621-
2) was used as diluent. Pre-treatment time was 20 min at 
97 °C using EnVision FLEX Target Retrieval Solution, 
High pH (50 ×) (Dako Omnis) (GV800). Both antibodies 
were incubated for 20 min. Hematoxylin (Dako Omnis) 
(GC80811-2) was used as counterstain.
PD-L1 IHC 22C3 pharmDx (Dako SK00621-2) was 
used strictly according to manufacturer’s recommendation 
on a Dako Autostainer Link 48 instrument.
Scoring of PD‑L1 expression
PD-L1 expression (Fig.  1) was assessed independently 
by two experienced pathologists (DL and EG), blinded 
to patients’ other characteristics and each other results, 
on whole sections. Membranous staining was regarded as 
positive, and staining intensity was not evaluated. PD-L1 in 
tumour cells was scored as positive or negative using ≥ 5% 
positive as cut-off, based on previous studies [14, 23].
For PD-L1 expression on peritumoral immune cells, the 
percentage of positive cells were evaluated in the visually 
most positive area of 1 mm2 in the invasive margins of the 
tumour on the scanned slides (same area for both patholo-
gists). In cases with > 10% discordance between the patholo-
gists, the slides were reviewed together, until consensus was 
reached. For expression in less than 10% of the immune 
cells, discordance of < 5% was accepted.
The cut-off for positive or negative classifications of 
patients based on PD-L1 expression in peritumoral immune 
cells, was determined experimentally.
Receiver operator characteristics (ROC) curve analy-
sis was used to determine cut-offs for PD-L1 expression 
Fig. 1  Immunohistochemistry of PD-L1. 20X magnification view of a immune PD-L1−/tumour PD-L1−. b Immune PD-L1−/tumour PD-L1+. 
c Immune PD-L1+/tumour PD-L1−. d Immune PD-L1+ / tumour PD-L1+. Scale bar represents 100 μm
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in immune cells, with disease-specific death and disease 
recurrence as the endpoints. The optimal cut-off point in 
both ROC curve analysis corresponded to the 25th per-
centile and was therefore chosen as the discriminant cut-
off to dichotomize expression of immune cells PD-L1 into 
positive/negative.
Immune scoring of CD3 and CD8 markers
All the sections were scanned at 40 × magnification using 
Leica SCN400 slide scanner (Leica Microsystems, Wetzlar, 
Germany) and uploaded onto the image analysis software 
 Visiopharm® (Hoersholm, Denmark). Tumour centre and 
invasive margin areas were marked manually on whole slide 
images and the same areas were used for the CD3 and CD8 
stained sections. Using Bayesian optimisations [24], an 
algorithm was developed to identify and label CD3+ and 
CD8+ T-cells in both regions.
Relative quantification of positive cells was obtained 
by dividing the Visiopharm-measured area of positive 
label by the estimation of mean area of a lymphocyte 
(60 µm2), thereby approximating the number of CD3+ and 
CD8+ T-cells per square millimetres (cells/mm2). All the 
cases were inspected, and unspecific staining and artefacts 
were manually removed from the analyses where appro-
priate. For individual CD3/CD8 analysis, patients were 
assigned either a “low” or “high” score for each individual 
staining (CD3 and CD8), in each tumour location (tumour 
centre and invasive margin and IM), using the 75th percen-
tile as a threshold. This created four categories (CD3 and 
CD8, in tumour centre and invasive margin as either high 
or low).
The Immunoscore was calculated as described else-
where [8]. Briefly, the densities (in cells/mm2) of CD3+ and 
CD8+ cells in both tumour centre and invasive margin were 
first converted into percentiles, and then the mean value of 
the four percentiles calculated. An Immunoscore of “Low”, 
“Intermediate” or “High” was then assigned to each patient 
according to their mean percentile scores, with cut-offs as 
0–25%, 25–70%, and 70–100% respectively, as described 
in [8].
Collection of clinical data and follow up
Clinical measurements as well as follow up data (cause and 
date of death, date of recurrence) were retrieved from the 
electronic patient records. Patients’ surveillance after sur-
gery was according to the national guidelines as an interval-
based serum CEA (quarterly) and imaging (e.g. a biannual 
CT-chest and US liver for the first 3 years, then annually) for 
up to 5 years after surgery. Colon cancers were usually fol-
lowed up by general practitioners while rectal cancers were 
seen by gastrointestinal surgeons in the hospital outpatient 
clinics. Any suspected recurrence or deviation on imag-
ing were worked up in-hospital and consulted in multidis-
ciplinary team meetings, where applicable. The patients’ 
electronic health records were queried for any documented 
events, and follow-up for this study was completed as of 24th 
September 2019.
Definition of survival endpoints
Recurrence-free survival (RFS) was defined as time from 
primary surgery until first clinical evidence (histologically 
confirmed or image-based) of recurrent disease. Disease-
specific survival (DSS) was defined as time from primary 
surgery and death imputable to CRC. Survival was assessed 
for overall survival (OS) defined as time from primary sur-
gery to death of any cause.
Statistical analyses
All statistical tests were done using IBM SPSS Statistics 
for Windows, Version 25.0 (IBM Corporation, Armonk, 
NY, USA). Associations between categorical variables 
were tested with Chi-square (or Fischer’s exact test, where 
appropriate) method and reported with odds ratios and 95% 
confidence interval (95% CI). Spearman’s rho or Pearson 
tests were used for correlations between continuous/ordinal 
variables, where appropriate. Mann–Whitney U test was 
used to compare differences in continuous or ordinal vari-
ables between groups. Inter-coder reliability score for PD-L1 
evaluation was estimated using the KALPHA extension for 
SPSS and expressed as Krippendorff’s alpha (α).
The Kaplan–Meier method with log rank comparison of 
factors was used to investigate survival curves differences 
between groups and are given as (months difference [95% 
CI]). Univariable proportional hazards are given in hazard 
ratios (HR) with 95% CI. All tests were two-tailed and a p 
value < 0.050 considered as statistically significant.
Results
The study cohort included 149 stage I–III CRC patients who 
underwent surgery with curative intent (Fig. 2). Patients’ 
descriptive parameters are included in Table 1.
PD‑L1 expression and EMAST
Of the 11 patients classified as PD-L1+ in tumour cells, 
nine were diagnosed with right-side CRC (82%, no rectum, 
p = 0.111) and were EMAST+ (82%; Table 2). Inter-coder 
reliability score for PD-L1 expression in tumour cells was 
high (Krippendorff’s α = 0.93; 95% CI 0.83–0.99). A weak 
correlation was also seen between expression of tumoral 
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Fig. 2  Flowchart of inclusion/
exclusion criteria. CRC denotes 
colorectal cancer; IHC denotes 
immunohistochemistry
Table 1  Variables associated 
with EMAST status
N = 149
Bold values indicate statistical significance (P < 0.050)
*One missing
Total n, (%) EMAST− n = 99 (66) EMAST+ n = 50 (34) p
Age < 0.001
 Median (range) 72 (37–92) 70 (37–91) 77.5 (50–92)
 ≤ 72 75 (50) 60 (80) 15 (20)
 > 72 74 (50) 39 (53) 35 (47)
Sex < 0.001
 Male 65 (44) 54 (83) 11 (17)
 Female 84 (56) 45 (54) 39 (46)
Localisation < 0.001
 Colon 124 (83) 74 (60) 50 (40)
 Rectum 25 (17) 25 (100) 0 (0)
Within colon < 0.001
 Right 70 (57.5) 25 (36) 45 (64)
 Left 54 (43.5) 49 (90) 5 (10)
Grade* < 0.001
 High 39 (26) 15 (38) 24 (62)
 Low 109 (74) 83 (76) 26 (24)
Stage 0.234
 I 51 (34) 30 (59) 21 (41)
 II 50 (34) 33 (66) 17 (34)
 III 48 (32) 36 (75) 12 (25)
MSI < 0.001
 MSS 105 (70.5) 97 (92) 8 (8)
 MSI-H 44 (29.5) 2 (5) 42 (95)
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PD-L1 and total number of unstable markers analysed for 
both EMAST and MSI (Fig. 3; p = 0.001). A higher number 
of markers from the two panels combined were indeed 
unstable in PD-L1+ tumours (median 9/10 vs 1/10 mark-
ers, p = 0.001), when dichotomised accordingly (Suppl. 
Table 1). Tumour PD-L1+ patients were significantly older 
(79 vs 71 years, p = 0.045) and had lower preoperative lev-
els of serum albumin (33.6 vs 38.1 g/L, p = 0.011) (Suppl. 
Table 1). All PD-L1+ tumours (11/11, 100%) were in the 
colon, while none of the 25 rectum tumours scored positive 
(p = 0.212).
In peritumoral infiltrating immune cells, the rate of 
PD-L1 expression was higher than in tumour cells (Fig. 1). 
No statistically significant association was found between 
expression of PD-L1 in immune cells and patients’ age, 
EMAST status or number of unstable markers (Suppl. 
Table 1). Again, a significant but small correlation was 
found between % PD-L1 and CD3/CD8 in immune cells, 
albeit not in the case of CD3 in the invasive margin. The two 
ROC analyses for determination of ideal cut-off value of % 
PD-L1 positive immune cells had AUC = 0.698, p = 0.012 
with disease-specific death and AUC = 0.648, p = 0.018 with 
disease recurrence as endpoint (data not shown). The 25th 
percentile cut-off showed no difference in the distribution 
among colon and rectum cancers, of which 73% and 76% 
Table 2  Associations with 
immune markers and EMAST 
status
Bold values indicate statistical significance (P < 0.050)
N = 149 Total n, (%) EMAST− n = 99 
(66)
EMAST+ n = 50 
(34)
OR (95% CI) p
PD-L1 in tumour cells 10.7 (2.2–51.4) 0.001
 Low 138 (93) 97 (98) 41 (82)
 High 11 (7) 2 (2) 9 (18)
PD-L1 in immune cells 1.0 (0.5–2.2) 0.973
 Low 39 (26) 26 (26) 13 (26)
 High 110 (74) 73 (74) 37 (74)
Immune cells in tumour centre
 CD3+ 2.37 (1.1–5.1) 0.025
  Low 112 (75) 80 (81) 32 (64)
  High 37 (25) 19 (19) 18 (36)
 CD8+ 2.4 (1.1–5.1) 0.025
  Low 112 (75) 80 (81) 32 (64)
  High 37 (25) 19 (19) 18 (36)
Immune cells in invasive margin
 CD3+ 3.22 (1.5–7.0) 0.002
  Low 112 (75) 82 (83) 30 (60)
  High 37 (25) 17 (17) 20 (40)
 CD8+ 2.4 (1.1–5.1) 0.025
  Low 112 (75) 80 (81) 32 (64)
  High 37 (25) 19 (19) 18 (36)
Immunoscore n.c. 0.020
 Low 31 (21) 24 (24) 7 (14)
 Interm 79 (53) 56 (57) 23 (46)
 High 39 (26) 19 (19) 20 (40)
Fig. 3  Correlation matrix of immune-related variables. For pure ordi-
nal variables (marked by the notation “cells/mm2”), Pearson correla-
tion coefficient is shown. For all other variable Spearman R-O tests 
were used. Bold correlation coefficients are significant (p < 0.05)
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showed PD-L1-positive immune cells, respectively. Inter-
coder reliability score for PD-L1 expression in immune 
cells was relatively high (Krippendorff’s α = 0.81; 95% CI 
0.72–0.88).
Immune cell types, Immunoscore and EMAST status
Higher density of CD3+ and CD8+ cells in tumour cen-
tre and invasive margins were found in EMAST-positive 
patients (Table 2).
Immunoscore was distributed into low (n = 31, 21%), 
intermediate (79, 53%) and high (n = 39, 26%) categories, 
respectively. EMAST-positive patients were proportionally 
more represented in the higher Immunoscore subclasses 
(Table 2). As expected, Immunoscore correlated strongly 
with each individual CD3+ and CD8+ tally. A stronger 
relationship between Immunoscore and % of PD-L1+ in 
immune (Spearman 0.365, p < 0.001) rather than in tumour 
cells (0.262, p = 0.001) was found (Fig. 3).
Tumours with PD-L1+ tumours had significantly higher 
counts of CD3 and CD8 in the invasive margin, as well as 
CD8, but not CD3 in the tumour centre (Suppl. Table 1).
Patients with PD-L1+ immune cells had significantly 
higher counts of CD3 and CD8 in both the invasive mar-
gin and tumour centre (Suppl. Table  1). Both immune 
PD-L1+ (p < 0.001) and tumour PD-L1+ (p = 0.037) patients 
were significantly associated with a high Immunoscore.
Risk of recurrence and recurrence‑free survival
During the follow up period, a total of 26 (17.4%) patients 
experienced recurrent disease. Eight recurrences (31%) 
were in the liver, eight in the lungs, 7 (27%) were local 
recurrences, and one (4%) each for bone, peritoneum and 
brain.
Generally, higher numbers of infiltrating lymphocytes 
correlated with lower risk of disease recurrences (Suppl. 
Figure 1).
A significant difference was found between the catego-
ries of the Immunoscore for RFS (Fig. 4; Table 3). No 
Fig. 4  Survival analyses comparing prognostic groups. Kaplan-Meier 
analysis of a recurrence-free survival (RFS) of immune PD-L1+/− 
groups. b RFS of immune PD-L1+/− groups, stratified for EMAST 
status. c RFS of Immunoscore groups (low-intermediate-high). d Dis-
ease-specific survival (DSS) of immune PD-L1+/− groups
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significant association between tumour PD-L1 and rate 
(p = 0.690) or time to recurrence (p = 0.520) were recorded. 
Of the patients with negative immune-PD-L1 expres-
sion, 12 (31%) presented with recurrent disease patients 
against 14 (13%) of those with immune-PD-L1+ . Patients 
with PD-L1+ immune cells had longer estimated RFS (72 
[68–75] vs 59 [49–69] months, p = 0.006) than immune-PD-
L1− patients, independently of EMAST status (p = 0.041 
and 0.021 in EMAST− and EMAST+ cases, respectively) 
(Fig. 4).
Overall and disease‑specific survival
At the time of final follow-up, a total of 35 (23%) patients 
had died. Of those, 15 (43%) were CRC-related deaths. 
Median follow up length was 68.8 months (range 0.4–79.6) 
from primary surgery to death or right-censoring.
Only nodal status (pN0 vs pN+ or stage I–II vs stage III) 
was associated with OS in univariate analyses (Table 3). 
When stratified according to the three Immunoscore levels, 
a high Immunoscore had significantly longer overall sur-
vival than low (74 vs 60 [50–70] months, p = 0.008), but not 
intermediate (74 [69–79] vs 68 [63–72] months, p = 0.192). 
No difference was noted in survival time when patients 
were divided according to tumour PD-L1 expression, 
whilst patients with a higher PD-L1 proportion in immune 
cells had longer DSS (log rank p = 0.009; Fig. 4; Table 3). 
When stratified for EMAST status, patients with PD-L1+ in 
immune cells had better DSS in the EMAST-negative group 
(log rank p = 0.033) but not in the EMAST+ group (log rank 
p = 0.107).
Discussion
In the current study, CRC having EMAST correlated 
with a higher count of intra- and peritumoral CD3+ and 
CD8+ T-cells and a higher Immunoscore compared to CRC 
cancers with no EMAST. Also, PD-L1 expression occurred 
both in immune cells and in tumour cells in CRCs, specifi-
cally those with EMAST and MSI.
While the patterns of expression in tissue does not 
directly translate into functional ability, there are several 
observations we would point out as being of interest.
First, expression of PD-L1 showed a dual role according 
to its localisation in this study. Tumour cell-confined PD-L1 
correlated with EMAST and generally increasing degree of 
MSI, while immune cells PD-L1 did not. EMAST indepen-
dently correlated with a generally higher immunogenicity, 
with higher levels of CD3+ , CD8+ and PD-L1+ in tumour 
cells. This is generally in accordance with the relationship 
between MSI, high mutational burden, generation of tumour 
neoantigens, and activation of the immune system [7, 25]. 
Notably, one study previously reported an association with 
EMAST and CD8+ but not CD4+ T-cells infiltration in 
tumour [26]. In a previous report, a link between EMAST 
and older age and a frailer phenotype in patients with 
EMAST positive cancers was found [6]. These observations, 
pertinent to a cumulative increase in genetic abnormalities 
(e.g. EMAST, MSI, mutation burden) during physiological 
and cellular senescence, may weigh in on the picture of a 
neoantigen-rich tumour microenvironment. Of note, while 
the distribution of immune cells expressing PD-L1 seemed 
comparable between colon and rectum cancers, PD-L1-ex-
pressing tumours were exclusively found in colon cancers. 
This may further confirm a relationship between PD-L1 and 
instability at microsatellites, as both MSI and EMAST are 
more prevalent in the colon.
A direct relationship between high Immunoscore and high 
PD-L1 expression in both tumour and immune cells was 
also shown in the present study. Tumours with low counts 
for CD3+ and CD8+ cells are associated with less overall 
(tumour/immune) PD-L1 expression. PD-L1 was here found 
to be rarely expressed in tumour cells, and strictly con-
nected to EMAST status, while more diffuse in infiltrating 
immune cells. This is concordant with recent reports placing 
tumour PD-L1 rates generally under 15–20% of CRCs, and 
immune PD-L1 consistently higher [27–32]. These obser-
vations may suggest that induction of PD-L1 is regulated 
Table 3  Univariate analyses for survival
Bold values indicate statistical significance (P < 0.050)
*Numbers in parentheses are events/total number of cases
Term HR 95% CI p
Recurrence-free survival (26/149)*
 PD-L1 in immune cells 0.35 0.16–0.76 0.008
 PD-L1 in tumour cells 0.53 0.07–3.87 0.527
 Immunoscore (int. + low vs 
high)
0.10 0.01–0.72 0.022
 pN (N0 vs N+) 6.94 2.91–16.52 < 0.001
 EMAST 0.35 0.12–1.02 0.054
Disease-specific survival (15/149)*
 PD-L1 in immune cells 0.28 0.10–0.77 0.014
 PD-L1 in tumour cells 0.98 0.13–7.44 0.982
 Immunoscore (int. + low vs 
high)
0.03 0.00–3.37 0.145
 pN (N0 vs N+) 229.76 1.44–36788.19 0.036
 EMAST 0.51 0.14–1.79 0.289
Overall survival (35/149)*
 PD-L1 in immune cells 0.61 0.30–1.23 0.165
 PD-L1 in tumour cells 1.78 0.63–5.05 0.277
 Immunoscore (int. + low vs 
high)
0.42 0.16–1.08 0.073
 pN (N0 vs N+) 3.17 1.62–6.19 0.001
 EMAST 1.04 0.52–2.09 0.915
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by different pathways in immune and tumour cells. On one 
side, EMAST (as MSI) tumours, due to their higher load of 
tumour neoantigens are possibly subject to a more vigorous 
cytotoxic immune response, and endogenously expressing 
PD-L1 to counteract it. In non-EMAST tumours with high 
Immunoscore, otherwise, modulation of immune response 
is achieved by expression of PD-L1 on immune cells, in a 
mechanism also referred to as adaptive immune resistance 
[33, 34]. Finally, tumours having both low Immunoscore and 
PD-L1 expression on immune cells lack an immune reaction 
in the tumour microenvironment and present with higher rate 
of recurrences, sooner.
Prognostically, only expression of PD-L1 in the peritu-
moral cells proved discriminant in both rate of- and time 
to recurrences, as well as for disease-specific survival. In 
terms of RFS, the association was independent of EMAST 
status and comparable to that of Immunoscore, suggest-
ing that immune expression of PD-L1 contributes to the 
protective effect of tumour immunosurveillance. Tumour 
PD-L1 was not associated with any of the survival end-
points examined. In contrast to Immunoscore, there is 
scarce data on the prognostic significance of PD-L1 
expression in CRC. The relationship between tumour-
expressed PD-L1 and tumour-infiltrating lymphocytes is 
being investigated in multiple cancers [35, 36]. The focus 
is however usually on tumour-expressed PD-L1, because 
of its predictive value for immunotherapy, while there is 
discordance on its prognostic role [32, 37, 38]. PD-L1 
positivity on peritumoral immune cells, on the other hand, 
is generally a sign of an active immune response and thus 
associated with improved survival [31, 32, 39, 40].
A limitation of the present study is the limited size 
of the cohort, with only 11 patients scoring positive for 
tumour PD-L1, therefore limiting the statistical power. 
However, the idea of modern personalized medicine is 
to identify particular subgroups with potential for refined 
therapy. Prevalence of tumour PD-L1 in MSI CRCs and 
the low (15–20%) incidence of the subgroup, warrant 
expansion of the cohort in order to investigate the find-
ings in larger cohorts and refined sub populations. A fur-
ther limit is the cut-off determination for immune PD-L1 
expression. Derived from ROC analysis for recurrence and 
disease-specific death, which are time-dependent variable, 
this method may only apply to the present cohort, in the 
elapsed follow up time. Indeed, a range of methods of 
PD-L1 scoring and subgrouping are described in the lit-
erature, including variation in antibodies used, without 
a generalised consensus. In the present study, the cut-off 
value used for PD-L1 expression in tumour cells (5%) was 
based on previous studies [14, 23, 29], including original 
anti-PD-1 immunotherapy clinical trials.
The current study correlates PD-L1 expression in 
tumour cells with EMAST. Moreover, the findings add to 
the mounting data on PD-L1 expression in peritumoral 
immune infiltrate and Immunoscore as prognostic factors in 
CRC. Finally, this study supports the differentiation between 
tumour- and immune cell expression of PD-L1 as representa-
tive of two distinct mechanisms of immune resistance.
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Prevalence and implications of elevated
microsatellite alterations at selected
tetranucleotides in cancer
M M C Watson1,2, M Berg1,2,3 and K Søreide*,1,2,4
1Department of Gastrointestinal Surgery, Stavanger University Hospital, Stavanger 4068, Norway; 2Gastrointestinal Surgical
Research Unit, Molecular Lab, Hillevåg, Stavanger University Hospital, Stavanger 4068, Norway; 3Centre of Organelle Research,
University of Stavanger, Stavanger 4068, Norway and 4Department of Clinical Medicine, University of Bergen, Bergen 5020,
Norway
Elevated microsatellite alterations at selected tetranucleotides (EMAST), a variation of microsatellite instability (MSI), has been
reported in a variety of malignancies (e.g., neoplasias of the lung, head and neck, colorectal region, skin, urinary tract and
reproductive organs). EMAST is more prominent at organ sites with potential external exposure to carcinogens (e.g., head, neck,
lung, urinary bladder and colon), although the specific molecular mechanisms leading to EMAST remain elusive. Because it is
often associated with advanced stages of malignancy, EMAST may be a consequence of rapid cell proliferation and increased
mutagenesis. Moreover, defects in DNA mismatch repair enzyme complexes, TP53 mutation status and peritumoural inflammation
involving T cells have been described in EMAST tumours. At various tumour sites, EMAST and high-frequency MSI share no
clinicopathological features or molecular mechanisms, suggesting their existence as separate entities. Thus EMAST should be
explored, because its presence in human cells may reflect both increased risk and the potential for early detection. In particular,
the potential use of EMAST in prognosis and prediction may yield novel types of therapeutic intervention, particularly those
involving the immune system. This review will summarise the current information concerning EMAST in cancer to highlight the
knowledge gaps that require further research.
Microsatellites are repeating units of one to six base pairs, which
are ubiquitous, abundant and repeated several times in eukaryotic
genomes. These repeats are prone to errors during DNA
replication, and the failure to correct such errors results in
microsatellite instability (MSI). Since its initial description as a
form of genetic instability in colorectal cancer (CRC), MSI has
been linked to a number of phenotypic characteristics and
clinicopathological features of tumours (Sinicrope and Sargent,
2012). The prognostic and predictive relevance of MSI in CRC has
been well documented (Sinicrope and Sargent, 2012). In CRC, MSI
is the hallmark of forms of hereditary non-polyposis CRC
(HNPCC; or Lynch syndrome) caused by germline mutations in
mismatch repair (MMR) genes. MSI is also detected in 15% of
sporadic CRC cases, usually as a consequence of epigenetically
silenced MMRs (Sinicrope and Sargent, 2012). Furthermore, the
presence of MSI has been demonstrated in other cancers, including
endometrial, ovarian and urinary tract cancers. Currently, MSI
appears to be a genetic aberration found in a wide range of human
solid tumours that is best defined in the context of colorectal
neoplasia; at tumour sites other than CRC, the clinical relevance
and frequency of MSI are variable (Catto et al, 2003; Pal et al, 2008;
Diaz-Padilla et al, 2013). In the clinical setting, such as when
screening for CRC, HNPCC or sporadic MSI, MSI is usually
classified as mononucleotide and dinucleotide repeats (Umar et al,
2004). Recently, a number of reports have also documented
instability at specific tetranucleotide repeats, a phenomenon
termed elevated microsatellite alterations at selected tetranucleo-
tide repeats (EMAST). As an emerging specific form of genetic
alteration, EMAST remains poorly described. However, EMAST
may hold clues for deeper insights into the roles of MSI in cancer
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biology, thus facilitating improved preventive, therapeutic and
prognostic/predictive strategies in human cancer. This review aims
to concisely present the current knowledge concerning EMAST in
human solid cancers; we briefly present the proposed molecular
mechanisms and describe the potential clinical implications for
human cancer.
MICROSATELLITES, REPEAT SIZE AND INSTABILITY
During DNA replication, microsatellites are prone to erroneous
duplication, which involves the addition or deletion of one or
several repeated units, and the failure of DNA proofreading
mechanisms to correct such errors results in instability at
microsatellites. Microsatellite alterations, such as the insertion/
deletion of a repeat, can produce deleterious effects via the
induction of strand slippage and frameshift mutations when a
protein-coding region is affected (Saeterdal et al, 2001; Kim et al,
2013). The results of such effects range from changes in the
physical and chemical properties of the translated proteins to
interference with transcription at promoter sites or the translation
of truncated and dysfunctional proteins.
Generally, repetitive elements can occur in a variety of patterns
and distributions (i.e., tandem, dispersed and paralogues). These
elements constitute as much as 50% of the genome, and
approximately one-fourth of empirically defined human promoters
are surrounded by or contain clustered repetitive elements.
However, the genomic distribution of microsatellites is rather
random; mononucleotides, dinucleotides and tetranucleotides are
primarily found in intronic and intergenic noncoding regions,
whereas other microsatellites (trinucleotides and hexanucleotides)
are located more abundantly within sequences involved in gene
transcription (Subramanian et al, 2003).
Previous attempts at defining MSI have not produced
straightforward results. Following the first MSI international
workshop at the National Cancer Institute (NCI) at Bethesda in
1998, the 2004 revised NCI/Bethesda microsatellite screening panel
(Umar et al, 2004), which is based on five mononucleotide and
dinucleotide microsatellites, defined ‘classical’ MSI as high-
frequency (MSI-H; X2 out of 5 markers are unstable or X40%),
low-frequency (MSI-L; 1 out of 5 markers is unstable orX20% and
o40%) or microsatellite-stable (MSS; no unstable markers
detected). In CRC, there is a consensus on the definitions of MSI
for clinical use (Umar et al, 2004), although defining the different
degrees of instability remains a matter of controversy. Based on the
Bethesda panel, MSS, MSI-L and MSI-H tumours contain different
numbers of altered microsatellites, suggesting that these forms of
MSI represent separate phenomena, at least at the molecular level.
However, MSS tumours and MSI-L unstable tumours are typically
grouped together, because both present similar clinical forms and
gross abnormalities. Notably, MSI-L is generally detected only
when dinucleotide markers are used, and some authors have
disputed the existence of MSI-L completely (Kim et al, 2013). MSI
is found with the highest frequency in mononucleotide repeats,
which are also the most frequently occurring nucleotide repeats
throughout the genome. Notably, tetranucleotide repeats occur at a
much lower frequency than mononucleotide repeats, and it is not
known whether forms of MSI involving nucleotide repeats of
different sizes share common underlying mechanisms. However,
the most clinically relevant microsatellites studied in cancer are
composed of mononucleotide (e.g., Gn), dinucleotide (e.g., CAn) or
tetranucleotide (e.g., AAAGn) repeats. Variations in the number of
repeats in microsatellite sequences among the population are
defined as microsatellite polymorphisms, as opposed to MSI, which
refers to such alterations within multiple cells of the same
individual (e.g., when comparing tumour and normal tissues).
Instability at tetranucleotides represents a variation of MSI that
was not addressed by the Bethesda definitions (Umar et al, 2004),
which are based on mononucleotide and dinucleotide markers.
However, in most EMAST-associated cancers, instability occurs at
loci containing AAAGn or ATAGn repeats.
PREVALENCE AND RELEVANCE OF EMAST IN HUMAN
CANCERS
EMAST has been reported in several cancers of solid organs
(Figure 1), including the colorectum (Haugen et al, 2008; Devaraj
et al, 2010; Lee et al, 2010; Lee et al, 2012), lungs (Ahrendt et al,
2000; Xu et al, 2001; Arai et al, 2013), ovaries (Singer et al, 2004),
bladder (Xu et al, 2001; Danaee et al, 2002; Catto et al, 2003;
Burger et al, 2006a), prostate (Perinchery et al, 2000; Burger et al,
2006b; Azzouzi et al, 2007), kidney (Xu et al, 2001; Catto et al,
2003), head and neck (Xu et al, 2001; Temam et al, 2004), non-
melanoma skin (Danaee et al, 2002) and uterus (Choi et al, 2008).
The estimated prevalence of EMAST according to previously
reported studies is presented in Table 1. In fact, the reported
prevalence and relationship between EMAST and clinicopatholo-
gical features and molecular mechanisms vary considerably across
tumour sites (Figure 1).
CRCs. Presumably because of the great impact that MSI has had
on the understanding of human cancer biology, the vast majority
of EMAST-related reports in the scientific literature concern CRC.
EMAST is found most frequently (460%) in advanced-stage
CRC with poor tumour differentiation (Lee et al, 2010). The
documented presence of EMAST in adenomas has been incon-
sistent, with reports ranging from 0% (Lee et al, 2012) to 33% (Lee
et al, 2010). The overall frequency of EMAST in CRC is much
higher (up to 60%) than the frequency of classical MSI-H (usually
15–20%) (Yamada et al, 2010), and EMAST occurs at high rates in
rectal cancers (Devaraj et al, 2010). EMAST is associated with the
MSI-L classification and demonstrates a worse prognosis with a
shorter time to recurrence and development of distant metastasis
in stage II and III CRC (Garcia et al, 2012). This worse prognosis is
observed regardless of the association of EMAST with greater
infiltration of CD8þ T cells in both the tumour and surrounding
stroma (Devaraj et al, 2010; Lee et al, 2012), a feature usually
associated with better prognosis in CRC. Thus the dual role of
inflammation in this setting warrants further investigation.
Respiratory tract cancers. The reported frequency of EMAST in
lung cancers ranges from 32% to 64.5% (Ahrendt et al, 2000;
Xu et al, 2001; Woenckhaus et al, 2003; Arai et al, 2013). However,
there appears to be a distinction between EMAST and MSI-H, and
mutations in TP53 are common in EMAST cancers (Ahrendt et al,
2000; Xu et al, 2001; Woenckhaus et al, 2003). EMAST was found
to be most prevalent in cases of the squamous subtype and early
stage disease (Xu et al, 2001; Woenckhaus et al, 2003; Arai et al,
2013), although it was associated with higher rates of lymph node
metastasis in another study (Woenckhaus et al, 2003). Addition-
ally, one study found a higher incidence of previous cancer history
in patients with EMAST (Arai et al, 2013), potentially suggesting a
‘field defect’ or cancer susceptibility related to EMAST.
Kidney and urinary tract cancers. The frequency of EMAST in
cancers of urogenital organs is markedly lower compared with that
in other solid tumours and is higher in the lower urinary tract
(urinary bladder) than the upper urinary tract (kidneys, ureters
and renal pelvis) (see Table 1, Figure 1).
In bladder cancer, EMAST-positive tumours (approximately
one-third of bladder tumours) have been associated with TP53
mutations and non-invasive lesions (Danaee et al, 2002). However,
a much lower EMAST frequency (5.3%) was demonstrated
in a large, non-selected cohort of urothelial bladder cancers, and
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EMAST was not found to be associated with TP53 status (Burger
et al, 2006a). In the urinary tract, EMAST appears to be unrelated
to classical MSI and occurs less frequently in the renal pelvis (Catto
et al, 2003). No firm associations between EMAST and
clinicopathological features or clinical outcomes have been
reported (Danaee et al, 2002; Catto et al, 2003; Burger et al,
2006a). The reported EMAST frequency in renal cell carcinomas is
very low, ranging fromo1% (Stoehr et al, 2012) to 12% (Xu et al,
2001). Based on the limited available evidence, it appears that the
prevalence of EMAST decreases from the upper to the lower
urinary tract, with no solid clinical relationships or molecular
mechanisms having been established in this area.
Reproductive organs. In cancers of the reproductive organs,
EMAST occurs slightly more often in malignancies of the female
reproductive organs, such as the ovaries (13%, Singer et al, 2004)
Table 1. Prevalence of EMAST among human solid malignancies
Site Author, year Cohort size (n) Definitions Prevalence (%)
Bladder Xu et al, 2001 38 X1/12 markers unstable 21%
Burger et al, 2006a, b 117 X1/10 markers unstable 9%
Catto et al, 2003 89 X1/8 markers unstable 45%
Danaee et al, 2002 57 X1/7 markers unstable 44%
Colorectal Lee et al, 2010 108 X2/5 markers 50%
Lee et al, 2012 108 X2/5 markers 50%
Devaraj et al, 2010 147 (only rectal) X2/5 markers 33%
Haugen et al, 2008 117 X1/7 markers unstable 60%
NSCLC Xu et al, 2001 47 X1/12 markers unstable 51%
Arai et al, 2013 65 X1/10 markers unstable 65%
Ahrendt et al, 2000 88 X1/13 markers unstable 35%
Prostate Burger et al, 2006a, b 81 X1/10 markers unstable 5%
Azzouzi et al, 2007 50 X2/4 markers 4%
Perinchery et al, 2000 40 X1/4 markers 25%
Renal Xu et al, 2001 25 X1/12 markers unstable 12%
Catto et al, 2003 71 (upper urinary tract) X1/8 markers unstable 23%
Head and neck Xu et al, 2001 18 X1/12 markers unstable 56%
Temam et al, 2004 54 X1/5 markers 48%
Non-melanoma skin Danaee et al, 2002 61 X1/7 markers unstable 75%
Ovarian Singer et al, 2004 53 X1/6 markers unstable 19%
Endometrial Choi et al, 2008 39 X1/6 markers unstable and no instability in mononucleotides and
dinucleotides
39%
Abbreviation: NSCLC¼ non-small cell lung cancer.




















Most often in serous
carcinoma (9%)
Prevalence 39%
Loss of MLH1, MSH2 in 33%
Loss of p53 in about 50%
Prevalence 35–65%
Often mutated p53, squamous
differentiation, stage I–II, pN+
No association with ‘classical’ MSI
Prevalence 33–60%
Reduced survival; T-cell infiltration,
often advanced tumour features
Downregulated MSH3
Prevalence 9–45%
No association with p53
No association with stage, grade, or
outcome
No association with classical MSI
Prevalence 4–25%
Not in early disease
Figure 1. Prevalence and main observed features of EMAST in human solid cancers.
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and uterus (38.5%, Choi et al, 2008), compared with the male
reproductive organs, although the overall available literature
remains limited.
Classical MSI is noted in approximately 12% of ovarian
cancers (Pal et al, 2008) and is most frequently associated with the
non-serous histological type. In contrast, EMAST appears predo-
minantly in the serous subtype of ovarian cancers; no EMAST has
been found in non-serous carcinomas (Singer et al, 2004).
Approximately 15% of endometrial cancers exhibit MSI-H, but
there are conflicting reports of the relation to clinical outcome (Diaz-
Padilla et al, 2013). EMAST has been reported at a higher frequency
(39%) than classical MSI, but these two markers showed no correlation
in type I endometrial carcinomas. Furthermore, most (70%) EMAST-
positive tumours exhibited normal expression of both MSH2 and
MLH1 in immunohistochemical analyses (Choi et al, 2008).
In prostate cancer, MSI is generally prevalent at dinucleotide
tandem repeats and is less common in trinucleotide and
tetranucleotide repeats (Perinchery et al, 2000). According to most
reports, the frequency of EMAST in prostate cancer iso5%
(Terrell et al, 1995; Burger et al, 2006b; Azzouzi et al, 2007).
In prostate cancer, EMAST is related neither to MSI nor to defects
in MMR proteins, TP53 mutational status or any histopathological
features (Burger et al, 2006b).
Other malignancies. Instabilities in tetranucleotide repeats have
been reported in both the MSI-H and MSI-L types of gastric
tumours, although EMAST has not been specifically investigated
in this setting (Kim et al, 2001). In a small study of 22 pheo-
chromocytomas (Kupka et al, 2008), 2 patients demonstrated MSI
in 1 and 2 of three tetranucleotide repeats (D2S443, D16S752 and
D21S1436) investigated; both cancers were defined as MSI-L by the
Bethesda panel. None of the endocrine tumours in that study
exhibited instability in the tetranucleotide markers used, although
13% were classified as MSI-H (Kupka et al, 2008).
EMAST was also analysed in one study of non-melanoma skin
cancer, where it was found at a high incidence (75%) and was
associated with TP53 or PTCH (patched gene) loss of hetero-
zygosity (Danaee et al, 2002). PTCH acts as receptor in the sonic
hedgehog signalling pathway, and loss-of-function mutations in
PTCH contribute to skin cancer development. The PTCH
gene harbours mutational hot-spot residues and regions,
including a slippage-sensitive sequence at the N-terminus
(Lindstrom et al, 2006).
EMAST frequencies in head and neck cancers have been reported
to range from 48% to 56% (Xu et al, 2001; Temam et al, 2004). Of
clinical relevance was one report showing that patients with
histologically proven (¼R0) radical and curative surgery, but who
displayed EMAST at the resection margins, had a higher risk of
tumour recurrence (Temam et al, 2004). ‘Molecular-positive’ resection
margins may thus be proposed as grounds for more aggressive
treatment or surveillance if validated as a broadened concept.
More recently, the length of an AAAG tetranucleotide repeat
tract and polymorphisms in a tetranucleotide repeat, both located
within the KCNQ1OT1 gene, have been shown to correlate with an
increased risk of breast cancer (Karimi et al, 2013) and
hepatocellular carcinoma (Wan et al, 2013), respectively.
CONCLUSIONS
The molecular mechanisms of EMAST have yet to be clearly
unravelled. EMAST induction and its contribution to carcinogen-
esis may stem from both exposure to external mutagens and
malfunctioning intrinsic cellular mechanisms. Experiments have
suggested that long microsatellites with higher numbers of repeats may
be prone to replication errors at higher frequencies compared with the
shorter ones. However, the consequences of EMAST development in
carcinogenesis require further investigation. The results from human
solid cancers have led to proposed mechanisms involving DNA repair
by TP53 and MSH3 and have suggested the immunological
involvement of T cells, at least in CRC, although precise mechanistic
understanding clearly requires further investigation.
The potential role of EMAST in early detection, prognostication
and prediction has been poorly investigated. However, some
findings have revealed the potential future use of this marker in
cancer. Variations of specific lengths in certain polymorphic
tetranucleotide repeats are associated with an increased cancer
risk, as recently reported for breast cancer and hepatocellular
carcinomas (Karimi et al, 2013; Wan et al, 2013). The high
prevalence of EMAST in the early stages of some cancers,
particularly those of the upper respiratory organs and lower
urinary tract, may suggest EMAST as a potentially exploitable
marker for preventive/early detection screening. In fact, in biopsies
from endoscopically normal colons, MSI in mononucleotide and
dinucleotide markers has been observed earlier than neoplastic
changes (Tug et al, 2012). Although markers suggestive of EMAST
have yet to be explored in the same manner, they EMAST markers
may be found more abundantly, because EMAST occurs at higher
frequencies. EMAST may also be generally related to environ-
mental carcinogen exposure and may therefore serve as a marker
of exposure or risk in certain cancers.
EMAST in the tissues of apparently tumour-free marginal sites
of surgical resections has been correlated with disease recurrence
(Temam et al, 2004). Therefore, EMAST in the tissues
of histomorphologically normal (R0 resected) surgical cancer
specimens could be used as a prognostic predictor of disease
recurrence in head and neck cancers. Optimal marker selection
may also lead to the feasibility of urine analysis for the early
detection or postsurgical surveillance of patients with bladder
cancer (van Tilborg et al, 2012).
Finally, the prognostic value of different forms of MSI in CRC
warrants further research (Garcia et al, 2012). The 5-year
recurrence-free survival trends for EMAST-positive and MSI-L
tumours are worse compared with those of MSI-H tumours,
suggesting differences in tumour biology that are currently not
fully appreciated and that may have consequences for the use of the
other available predictive and prognostic markers.
Taken together, these data suggest that EMAST should be
further investigated for its potential use in screening and/or as a
prognostic and predictive biomarker. In the fields of clinical and
translational oncology, important steps need to be taken to
improve the understanding of the role of EMAST in cancer. In our
view, one unresolved issue remains regarding whether EMAST
represents an ‘innocent bystander’ in cancer or an ‘active partner’
in carcinogenesis. Based on the emerging findings and cumulative
reports discussed above, EMAST may have diverse roles in
carcinogenesis and tumour biology at different tumour sites.
Nevertheless, common underlying principles may be crucial for
understanding cancer behaviour and may yield new tools for
prevention, early detection or personalised treatment.
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PROTOCOL
Assessment of clinically related 
outcomes and biomarker analysis 
for translational integration in colorectal 
cancer (ACROBATICC): study protocol for a 
population-based, consecutive cohort 
of surgically treated colorectal cancers 
and resected colorectal liver metastasis
Kjetil Søreide1,2,3*, Martin M. Watson1,2, Dordi Lea2,4, Oddmund Nordgård5, Jon Arne Søreide1,3, 
Hanne R. Hagland2,6 and ACROBATICC collaborators
Abstract 
Background: More accurate predictive and prognostic biomarkers for patients with colorectal cancer (CRC) prima-
ries or colorectal liver metastasis (CLM) are needed. Outside clinical trials, the translational integration of emerging 
pathways and novel techniques should facilitate exploration of biomarkers for improved staging and prognosis.
Methods: An observational study exploring predictive and prognostic biomarkers in a population-based, consecu-
tive cohort of surgically treated colorectal cancers and resected colorectal liver metastases. Long-term outcomes 
will be cancer-specific survival, recurrence-free survival and overall survival at 5 years from diagnosis. Beyond routine 
clinicopathological and anthropometric characteristics and laboratory and biochemistry results, the project allows 
for additional blood samples and fresh-frozen tumour and normal tissue for investigation of circulating tumour cells 
(CTCs) and novel biomarkers (e.g. immune cells, microRNAs etc.). Tumour specimens will be investigated by immuno-
histochemistry in full slides. Extracted DNA/RNA will be analysed for genomic markers using specific PCR techniques 
and next-generation sequencing (NGS) panels. Flow cytometry will be used to characterise biomarkers in blood. Col-
laboration is open and welcomed, with particular interest in mutual opportunities for validation studies.
Status and perspectives: The project is ongoing and recruiting at an expected rate of 120–150 patients per year, 
since January 2013. A project on circulating tumour cells (CTCs) has commenced, with analysis being prepared. Inves-
tigating molecular classes beyond the TNM staging is under way, including characteristics of microsatellite instability 
(MSI) and elevated microsatellite alterations in selected tetranucleotides (EMAST). Hot spot panels for known muta-
tions in CRC are being investigated using NGS. Immune-cell characteristics are being performed by IHC and flow 
cytometry in tumour and peripheral blood samples. The project has ethical approval (REK Helse Vest, #2012/742), 
is financially supported with a Ph.D.-Grant (EMAST project; Folke Hermansen Cancer Fund) and a CTC-project (Nor-
wegian Research Council; O. Nordgård). The ACROBATICC clinical and molecular biobank repository will serve as a 
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(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
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Background
Colorectal cancer represents a formidable health burden 
worldwide with an expected 60 % increase towards 2030 
[1]. Currently, CRC ranges as the second most frequent 
cancer in both genders in the Western world. Despite an 
increasingly favourable prognosis due to stepwise pro-
gression in surgical and oncological management [2], still 
about 40–50 % will develop metastasis and die from the 
disease. The liver is the most frequent site for metastasis, 
followed by the lungs, and is also the rate-limiting organ 
step for long-term survival. For non-metastatic disease, 
prognosis is guided through the tumour-node-metasta-
sis (TNM)-system, which heavily relies on the status of 
lymph nodes for current staging [3, 4]. Further, node sta-
tus may vary with the underlying molecular composition 
of primary tumour [5, 6]. Also, more refined node-exam-
ination including ultrastaging by immunohistochemistry, 
sentinel node techniques or use of molecular markers to 
identify malignant cells have not yielded a higher pre-
cision overall [7, 8]. Furthermore, other methods and 
techniques of staging patients, such as the use of “liquid 
biopsies” i.e. by investigating circulating tumour cells 
(CTCs) or other tumour constituents in peripheral blood 
(e.g. microRNAs), may prove to have higher prognostic 
and predictive value in both primary and metastatic CRC 
[9–12]. Notably, well-described molecular routes of pro-
gression in CRC have been linked to specific prognosis 
and outcomes, including microsatellite instability (MSI), 
CpG-island methylator phenotype (CIMP) and chromo-
somal instability (CIN) [13–17].
While the TNM is the best staging system at hand for 
clinical decision making, the TNM system is known to 
be imperfect [4], and substantial over- and undertreat-
ment results from failure to accurately predict disease 
outcomes. Indeed, increased knowledge of cancer het-
erogeneity has led researchers and clinicians alike to 
pursue better ways of stratifying therapy to individual 
risk and effects response and efficacy of therapy [18]. 
One suggested consensus taxonomy has emerged for 
novel risk-groups [19], however these have yet to be 
implemented in clinical practice. Variation in definition 
of common denominators for disease stratification may 
be due to a number of reasons, including heterogene-
ous patient groups investigated; investigations done on 
patients recruited to randomized trial with strict inclu-
sion criteria; variation in tumour sampling, and; vari-
ation in molecular analyses and techniques, to mention 
but a few [14, 20–22]. Thus, exploring biomarkers and 
the described genetic and epigenetic pathways in CRC 
[23, 24] by well-defined population cohorts with access to 
biobanking beyond routine samples is crucial (Fig. 1).
The aim of this prospective project is to facilitate pro-
spective accrual of patients with snap-frozen blood sam-
ples and fresh-frozen tissue outside routine clinical care, 
for more refined molecular evaluation (Fig.  1). For one, 
we will explore the role of microsatellite instability (MSI) 
and specifically a form found in tetranucleotide repeats 
(elevated microsatellite alterations in selected tetranucle-
otides; EMAST), which is found at varying frequencies 
in several cancers [25]. EMAST is a less-well described 
molecular trait in CRC, however, recent data point to a 
prognostic role and as a potential modulator of cancer 
biology [26–28]. The role of MSI and EMAST in rela-
tion to presently well-described prognostic mutations, 
such as KRAS and BRAF [29, 30], is not well described. 
Also, investigation into putative mechanisms leading to 
EMAST and the consequence for a predictive and prog-
nostic role is warranted. Second, a cohort of consecutive 
patients will be evaluated for CTCs in resectable stage I–
III CRC for its prognostic value. Third, as the role of the 
immune system is increasingly recognized as an integral 
component to carcinogenesis, cancer biology and patient 
prognosis [31–33], the project will investigate elements 
of the immune system in tumour samples as well as in 
peripheral blood. Finally, additional expansion of related 
projects are emerging with novel techniques, particularly 
with the availability of next-generation sequencing. Here 
we present the study design and protocol for a popula-
tion-based translational cancer research project.
Methods
Study ethics approval
The project and research biobank has been approved by 
the Regional Ethics Committee of the Western Health 
Authority (REK Helse Vest, #2012/742) and by the Insti-
tutional review board (Helse Stavanger HF Protocol 
Record #29034/2012). The project has been registered at 
www.ClinicalTrials.gov NCT#01762813.
long-term source for novel exploratory analysis and invite collaborators for mutual validation of promising biomarker 
results. The project aims to generate results that can help better discern prognostic groups in stage II/III cancers; 
explore prognostic and predictive biomarkers, and help detail the biology of colorectal liver metastasis for better 
patient selection and tailored treatment. The project is registered at http://www.ClinicalTrials.gov NCT01762813.
Keywords: Biomarker, Cancer, Population-based, Translational research, Colorectal cancer, Liver metastasis, 
Circulating tumour cells, Genetics
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Consenting
Patients are informed and consented in the surgery out-
patient clinic or, if directly admitted, in the surgical ward, 
before admission for surgery. A trained research nurse 
certified in Good Clinical Practice does consenting of 
patients and registration.
Study population
Stavanger University Hospital serves as the only hospi-
tal for a population of about 350,000 inhabitants in the 
South-Western part of Norway. The population is pre-
dominant of Caucasian origin, the average population 
age slightly younger than the national average. Socioec-
onomic differences are not extreme in the country; the 
life expectancy is just below 80 years for men and about 
81 years for women. With no other competing hospitals 
in the region and a social security system ensuring equal 
care for all patients, the study population allows for relia-
ble, unselected, population-based and representative data 
sampling with little risk of bias.
We have previously reported epidemiological charac-
teristics to other disease categories based on the same 
non-selected, unbiased conditions, which should validate 
the methodology to the current population-based per-
spective [34–39].
With low migration in the region, long-term follow 
up is feasible and allows for high precision in catching 
new events (disease related or other) with impact on 
Fig. 1 The ACROBATICC project flow sequence and rationale for cancer biology investigation. a Illustrated is a simple workflow of patients’ recruit-
ment and samples of blood (red vials) and tissues (blue vials) from initial diagnosis, before and after surgery and during follow up. Overall, disease-
free and cancer-specific survival will be analysed at 5 years. b Illustrated are the specific levels of patient information gathered for prognostic and 
predictive use, ranging from clinicopathological characteristics (such as sex, age, body weight and height) to genetic and epigenetic mechanisms 
(including microsatellite instability; CpG-island methylator phenotypes and chromosomal instability) and specific tumour-host interactions (such 
as immune-response in tumor; cancer metabolism and role of circulating tumor cells). With access to newer techniques and development of novel 
hypothesis, the project will allow for exploration of other predictors, as well as serve as external validation cohort in collaborative research
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outcomes, as previously reported [40, 41]. The risk of 
loosing patients to long-term follow-up is thus minimal.
All Norwegian citizens have a unique 11-digit social 
security number that allows identification through the 
hospital electronic hospital records with national regis-
tries, including the Norwegian Patient Register and the 
Cancer Registry of Norway. All CRC patients are regis-
tered to the National Colorectal Cancer Registry via an 
electronic template record form. The study will comply to 
the strengthening the reporting of observational studies 
in epidemiology (STROBE) recommendations on what 
should be included in an accurate and complete report of 
any observational study [42].
Inclusion and exclusion criteria
All consecutive patients diagnosed with operable pri-
mary or metastatic colorectal cancer and able to 
provide informed, written consent are included. Partici-
pants can at any time withdraw from the study without 
need for providing any explanation for the withdrawal, 
upon which the records will be destroyed and deleted. 
Excluded are patients presenting as emergencies and 
unable to consent, or patients unable to understand oral 
and written Norwegian or, patients whose cognitive sta-
tus does not allow for informed consent.
Study period
The study commenced in January 2013 and recruit-
ment is ongoing, for an expected closure of recruitment 
in 2018, with final 5-year follow-up to be completed in 
2022.
Study number and sample size
For prognostic information and estimated sufficient num-
bers of patients and events, we expect to recruit about 
150 patients per year. With an expected 35–45 % recur-
rence rate within 5  years of primary diagnosis—which 
is expected from previous regional and national data of 
curatively resected CRC in Norway [2, 40, 43]—and, an 
accrual commencing over at least 5 years (2013–2018) we 
expect to have about 750 patients with operable primary 
and/or metastatic CRC for evaluation at the end of the 
period. In stage I-III CRC, the recurrence rate at 35–45 % 
by 5 years [2, 40, 43] should yield appropriate number of 
events (cancer-specific survival) for creation of test-sets, 
validation-sets and prospective evaluation. Recurrence 
rates are expected to be even higher in colorectal liver 
metastasis (>80 % recurrence within 5 years), suggesting 
fewer patients are needed to evaluate the endpoint.
Clinical work‑up and care
The Department of Gastrointestinal Surgery provide 
all clinical work-up and surgical care for patients with 
colorectal cancer and subsequent evaluation for metas-
tases, resectable or non-resectable. Oncologic care is 
provided at the Department of Oncology. All radiologic 
work-up (except PET/CT scans) are performed at the 
Department of Radiology. Specimen evaluation and tis-
sue blocks preparation for routine diagnostics are per-
formed at the Department of Pathology. Routine blood 
tests are analysed at the Department of Clinical Chem-
istry. Storage of research samples (fresh-frozen) are 
archived in an intramural research biorepository at the 
Stavanger University Hospital. Subsequent DNA and 
RNA retrieval and elaborate laboratory work outside 
routine diagnostics are performed at the Laboratory for 
Molecular Biology, except if otherwise stated.
All patient care are performed under the recommended 
national guidelines issued by the multidisciplinary Nor-
wegian Gastrointestinal Cancer Group (NGICG), for 
both colorectal cancer (NGICG-CRC) and liver metasta-
sis (NGICG-HPB), respectively.
Collaboration
Interested collaborators are welcome to make contact. 
Discussion is extant with other groups and thus has the 
potential to generate an international cohort for compar-
ison and validation of results. No external collaboration 
is yet confirmed but discussion in progress.
The cohort material will similarly also be available for 
cross-evaluation with other cohorts generated elsewhere, 
and will be beneficial for external validation purposes 
and hypothesis-generating experimental studies.
Samples
Issues to attend to for biomarker research and report-
ing have been addressed in several leading journals [21, 
22]. Consequently, the current study will seek to comply 
and report according to the biospecimen reporting for 
improved study quality (BRISQ) recommendations for all 
tissue sampling and storage in the study [44]. For parts 
of the study relating to clinical prognosis, we will aim to 




Resected specimens are handled at the Department of 
Pathology according to protocol. An electronic tem-
plate is followed and applied for gross examination and 
microscopic description of pathologic features and data 
for staging. Staging is done per the TNM-system (AJCC 
7th edition). Representative tissue slides (resection ends 
or normal tissue distant from primary tumour; several 
tumour slides including most invasive front; all sampled 
lymph nodes) are formalin-fixed paraffin-embedded 
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(FFPE) for routine H&E diagnostics and microscopy. 
Lymph nodes are sampled per protocol and aimed to 
achieve at least 12 nodes and, if less, a ‘lymph node 
revealing solution’ (a mixture composed of 95 % ethanol, 
diethyl ether, glacial acetic acid, and buffered formalin; 
also called GWEF) is applied to mesenteric fat in order to 
enhance node recovery [46].
Frozen fresh tumour tissue and normal sample
Before formalin fixation and immediate upon retrieval of 
the specimen, representative fresh tumour samples are 
obtained (at least three per tumour), stored in meticu-
lously marked vials, and frozen in liquid nitrogen. Time 
is kept to a minimum between resection and delivery at 
Pathology in order to minimize loss of RNA quality [47, 
48], usually delivered by an orderly within 15  min of 
retrieval from the operating room to the laboratory.
For the rare occasional procedures commencing or 
proceeding outside opening hours of the Department 
of Pathology, the surgeon in charge samples the fresh 
tumour biopsies per protocol and provides this in a port-
able insulated box container with dry ice for storage, nor-
mally <12 h. Samples are then collected by a technician 
and processed per protocol as early as possible the next 
morning.
Blood samples
Peripheral blood samples are drawn (usually) from the 
antecubital vein on admission before surgery and on 
the outpatient follow-up appointment, approximately 
4  weeks after surgery. Subsequent blood is drawn if 
patient is readmitted for new surgery for recurrence or 
metastatic disease, and then again if a second curative-
intent surgery (e.g. resection of new large bowel tumour; 
local recurrence; or, metastasectomy) is planned. Blood 
samples are processed to serum and plasma by centrifu-
gation and two vials of full blood (EDTA-containers) are 
frozen and stored in −80 °C freezers together with pro-
cessed samples.
Circulating tumour cell (CTC) detection
Peripheral blood samples (9  ml) are collected in EDTA 
tubes and subjected to density centrifugation within 20 h 
(preferably 2 h) from the collection time. RNA is isolated 
from the peripheral blood mononuclear cell fraction and 
reverse transcribed. Circulating tumour cells (CTCs) are 
then detected indirectly by measuring epithelial-specific 
mRNAs, which are not present in normal blood cells, as 
surrogate markers [12, 49, 50]. mRNA concentrations are 
measured by quantitative reverse-transcription PCR. The 
background levels in blood samples from healthy control 
persons are utilized as a reference material to determine 
which patient samples are positive for CTCs.
DNA/RNA extraction
DNA and RNA are extracted from freshly frozen tumour 
and normal (surgical resection margins or normal tissue 
sampled distant from primary tumour) using the QIA-
CUBE (Qiagen) instrument and dedicated reagents and 
kits, according to manufacturers instructions. Weighted 
15–20  mg of tissue are resuspended in lysis buffer and 
homogenized in the presence of 5  mm Ø steel beads, 
in a TissueLyser LT (Qiagen), at 50  Hz, for 4  min. Two 
consecutive protocols are then used on the QIACUBE 
instrument to extract DNA first, and RNA later (from 
flow through of first protocol) via the use of AllPrep 
DNA/RNA/miRNA Universal Kit. Concentration, purity 
(A260/280) and presence of phenol and protein con-
taminants in the eluted sample (A260/230) are measured 
and noted with a NanoDrop (ThermoFischer) intru-
ment. Extracted DNA and RNA are labelled and stored 
at −80  °C in the aforementioned intramural biobanking 
facility.
Employed molecular techniques
Mentioned examples here are not exclusive, but include:
Immunohistochemistry (IHC)
Antigen retrieval and antibody dilution are optimized 
prior to the study onset for the different antibodies. To 
ensure uniform handling of samples, all sections are 
processed simultaneously. Paraffin sections adjacent to 
the haematoxylin-eosin (H&E) sections used for histol-
ogy are mounted onto Superfrost Plus slides and dried 
overnight at 37 °C followed by 1  h at 60 °C. Sections 
are deparaffinised in xylene and rehydrated in decreas-
ing concentrations of alcohol. Antigen is retrieved using 
Tris–EDTA (pH 9.0) as the retrieval buffer. Endogenous 
peroxidase activity is blocked with a peroxidase-block-
ing reagent. The immune complex is visualized with the 
Dako REAL EnVision Detection System, Peroxidase/
DAB, Rabbit/Mouse (K5007; Dako). Sections are incu-
bated with EnVision/HRP, Rabbit/Mouse for 30  min 
and diaminobenzidine (DAB+) chromogen. The sec-
tions are counterstained with haematoxylin, dehydrated, 
and mounted. All steps are performed using DakoAuto-
stainer and TBS (S1968; Dako) with 0.05 % Tween 20 as 
wash buffer. Quality assessment and scoring of the sam-
ples are executed by an experienced pathologist and with 
use of digital pathology software (Visiopharm) for some 
antibodies.
Candidate markers for investigation are in develop-
ment, and includes (but not limited to) suggested mark-
ers for immune cells (e.g. CD4+, CD8+, CD45RO+) and 
as suggested in the Immunoscore [51], potential mark-
ers of differentiation (e.g. CDX2) in CRC stage subtypes 
[52], and markers related to mechanistic insight, such as 
Page 6 of 9Søreide et al. J Transl Med  (2016) 14:192 
MSH3 and its relation to EMAST [53, 54]. Other markers 
will be employed for specific subprojects as needed, e.g. 
for validating protein expression for gene variations.
Flowcytometry
Freshly drawn blood is collected in EDTA coated blood 
vacuum containers. Percentages of human CD4+ and 
CD8+ T-lymphocytes in erythrocyte-lysed whole blood 
are determined by flow cytometry. The antibody kit is 
acquired from BD Biosciences (Cat no: 342417) with CD3 
FITC/CD8 PE/CD45 PerCP/CD4 APC conjugated stain-
ing. Cells are prepared according to protocol and 100 µl 
whole blood is used. BD Pharm Lyse (Cat no: 555899) 
is used at appropriate dilution to lyse erythrocytes. The 
samples are run on an Accuri C6 (BD biosciences) or a 
Cytoflex (Beckman-Coulter) flow cytometer both sys-
tems equipped with a blue and red laser, two light scatter 
detectors, and four fluorescence detectors with optical 
filters optimized for the detection of FITC, PE, PerCP, 
and APC. Further analysis of results is being done using 
the corresponding software (BD Biosciences Accuri C6 
analysis software and CytExpert Beckman-Coulter).
Next generation sequencing (NGS)
Template preparation and chip loading is carried out 
using the Ion Chef™ System. With the use of CRC-spe-
cific, validated custom and commercially available panels, 
targeted DNA ion semiconductor sequencing of tumour 
material is performed on the Ion Torrent™ Personal 
Genome Machine® (PGM, ThermoFischer) platform. 
Data analysis against the reference (human) genome is 
executed in-house with the aid of the Torrent Suite™ and 
Ion Reporter™ softwares.
Statistical analysis and endpoints
The project is exploratory and thus no formal statisti-
cal power has been done. The population-based, obser-
vational, real-life, non-selected cohort will allow for 
adequate power based on the expected recruitment of 
a cohort size of 750 patients, of which an expected one-
third (about 250) will have recurrence or death from 
disease. With the high number of events, this will allow 
for reasonable multivariable adjustments for outcomes. 
For smaller samples in subgroups (e.g. only stage II; or, 
only patients with resected liver metastasis), hypothesis-
generating results will be pursued with appropriate sized 
prospective cohort samples with internal and external 
validation cohorts, where available.
The main endpoints will be cancer-specific, recur-
rence-free and overall survival, which will be analysed 
with Kaplan–Meier figures and log rank test. Explora-
tory analyses will be done using descriptive techniques 
for hypothesis-generating results. For laboratory values 
without established cut-offs, we will apply receiving-
operator characteristics (ROC) analyses for optimal cut-
off determination [55]. For prognostic factors, we will 
apply appropriate multivariable regression analyses for 
appropriately adjusted analyses.
Discussion
The ACROBATICC projects aim to integrate the routine 
clinical work-up and treatment of patients with primary 
CRC and resectable liver metastasis with state-of-the-art 
molecular technology investigations of blood samples 
and tumor tissues. The aim is to explore and identify bet-
ter predictive and prognostic biomarkers that may even-
tually help in clinical decision-making for more precise, 
personalized and tailored treatment. The ACROBATICC 
clinical and molecular biobank repository will serve as 
a long-term source for novel exploratory analysis and 
invite collaborators for mutual validation of promising 
biomarker results. The project aims to generate results 
that can help better discern prognostic groups in stage II/
III cancers; explore prognostic and predictive biomark-
ers, and help detail the biology of colorectal liver metas-
tasis for better patient selection and tailored treatment 
[23, 28, 56].
The role of population-based cancer biobanking is 
increasingly recognized as important for exploratory and 
confirmatory studies at an unselected, population-level. 
While regular diagnostic biobanking [i.e. formalin-fixed 
and paraffin embedded (FFPE) tissue blocks] allow for 
valuable analyses outside routine descriptive data, such 
repositories may have a number of medicolegal and 
laboratory limitations which may be overcome by spe-
cific research-driven projects. The current translational 
cancer research project will allow for further in-depth 
analyses into cancer biology otherwise not available from 
material obtained by routine care.
The use of “liquid biopsy” has gained considerable 
attention as a novel source of biomarkers. Blood-based 
biomarkers could prove to be practical tools for CRC 
detection, as the monitoring of biomarkers in biological 
fluids offers many advantages, including minimal inva-
siveness and easy accessibility [57]. In the current study, 
we will have the opportunity to explore for tumour-spe-
cific markers in blood and tissue that may be related to 
prediction and prognosis of outcome.
Lack of uniform research designs, poor quality con-
trol and large variation in reporting have hampered bio-
marker research and comparison of data in the past. This 
has invariably led to a number of promising but non-
validated biomarkers in past studies. Currently, a large 
number of guidelines and recommendations are avail-
able to instruct, inform and impede better and more uni-
form reporting of results. However, the number of such 
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guidelines is increasing rapidly [58], with some suggest-
ing there be too many guidelines to possibly comply to. 
However, we believe that a core set of important guides 
help set useful framework for reporting and help avoid 
huge deviation from recommended practice. Evaluation 
of compliance to such guidelines suggest that consider-
able deviation and lack of reporting core data still exist in 
biomarker research studies [59]. Thus, we would seek to 
adhere and comply with the recommendations addressed 
in the protocol and any other relevant recommendations, 
as issued by the EQUATOR network (http://www.equa-
tor-network.org).
Project status
The project is currently recruiting patients and labora-
tory work on the CTCs is ongoing, as well as laboratory 
work on MSI and EMAST in primary tumours. Hot spot 
panels of known CRC mutations with NGS technology is 
being prepared. A pilot, feasibility study to test for same-
time comparison of patients’ circulating immune-cells in 
peripheral blood and comparison to tumour-infiltrating 
cells in the cancer specimen is currently being conducted.
Future aspects
We envision several add-ons to be possible with increases 
resources and manpower in the project. For one, patient 
reported outcomes (PROs) is an increasing are of inter-
est and would yield yet another dimension to the clinical-
translational aspect of the project [60]. Also, the sampled 
biopsies will allow for a number of other experiments and 
analyses, such as exosomic DNA, microRNA and other 
emerging biomarkers. Further, other sampling techniques 
and specimens would be feasible in the future, such as 
sampling and investigating faeces for both genetic and 
epigenetic biomarkers [24], but also investigating the 
microbiome for its putative role in carcinogenesis but 
also possible influence on cancer biology [61, 62]. Last, 
but not least, we would pursue international collabora-
tion for mutual validation of similar ongoing biomarker 
projects [63]. The prospective cohort results will seek 
collaboration for external validation studies but may also 
serve as an external validation cohort for other research 
groups interested in collaboration.
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